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Platelets play a crucial role in haemostasis by preventing bleeding at sites of vascular injury. 
Inherited or acquired platelet defects can impair haemostasis resulting in bleeding symptoms of 
varying severity ranging from mild to excessive which can be life threatening. Diagnosis of 
mild platelet-based bleeding disorders is challenging due to the absence of a gold standard 
technique and their variable bleeding symptoms and bleeding phenotypes observed in healthy 
individual as well as other haemostatic disorders. Furthermore their bleeding symptoms often 
only manifest after haemostatic challenge. The work in this thesis built on the previous studies 
in the genotyping and platelet phenotyping project allowing further characterization of inherited 
platelet function defects in individuals with mild bleeding disorders. The bleeding symptoms 
of patients were evaluated using the bleeding assessment tool, and its likelihood in diagnosing 
platelet function defects was assessed and recorded. Platelet aggregation and secretion in 
samples from 206 patients were investigated during the course of this thesis and were 
categorised on the basis of the observed defects. Surprisingly, in over a half of these patients, 
an ex vivo platelet function defect was not found. The genetic investigation of selected cases 
using whole exome sequencing identified mutations in number of genes previously known to 
be critical in platelet biology. However, subsequent functional studies are required to further 
understand their contribution to the platelet defect observed in these patients. This thesis also 
focused on evaluation of three other platelet techniques by comparison with lumi-aggregometry 
to assess their overall potential in detecting platelet function defects. Further studies are still 
needed to further assess the potential of these techniques before they can be applied in routine 
clinical diagnosis.   
 
 
Publications arising from this work 
ii 
 
PUBLICATIONS ARISING FROM THIS WORK 
i) Published manuscripts 
a. Al Ghaithi R, Drake S, Watson SP, Morgan NV and Harrison P Comparison of multiple 
electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild 
bleeding disorders. Journal of Thrombosis and Haemostasis 2017 15(10):2045-2052.  
b. Jun Mori, Zoltan Nagy, Giada Di Nunzio, Christopher W. Smith, Mitchel J. Geer, Rashid 
Al Ghaithi et al. Maintenance of platelet homeostasis by the kinase-phosphatase pair Csk-
CD148 in mice. Submitted  
 
ii) Published abstracts  
a. R. Al Ghaithi, J. Mori, L. Hardy, H. Philippou, E. Hethershaw, YA. Senis, NV. Morgan and 
P. Harrison.  Evaluation of the Total Thrombus-formation System (T-TAS): Application to 
Human and Mouse Blood Analysis. Accepted for poster presentation at International Society 
on Thrombosis and Haemostasis 2017 Congress (Berlin, Germany). (abstract reference PB 
2230) 
b. R. Al Ghaithi, J. Mori, L. Hardy, H. Philippou, E. Hethershaw, NV. Morgan, YA. Senis and 
P. Harrison. Evaluation of the Total Thrombus-formation System (T-TAS): Application to 
Human and Mouse Blood Analysis. Accepted for oral presentation at A Joint Meeting of BSHT 
/ AiP / UK Platelet Group 2016 (Leeds, UK).  
c. Al Ghaithi R, Drake S, Watson SP, Morgan NV and Harrison P Comparison of multiple 
electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild 





I wish to dedicate this work firstly to my parents who brought me up in the best 
possible manner. Then to my family, my beloved wife Nasra Al Jahdhami whose 
sacrifice and her unconditional love have greatly contributed to the success of this 
work, and to my three lovely children, Hafidh, Muthla and Maher who always 






In the name of Allah, Most gracious, Most merciful. Praised being to Him who granted me with 
good health and gave me the strength to complete this work. Deepest thanks must go to Dr Paul 
Harrison for giving me the opportunity to study and work on this research under his supervision 
and for his continuous encouragment, advice and support for me throughout my research. 
Special thanks for Professor Steve Watson to allow me to be part of the Birmingham platelet 
group and to work in his laboratory and also for his supervision, advice and support. Special 
thanks also go to Dr Neil Morgan whom I worked very closely in the GAPP project and his 
advice and guidance for the genetic study.   
I am grateful to the Government of Sultanate of Oman who funded this research and financially 
supported me thought out my study. Special thanks go to the Ministry of Health in Oman 
especially to Dr Qasem Al Salmi and Dr Muhanna Al Musalhi to nominate, motivate and 
supported me for this study. Special thanks also go to the Oman cultural attaché in London for 
facilitating all my academic and financial issues.  
Special thanks go to people who worked with me in the GAPP project, Dr Sarah Fletcher, Mrs 
Sian Drake, Dr Ben Johnson and Miss Annabel Maclachlan for their help and support. Thanks 
also to Dr Ban Dawood, Dr Marie Lordkipanidze and Dr Gillian Lowe for their previous 
contributions and for setting up the GAPP project. Thanks to Professor Yotis Senis and his team 
(platelet signalling group) for collaboration and   help with the animal models. Thanks to Dr 
Alexander Brill for assessing all of my annual reports and providing me with feedback and 
advice. Thanks to Dr Steve Thomas and Dr Natalie Poulter for teaching me platelet spreading 
and analysis of platelet under the electron microscopy. Special thanks also to Vikki Harrison, 
Stephanie Watson, Beata Grygielska and Gayle Halford for all of their help and support. I thank 
my office mates and members of the Watson (platelet) group for all the wonderful time I spent 
throughout my studies. Thanks to everyone in the research laboratory at the QEH for their help 
and support. 
 I am very grateful to all of my Omani friends and family members here in UK and back home 
for their encouragement and support. 





LIST OF ABBREVIATIONS 
 
ACMG - American College of Medical Genetics and Genomics 
ADP - Adenosine diphosphate   
ARC - Arthrogryposis-renal dysfunction-cholestasis  
ATP - Adenosine triphosphate  
AUC - Area under the curve  
BAT - Bleeding Assessment Tool 
BSS - Bernard-Soulier syndrome 
BT - Bleeding time  
CHS - Chediak-Higashi syndrome 
CLEC-2 - C-type lectin-like receptor-2  
COX1 - Cyclooxygenase 1 
CPA - Cone and platelet analyser 
CRP - Collagen-related peptide 
DNA - Deoxyribonucleic acid  
GAPP - Genotyping and Phenotyping of Platelets 
GT - Glanzmann thrombasthenia  
GTP - Guanosine-5’- triphosphate 
GP - Glycoprotein 
GPCRs - G protein–coupled receptors 
GDP - Guanosine diphosphate 
GPS - Grey platelet syndrome 
HMW - High molecular weight  
HPO - Human Phenotype Ontology 
HPS - Hermansky-Pudlak syndrome 
Ig - Immunoglobulin 
IPA - Impedance platelet aggregometry 
IPF - Immature platelet fraction  
ISTH - International Society on Thrombosis and Haemostasis 
ITAM - Immunotyrosine-based activation motif 
ITP - Immune thrombocytopenic purpura  
JAMs - Junctional adhesion molecules 
KO - Knock out 
Lumi-LTA - Lumi-aggregometry 
LTA - Light transmission aggregometry 
MAF - Minor allele frequency  
MEA - Multiple Electrode Aggregometry 
MFI - Median fluorescence intensity  
MKs - Megakaryocyte 
MPV - Mean platelet volume  




NO - Nitric oxide 
NPV - Negative predictive value  
OCA - Oculocutaneous albinism 
OCS - Open canalicular system  
OT - Occlusion time 
PCR - Polymerase Chain Reaction  
PFD - Platelet function defects 
PFT - Platelet function testing  
PGI2 - Prostacyclin 
PI3K - Phosphoinositide 3-kinases 
PLCβ - Phospholipase C-β 
POC - Point of care 
PPP - Platelet poor plasma 
PPV - Positive predictive value  
PRP - Platelet rich plasma 
PS - Phosphatidylserine  
PT-VWD - Platelet-type von Willebrand disease 
PTF - Platelet thrombus formation 
QPD - Quebec platelet disorder  
ROC - Receiver-operator curve  
ROTEM - Rotational thromboelastometry  
RPFT - Remote platelet function test  
SIFT - Sorting Intolerant from Tolerant  
SLE - Systemic lupus erythematosus  
SLMA - Signalling lymphocyte activation molecules 
SNV - Single nucleotide variant  
SPD - Storage pool disease  
T-TAS - Total Thrombus-formation System 
TEG - Thromboelastography  
TPO - Thrombopoietin 
TRAP - Thrombin receptor activating peptide 
TTF - Total thrombus-formation  
TxA2 - Thromboxane A2  
uPA - Urokinase plasminogen activator  
VWD - von Willebrand disease 
VWF - von Willebrand factor 
WES - Whole exome sequencing 
WGS - Whole-genome sequencing 
WT - Wild type  







Publications arising from this work…………….…………………..……………… ii 
Published manuscripts………………………….……………………………..…… ii 
Published abstracts………………………………………………………………… ii 
Dedication………………………………………………….……………………… iii 
Acknowledgements…………….……………………….………….……………… iv 
List of abbreviations……………………………………..………………………… v 
Contents…………….…………………………..…………..……………………… vii 
List of figures………………………………………..………..…………………… xi 
List of tables…………………………………………………….……….………… xv 
 
1.0 CHAPTER ONE: GENERAL INTRODUCTION….………..……………. 1 
1.1 Platelet physiology…………………………………………….………………. 1 
1.1.1 Overview…………………………………….………………………………. 1 
1.1.2 Platelet formation……………………………….…………………………… 1 
1.1.3 Platelet morphology………………………….…………….………………… 2 
1.1.4 Platelet function…………………...………………………….……………… 3 
1.1.4.1Adhesion…………………………………………………………………… 4 
1.1.4.2 Activation and spreading………………..………………….………………  4 
1.1.4.3 Secretion and aggregation………………………………….……………… 5 
1.1.4.4 Platelet pro-coagulant activity…………………...………………………… 5 
1.2 Platelet receptors, agonists and signalling pathways…….……..……………… 7 
Platelet signalling pathways………..………….……..………….………………… 10 
1.2.1 G protein–coupled receptors………………………………………………… 10 
1.2.1.1 Gi proteins………………………….……………………………………… 10 
1.2.1.2 Gq proteins………………………………………………………………… 11 
1.2.2 Glycoprotein receptors……………….……………………………………… 13 
1.2.3 Other platelet receptors……………………………………………………… 15 
1.3 Platelet disorders………………………………………………………………. 16 
1.3.1 Defects in platelet adhesion…………………………………………………. 16 
1.3.2 Defects in platelet aggregation ……………………………………………… 18 
1.3.3 Defects in platelet secretion………………….………………………………  18 
1.3.4 Defects in agonist receptors………….………………………………………  22 
Defects in ADP receptors……………..……………………………………………  22 
Defects in collagen receptor (α2β1)……………..………………………………… 24 
Defects in collagen receptor (GPVI)…….………………………………………… 24 
1.4 Diagnosis of Platelet Function disorders……………………………………… 31 
1.4.1 Phenotyping of platelet function disorders……..……………………………  32 
1.5 The Genotyping and Phenotyping of Platelets (GAPP) study………………… 40 




2.0 CHAPTER TWO: MATERIALS AND METHODS………….…………… 43 
2.1 Study approval………………………………...…………….…………………. 43 
2.2 Materials………………………………………………….…….……………… 45 
2.3 Patient recruitments and blood sample collection………….…..…….………… 47 
2.3.1 Patient recruitments……………………………….…….……………………  47 
2.3.2 Blood sample collection…………………………..…….…………………… 48 
2.4 Blood sample preparation and processing….…………………………..……… 49 
2.4.1 Whole Blood Platelet Counting using the Sysmex XN-1000 Analyser…...… 49 
2.4.2 Preparation of PRP and PPP………………………………………………… 49 
2.4.3 Platelet counting of PRP…………………..…………………….…………… 50 
2.4.4 Storage of platelets for protein analysis………………………...…………… 50 
2.5 Platelet function assay in whole blood………………………………………… 50 
2.6 Platelet function assay in platelet-rich plasma………………………………… 51 
2.7 Measurement of platelet ATP secretion………………………..……………… 51 
2.8 Evaluation of platelet function using RPFT…………………………………… 52 
2.9 Evaluation of thrombus formation under flow conditions on human blood...… 53 
2.9.1 Antithrombotic effects of ticagrelor and rivaroxaban under flow conditions.. 54 
2.9.2 Evaluation of thrombus formation under flow conditions on mouse blood..… 54 
2.10 Genetic analysis……………….……………………………………..………. 55 
2.10.1 DNA extraction………………………..…………………..………………. 55 
2.10.2 Polymerase Chain Reaction (PCR)…………….…….…….……………… 56 
2.10.3 Sanger Sequencing……………….……..…….…………………………… 57 
2.10.4 Whole gene sequencing using NGS…………..…………………………… 59 
2.10.5 Conservation and pathogenicity prediction………….….…….…………… 60 
2.11 Statistical analysis…………………………….……………………………… 62 
 
3.0 CHAPTER THREE: PHENOTYPE OF INDIVIDUALS SUSPECTED WITH 
MILD BLEEDING DISORDERS USING LIGHT TRANSMISION 
AGGREGOMETRY…………….………………..………………………………………  63 
3.1 Introduction…………………….……………………………………………… 63 
3.2 Aim……………………………………….…....………….…………………… 64 
3.3 Results………………………………………….……………………………… 65 
3.3.1 Overall patient recruitment…………………………….…….………….…… 65 
3.3.2 Platelet parameters and ATP secretion values…….…..………………….….. 71 
3.3.3 Overall aggregation results and platelet defect classification….….……….… 77 
3.3.4 Analysis of patients with thrombocytopenia……………..………………….. 80 
3.3.5 Assessment of ISTH Bleeding score among patients with normal platelet 
count…………………………………….…………………………………………. 92 
3.3.6 Investigation of families with a history of excessive bleeding……….…..….. 100 
3.3.7 Case presentation from patients with various categories of platelet defects…  103 




3.3.7.2 Index case No.2 - A patient with cyclooxygenase pathway defect….…..….. 105 
3.3.7.3 Index case No.3 - A patient with a possible dual platelet defect 
(cyclooxygenase pathway and Gi signalling)……………………………………… 107 
3.3.7.4 Index case No.4 - A patient with a suspected dense granule secretion 
defect………………………………………….…………………………………… 109 
3.4 Discussion………………………………………..………………………….… 112 
 
4.0 CHAPTER FOUR: GENOTYPING OF PATIENTS IDENTIFIED TO HAVE A 
PLATELET DEFECT…………………………………………...………………………. 117 
4.1 Introduction……………………………….…………………………………… 117 
4.2 Aim…………………………………….………………….……….…………...  118 
4.3 Results……………………………………………………………….………… 119 
4.3.1 Overall patients’ demographics and platelet parameters….…….…………… 119 
4.3.2 Variants found in patients suspected to have Gi defects…….…….…………  122 
4.3.3 Variants found in two patients with dual defects and one patient suspected 
with a defect on the PAR-1 receptor………………….………………………….… 127 
4.3.4 Variants found in patients suspected to have a cyclooxygenase pathway 
defect…………………………………………………………………………….… 129 
4.3.5 Defect in genes that were identified in multiple patients..…………...……… 133 
4.3.6 Genetic analysis of an index case presented with a Gi signalling defect and 
her family members…………………….…….…………………………………… 136 
4.3.7 Genetic analysis of a family presenting with a platelet secretion defect….… 142 
4.4 Discussion………...…………………………………………………………… 147 
4.4.1 Limitation and suggestions…………………………………………….……. 153 
 
5.0 CHAPTER FIVE: COMPARISON OF MULTIPLE ELECTRODE 
AGGREGOMETRY WITH LUMI-AGGREGOMETRY FOR THE 
DIAGNOSIS OF PATIENTS WITH MILD BLEEDING DISORDERS…….. 154 
5.1 Introduction…………………………………………………………….……… 154 
5.2 Aim……………………………………………….……….……………………  155 
5.3 Results……………………………………………………….………………… 157 
5.3.1 Overall demographics and platelet parameters of patients and healthy 
controls…………………….………………………………………………….……  157 
5.3.2 Correlation between platelet counts and aggregation results by MEA and 
lumi-LTA………………………………………………………………………..…  160 
5.3.3 Overall comparison between MEA and Lumi-LTA……………….………… 163 
5.3.4 Analysis and identification of patients with various platelet function defects 166 
5.3.5 Analysis of MEA sensitivity in response to specific agonists……….………  170 
5.3.6 Analysis of patients with low ATP secretion levels and thrombocytopenia… 172 





6.0 CHAPTER SIX: EVALUATION OF THE TOTAL THROMBUS-
FORMATION SYSTEM (T-TAS): APPLICATION TO HUMAN AND 




6.1 Introduction……………………………….…………………………………… 179 
6.2 Aim………………………………………………………………..……………  181 
6.3 Results……………………………………………….………………………… 183 
6.3.1 Measurement of T-TAS in healthy subjects………………………..………... 183 
6.3.2 Measurement of blood from healthy subjects spiked with antithrombotic 
drugs…………………………………………..…………………………………… 193 
6.3.3 Measurement of T-TAS in samples from patients recruited into the GAPP 
study with suspected platelet function defects…………..………………………… 197 
6.3.4 Analysis and identification of patients with various platelet function 
defects……………………………………………………………………………… 203 
6.3.5 Measurement of T-TAS in samples from GAPP patients with 
thrombocytopenia recruited with suspected platelet function defects…..….…..….. 205 
6.3.6 Measurement of T-TAS in samples from WT mice………….………………  208 
 6.3.7 Comparison of T-TAS measurements between blood samples from WT mice 
and humans………………………………………...…………………………….…   211 
 6.3.8 Measurement of T-TAS in blood from genetically modified mice…….…… 214 
6.4 Discussion…………….………………….……….……….…………………… 222 
 
7.0 CHAPTER SEVEN: PROSPECTIVE STUDY TO EVALUATE THE 
REMOTE PLATELET FUNCTION TEST (RPFT)…………………..………. 227 
7.1 Introduction……………………….…………………………………………… 227 
7.2 Aim…………………………..……………..………..………………………… 228 
7.3 Results………….……………………………………………………………… 229 
7.3.1 Sample recruitment and determination of cut off values…………..………... 229 
7.3.2 Overall patient results…………………….……………...………………..….  233 
7.3.3 Overall agreement between lumi-LTA and RPFT….………………………... 237 
7.3.4 Performance of RPFT in patients with Gi and dense granular secretion defect.  241 
7.3.5 Performance of RPFT in patients with Cox and multiple platelet defects……  244 
7.4 Discussion………………………………………………………...……………  249 
 
8.0 CHAPTER EIGTH: GENERAL DISCUSSION………..…………………..  252 
8.1 General discussion………………….………………….……………………….  252 
List of references………………….………………………….…………………….  259 
Appendix 1- Patient Information Sheet and Consent Form.…….………………….  i 
Appendix 2- ISTH Bleeding Assessment Tool.…………………………………….  ix 
Appendix 3- List of known 357 platelet related genes…….……………………….  xxviii 
Appendix 4- RPFT Questionnaire form and Feedback responses……………….….  xxx 
List of figures 
xi 
 
LIST OF FIGURES 
 
CHAPTER ONE……………………………………………….………………………….. 1 
1.1 Stages in platelet plug formation…….…………………………………………….……  6 
1.2 Example of an aggregation trace obtained with Lumi-LTA…….……………………… 36 
1.3 Map showing the UK-GAPP study collaboration network…………………………….. 42 
 
CHAPTER TWO………………………………………………………………………….. 43 
2.1 GAPP approach to investigate patients with platelet disorders………………………… 44 
2.2 Bioinformatics pipeline used to analysis WES data……………………………….…… 61 
 
CHAPTER THREE…………………………………………………….………………….. 63 
3.1 Overall number of participants recruited in the GAPP study……….…………………...  66 
3.2 Gander distribution among patients recruited to the GAPP study….…………………… 67 
3.3 Age distribution amongst patients recruited in the GAPP study……..………………….. 68 
3.4 Summary of blood samples referred to the GAPP study………………………..………. 69 
3.5 Summary of platelet function results from each haemophilia centre….…………..…….. 70 
3.6 Measurement of platelet count in whole blood from healthy controls and patients....….. 73 
3.7 Measurement of platelet count in PRP from healthy controls and patients……….…..… 74 
3.8 Measurement of MPV values in whole blood from healthy controls and patients…....… 75 
3.9 ATP secretion values in PRP in response to PAR-1 100 µM from healthy controls and 
patients……………………………………………………………...……………………….. 76 
3.10 Comparison between normal and abnormal platelet aggregation results identified 
among patients recruited in into the GAPP study……………….…….…………………….. 78 
3.11 Distribution of platelet function defects among 206 patients recruited into the GAPP 
study……………………………………………………………...………………………….  79 
3.12 Overall number of participants recruited among patients with normal platelet count and 
patients with thrombocytopenia…………………………..……….………………………… 81 
3.13 Age distribution amongst patients with normal platelet count and those with 
thrombocytopenia………………………………………………………………………..….. 82 
3.14 Distribution between male and female among patients with normal platelet count and 
patients with thrombocytopenia………………………………….……….…………………. 83 
3.15 Measurement of platelet count in whole blood among healthy controls (n=116), 
patients with normal platelet count and patients with thrombocytopenia.…….………...…… 85 
3.16 Measurement of PRP platelet count among patients with normal platelet count and 
patients with thrombocytopenia…………………………………….……………………….. 86 
3.17 Measurement of MPV in whole blood among patients with normal platelet count and 
patients with thrombocytopenia……………………………….……………..………………  87 
3.18 Overall comparisons between number of samples found to have no platelet defect and 
samples with platelet defects among patients with normal platelet count and patients with 
thrombocytopenia…………………………………………….…….……………………….. 89 
List of figures 
xii 
 
3.19 Classification of platelet function defects among patients with normal platelet count 
and patients with thrombocytopenia………………………………………………………… 90 
3.20 Measurement of ATP secretion values among healthy controls patients with normal 
platelet count and patients with thrombocytopenia………………………….……………… 91 
3.21 Association between the ISTH BAT score and the presence of a platelet function defect 
on lumi-LTA…………………………………………………...………….………………… 93 
3.22 Comparison of ISTH BAT score between male and female patients…………….……. 94 
3.23 Association between the ISTH BAT score and the type of platelet function defect on 
lumi-LTA……………………………………………………………...…………………….. 95 
3.24 Comparison of ISTH BAT score between patients with normal and low platelet count 
in whole blood………………………………………………………………………………. 96 
3.25 ROC analysis of platelet function defects by lumi-LTA and the ISTH BAT score..….. 98 
3.26 Demographics and summary of platelet phenotyping of family members with normal 
platelet count and thrombocytopenia………………………………...……………….…….. 101 
3.27 Demographicsand summary of platelet phenotyping of family members with a variety 
of platelet counts…………………...….……………………………………………………. 102 
3.28 Representative traces from a patient with Gi signalling defect………………...……… 104 
3.29 Representative traces from a patient with cyclooxygenase pathway defect……….….. 106 
3.30 Representative traces from a patient with a dual defect (cyclooxygenase pathway and 
Gi signalling defects)………….……………………….……………………….…………… 108 
3.31 Representative traces from a patient with dense granular secretion defect….….……... 110 
CHAPTER FOUR…………………………………………………………….…………… 117 
4.1 Pedigree from family one investigated for bleeding disorders……………...…………..  137 
4.2 Electropherograms of sanger analysis from four members of family one showing the 
nucleotide change in comparison with a control…………………..………….……………..  141 
4.3 Pedigree from family two presenting the inheritance of VPS39 mutation………...…… 143 
4.4 Analysis of VPS39 gene mutation found in all four members of family………...……..  146 
CHAPTER FIVE………………………………………………………………………….. 154 
5.1 MEA typical normal aggregation curves and the analytical parameters…….…………. 156 
5.2 Correlation between MEA and whole blood platelet counts…………………………… 161 
5.3 Correlation between Lumi-LTA and PRP counts…………………………….………… 162 
5.4 Summary of results from patients with normal and abnormal results detected by Lumi-
LTA or MEA………………………………………………..……………...………………. 164 
5.5 Classification of patients with various platelet function defects detected by lumi-LTA 
and MEA………………………………………………………………...…………………..  164 
5.6 Summary of results from patients with normal and abnormal results detected by Lumi-
LTA and MEA using an identical panel of agonists…………………….………...………..  168 
5.7 Correlations between MEA and lumi-LTA in after stimulation with, ADP 10 μM, 
Collagen 3 µg/ml, PAR-1 peptide 100 µM and Arachidonic Acid 0.5 mM……….………. 169 
List of figures 
xiii 
 
CHAPTER SIX…………………………………………………...……………………….. 179 
6.1 T-TAS typical normal flow pressure curves and the analytical parameters collected for 
quantification…………………………………………………………………….…………. 182 
6.2 Measurements of blood from healthy controls using the PL chip…………..………….. 184 
6.3 Measurements of blood from healthy controls using the AR chip……………...……… 185 
6.4 Distribution of repeat measurements of 1 sample obtained from a healthy subject on the 
PL chip………………………………..………………………………….…………………. 189 
6.5 Distribution of repeat measurements of the same sample from 1 healthy control on the 
AR chip………………………………………………………………..……………………. 190 
6.6 Effects of the antiplatelet agent ticagrelor on PL chip measurements……...………….. 194 
6.7 Effects of the antiplatelet agent ticagrelor on AR chip measurements………...………..  195 
6.8 Effects of rivaroxaban on AR chip measurements……………….…………………….. 196 
6.9 Measurement of thrombus formation with whole blood from healthy controls and 
patients in the PL chip (1000 s-1)………………………..…………………………………. 198 
6.10 Summary of overall patients results analysed on lumi-LTA and T-TAS……………... 199 
6.11 Measurements of thrombus formation in the PL-chip (1000 s−1) within samples from 
patients found to have no platelet defect by Lumi-LTA…………………………………… 201 
6.12 Measurement of thrombus formation in the PL-chip (1000 s−1) within samples from 
patients with platelet defects defined by lumi-LTA………..………………………………. 202 
6.13 Classification of platelet function defects among patients detected by lumi-LTA and 
T-TAS………………………………………….…………………………………………… 204 
6.14 Measurement of thrombus formation in the PL-chip (1000 s−1) within samples from 
patients with thrombocytopenia……………….….………………………………………… 206 
6.15 Summary of an overall comparison between normal and abnormal results detected by 
lumi-LTA and T-TAS from patients with thrombocytopenia….........……………………… 207 
6.16 Distribution of thrombus formation values in blood from WT mice tested in the PL-
chip……………….……………….……….……….…….………………………………….  209 
6.17 Measurements of thrombus formation within the PL-chip (1000 s−1) with blood from 
humans and WT mice……….…………………….………………………………………...   212 
6.18 Measurements of thrombus formation within AR-chip (240 s−1) with blood from 
humans and WT mice………….…………….……………………………………………… 213 
6.19 Measurements of thrombus formation in blood from WT and CD148 knockout mice 
within the PL-chip (1000 s−1)………………..……..………………………………………. 216 
6.20 Measurements of thrombus formation in blood from WT and CD148 knockout mice 
within the AR-chip (240 s−1)…………………...………………….………………………. 217 
 
 
5.8 Summary of results from patients detected by Lumi-LTA and MEA using a specific 
agonists…………………………………..…………………….……………………………   171 
5.9 Patients with aggregation responses by MEA from patients with low ATP secretion 
values and thrombocytopenia…………………………...………………………………….. 174 
  
List of figures 
xiv 
 
6.21 Measurements of thrombus formation in blood samples from WT mice and CSK 
knockout mice within the PL-chip (1000 s−1)……………….…………………………….. 218 
6.22 Measurements of thrombus formation with blood from WT and CSK KO mice within 
the AR-chip (240 s−1)………………..………………...…..…………………………….….  219 
6.23 Measurements of thrombus formation in blood from WT and double KO (CD148 and 
CSK) mice within the PL-chip (1000 s−1)……………………….….………..……….….… 220 
6.24 Measurements of thrombus formation in blood samples from WT and double KO 
(CD148 + CSK) mice within the AR-chip (240 s−1)……………………….………………   221 
 
CHAPTER SEVEN……………………………………………..………………………… 227 
7.1 P-selectin and CD63 expression measured by RPFT in healthy controls with control 
baseline and after stimulation with various platelet agonists………………………………. 232 
7.2 P-selectin measured by RPFT in healthy controls and patients after stimulation with 
various platelet agonists……………………………………………………………………..  234 
7.3 CD63 measured by RPFT in healthy controls and patients after stimulation with various 
platelet agonists……………………………………….……..……………………………… 235 
7.4 Classification of patients’ results analysed by lumi-LTA and RPFT. ……...…………..  236 
7.5 Classification of overall patient results showing normal and abnormals in comparison 
between samples detected by P-selectin, CD63 and lumi-LTA……….…………………… 239 
7.6 P-selectin and CD63 measured by RPFT in patients with a defect in Gi pathway as 
determined by lumi-LTA…………………………………………………………………....  242 
7.7 P-selectin and CD63 measured by RPFT in patients with a defect in dense granular 
secretion as determined by lumi-LTA……………………………………………………… 243 
7.8 P-selectin and CD63 measured by RPFT in patients with a defect in cyclooxygenase 
pathway as determined by lumi-LTA…………….…………………………………………  245 
7.9 P-selectin and CD63 measured by RPFT in patients with a multiple defects as 
determined by lumi-LTA……………………………………………………………………  246 
7.10 P-selectin and CD63 expression measured by RPFT in patients with false positive 
















LIST OF TABLES 
 
CHAPTER ONE…………………………..………….…………………………………… 1 
1.1 Major platelet agonists and their surface receptors…………………………………….. 9 
1.2 Brief reference guide on inherited platelet disorders……..……………………………. 30 
 
CHAPTER TWO………………………………………………………….……………… 43 
2.1 Panel of agonists and concentrations used to perform lumi-LTA within the GAPP 
study……………………………..…………………………………………………….…… 46 
2.2 Panel of agonists and concentrations used to perform Platelet Aggregation using Whole 
Blood Multiplate Aggregometer within the GAPP study………………….……..………… 46 
 
CHAPTER THREE………………………………………………………………………. 63 
3.1 Summary of platelet parameters and ATP secretion values obtained from healthy 
controls and patients…………………………………………….………………………….  72 
3.2 Comparison of platelet parameters and ATP secretion values between patients with 
normal platelet count and patients with thrombocytopenia………..………………………. 84 
3.3 A comparison study to analyse the ISTH BAT score of 11 and over in predicting the 
presence of a platelet defect on lumi-LTA……………..…………………………………..  99 
 
CHAPTER FOUR……………………………………...…………………………………. 117 
4.1 Demographics of 25 patients that were analysed by genetic testing…….……………...  121 
4.2 Summary of pathogenicity prediction and classification of the variants identified in 
patients with a Gi defect………………..…………..…………...…………………………..  126 
4.3 Summary of pathogenicity prediction and classification of the variants identified in two 
patients with dual defects and one patient with PAR-1 receptor defect.…………………….  128 
4.4 Summary of pathogenicity prediction and classification of the variants identified in 
patients with cyclooxygenase pathway defect……………….……….……………………..  132 
4.5 Summary of defect in genes that were identified in more than one patient..…………... 135 
 
CHAPTER FIVE…………………………...…………….……………………………….. 154 
5.1 Summary of platelet parameters and ATP secretion values obtained from healthy 
controls and patients……………….……………………...………...………………………  158 
5.2 Summary of MEA results with various agonists obtained from whole blood from 
healthy controls…………………………………….……….………………………………  159 
5.3 Analysis of the overall agreement between MEA and lumi-LTA in patient samples…. 165 
5.4 Comparison between lumi-LTA and MEA on overall results, patients with 
thrombocytopenia and patients with reduced ATP secretion by lumi-LTA…..…………… 173 
 
 






CHAPTER SIX………………………..………………………………………………….. 179 
6.1 T-TAS measurements in the PL chip using three different shear rates obtained from 
healthy controls……………………………………..……………………………………… 186 
6.2 T-TAS measurements in the AR chip using two different shear rates obtained from 
healthy controls…….………………………………………………………………………. 187 
6.3 Intra-assay coefficients of variation (CV) in PL chip measurements obtained from a 
healthy control…………….……………..…………………….……………………………  191 
6.4 Intra-assay coefficients of variation (CV) in AR chip measurements obtained from a 
healthy control……………………………………………….……..………………………. 192 
6.5 Analysis of the agreement between the T-TAS and lumi-LTA in patient samples....….. 200 
6.6 T-TAS measurements in samples from WT mice performed on both PL and AR chips 
using different shear rates…………………………………….….……….………………… 210 
 
CHAPTER SEVEN…………………………………….…………………………………. 227 
7.1 List of RPFT kits distributed to 6 haemophilia centres……..…….…………………….  230 
7.2 Summary of p-selectin and CD63 expression measured with RPFT in samples from 
healthy controls after stimulation with various agonists…….….…….……………………..  231 
7.3 Overall classification of results by lumi-LTA and RPFT in patient samples….…..…….. 238 
7.3 Classification of RPFT results in patient samples comparing between lumi-LTA and P-









 CHAPTER ONE: GENERAL INTRODUCTION 
1.1Platelet physiology 
1.1.1 Overview 
Platelets are small enucleate blood cells with a diameter of 2-3 µm. They are produced in large 
numbers in the bone marrow by mature megakaryocytes (MKs) with a production rate of 
approximately 100 x 109 platelets per day to maintain a normal circulating count of (150–400) 
× 109 platelets per litre of blood. The lifespan of platelets is estimated to be 7-10 days after 
which they are eliminated by the reticulo-endothelial system (Ghoshal and Bhattacharyya, 
2014).  
The history of discovery of platelets is dated as early as 1780 when Hewson described very 
small undefined particles in the blood (Hewson, 1780).  Throughout the 1800s a number of 
other scientists described platelets with a variety of different names, morphology and diameter. 
Moreover, understanding of their origin, significance and function had stimulated much debate 
(Gazzaniga and Ottini, 2001). In 1882 an Italian pathologist Giulio Bizzozero described 
platelets as the third distinctive cellular element of circulating blood but unrelated to 
erythrocytes and leukocytes. Remarkably, Bizzozero also demonstrated that platelets were vital 
for both haemostasis and thrombosis by using microscopy to study their interactions with sites 
of vessel wall injury within the circulating blood of living animals (Bizzozero, 1882).  
1.1.2 Platelet formation 
The formation of platelets is unique as they arise from the cytoplasmic fragmentation of MKs, 
the precursor cell reside within the bone marrow (Vainchenker et al., 2013). This process, also 







the cytokine thrombopoietin (TPO) where the MK undergoes maturation through the process 
of endomitosis to amplify its deoxyribonucleic acid (DNA). This is followed by a rapid 
cytoplasmic expansion phase resulting in a dramatic increase in protein biosynthesis and 
organelle expansion necessary for mature platelet function and structure (Machlus and Italiano, 
2013). The mature MK then undergoes massive reorganization and transformation of the 
cytoplasm to form elongated pseudopodia known as proplatelets.  Platelet organelles are then 
transported from the cytoplasm of MK to the ends of proplatelets. Individual platelets are then 
shed from proplatelets directly into the circulation (McCormack et al., 2006).  
1.1.3 Platelet morphology 
Platelets can be structurally divided into distinct functional zones. The peripheral zone 
comprises the plasma membrane consisting of a phospholipid bilayer which can then be further 
divided into three areas. 1) The exterior coat which is the site of expression of a wide range of 
surface receptors that trigger platelet activation, adhesion and aggregation. 2) The unit 
membrane is the middle layer of peripheral zone and is rich in phospholipid which is important 
for the interaction with coagulation proteins and 3) The sub-membrane region is an important 
zone for the platelet signalling and intracellular trafficking (Gresele et al., 2002).   
The sol-gel zone is composed of the cytoplasmic matrix with a cytoskeleton that supports the 
discoid shape of resting platelet. The cytoskeleton also plays essential roles in supporting 
platelet shape change, pseudopod extension, internal contraction and secretion during platelet 
activation (White and Krivit, 1967). The open canalicular system (OCS) is another important 
element in platelet structure. This membrane system plays an essential role in providing entry 







exterior. Furthermore the OCS serves as a reservoir for many platelet receptors (Ghoshal and 
Bhattacharyya, 2014).  
 The other important feature of platelet structure is the organelle zone. It has two major storage 
granules, the alpha and the dense granules. The alpha granules are the most abundant. Each 
platelet can contain up to 80 alpha granules which make up roughly 10% of its volume. Alpha 
granules contain over 300 proteins including membrane P-Selectin, von Willebrand factor 
(VWF) and fibrinogen which are important molecules for adhesion and aggregation (Blair and 
Flaumenhaft, 2009). The dense granules are the storage sites of non-metabolic elements such 
adenosine diphosphate (ADP), adenosine triphosphate (ATP), serotonin, polyphosphate and 
calcium which are secreted during platelet release reaction and play important roles in recruiting 
other platelets during aggregation (Ruiz et al., 2004).  In addition, platelets also have other types 
of granules called lysosomes which contain hydrolytic enzymes such as acid phosphatase 
(Gresele et al., 2002). Despite the absence of nuclei, platelets contain mitochondria which are 
responsible for the cell metabolic and energy requirements (Ghoshal and Bhattacharyya, 2014). 
1.1.4 Platelet function 
The primary function of platelets is to arrest bleeding. When a blood vessel is damaged, 
platelets are immediately recruited to the site of injury where they accumulate to prevent 
excesssive blood loss. During this process platelets undergo adhesion, activation, aggregation 
and provide a surface for efficient thrombin generation (Kitchen et al., 2009). In addtion, 
platelets are also known to involve in several other physiologic and pathologic processes such 
as wound healing, thrombosis, inflammation, anti-microbial host defence and tumour growth 









Adhesion is generally viewed as the first step of platelet function and it is essential process in 
response to vascular injury.  In normal vessels platelets are marginated towards the vessel wall 
and the vascular endothelium. However, when vascular injury occurs sub-endothelial matrix 
components are exposed which initiate platelet adhesion (Ruggeri and Mendolicchio, 2007). 
The process of adhesion is mediated by various platelet receptors. For example the initial step 
involves interactions between platelet GPIb-IX-V complexes with the A1 domain of 
immobilized VWF, Although this binding is insufficient for firm adhesion it does promote 
transient tethering of platelets especially in areas of the highest levels of shear stress (Savage et 
al., 1996). For firm adhesion, platelets are required to directly bind to collagen; this process is 
mediated through the collagen receptors including GPVI and integrin α2β1. The binding of 
platelets to collagen particularly through GPVI receptor is essential for platelet activation and 
signal transduction (Massberg et al., 2003).   
1.1.4.2 Activation and spreading  
Following adhesion, platelets undergo activation. The binding of agonists to their specific 
surface receptors lead to a series of events resulting in increases of the intracytoplasmic 
concentration of calcium ions released from intracellular stores and calcium influx through the 
plasma membrane (Rumbaut and Thiagarajan, 2010). As a result, platelets will undergo a 
number of structural and functional changes that lead to platelet activation. 
Upon activation platelets undergo a dramatic reorganisation of the cytoskeleton leading to the 
transformation from disks to fully spread cells. This process also increases platelet surface area 







interactions of the platelet with the surface and with other platelets. It also provides a solid base 
for thrombus formation (Lee et al., 2012).     
 1.1.4.3 Secretion and aggregation  
Aggregation is initiated by activated platelets when they secret soluble agonists such ADP and 
serotonin from their dense granules and by the generation of thromboxane A2 (TxA2). This 
recruits additional platelets to form platelet aggregates necessary for the formation of a stable 
haemostatic plug. The process of aggregation is mediated mainly through the αIIbβ3 complex, 
an integrin receptor present on the plasma membrane, the OCS and α-granules (Rumbaut and 
Thiagarajan, 2010). In resting platelets αIIbβ3 exists as an inactive form. However, upon platelet 
activation the molecule becomes active by undergoing a conformational change and can then 
bind plasma fibrinogen and VWF thus promoting bridging of adjacent platelets together (Varga-
Szabo et al., 2008).  
1.1.4.4 Platelet pro-coagulant activity 
Activated platelets are also known to contribute to the overall coagulation process. Firstly they 
provide a surface for the generation of thrombin  through exposure of the procoagulant 
phospholipid, phosphatidlyserine (PS) from the inner  leaflet of the platelet surface,  and 
secondly through the release of additional coagulation factors from the α-granules leading to a 
local increase in the concentration of coagulation factors. Generation of thrombin therefore 
occurs at the appropriate site and further reinforces platelet activation and thrombus growth 









Figure 1.1 Stages in platelet plug formation. (A) Prior to vascular injury, normal endothelial 
cells release NO and PGI2 to maintain platelet quiescence (B) Vessel wall injury exposes 
platelets to the subendothelial matrix to promote platelet adhesion to immobilised VWF and 
collagen. (C) Activated platelets then further release molecules that mediate platelet recruitment 
to promote thrombus formation. (D) Development of the platelet plug at the site of injury by 
procoagulant activity and stabilization with fibrin. ADP, adenosine diphosphate; NO, nitric 













1.2 Platelet receptors, agonists and signalling pathways  
Platelet membranes express a wide variety of surface receptors through which platelets interact 
with and sense their immediate environment. By interacting with specific agonists, surface 
receptors play an important role in promoting platelet function both in health and disease 















Effect and physiological role 
 




GPVI Major signalling receptor for 
collagen 
 
α2β1 Supports adhesion by collagen 
 
Fibrinogen αIIbβ3 Aggregation, spreading and clot 
retraction 
Fibronectin  α5β1,  αIIbβ3 Adhesion through α5β1 
 
Laminin α6β1 Adhesion 
 





Adrenaline  α2 Positive feedback agonist 
 









Maturation of megakaryocytes, 










PAF PAF Positive feedback agonist 
 
Prostacyclin (PGI2) IP Inhibition of platelet activation 
 
Thromboxane A2 TP Major positive feedback agonist 
 




















P2Y1 Early role in platelet activation 
 
P2Y12 Major positive feedback receptor 
 

















CD40 and αIIbβ3 
Interaction with other blood cells, 
role in immune response and in 
inflammation 
P-selectin glycoprotein 
ligand 1 (PSGL-1) 
 
P-selectin Interaction with leukocytes 







Role in foetal vascular development 
 
Possible role in platelet activation 
and in atherosclerosis and cancer 
progression (?)  
EphrinB1 
 
EphA4 and EphB1 Late events in platelet activation (?) 




Sky, Axl and Mer Supports platelet activation (?) 
Table 1.1: Major platelet agonists and their surface receptors. (?) Indicates a putative 








Platelet signaling pathways 
1.2.1 G protein–coupled receptors 
G protein–coupled receptors (GPCRs) are the largest class and most diverse family of 
membrane proteins. They also referred as heptahelical receptors as they are composed of seven-
transmembrane domains. They activate heterotrimeric G proteins that consist of α, β, and γ 
subunits. GPCRs use four classes of α units (Gαs Gαq Gαi and Gα12/13), each of which promote 
different signaling effects.  Activation of these receptors cause dissociation of guanosine 
diphosphate (GDP) from the α-subunit and facilitates guanosine-5’- triphosphate (GTP) 
binding. As a result, the α subunit is dissociated from the βγ subunit complex and can bind to 
target proteins such as adenylyl cyclase and phospholipase Cβ (Kobilka, 2007).  
1.2.1.1 Gi proteins 
Gi proteins are highly expressed in platelets, with Gαz and Gαi2   being the most abundant of this 
group. The proteins are so-named for their inhibitory effect on adenylyl cyclases resulting in a 
decreased level of cAMP. In addition, Gi proteins are also involved in activation of 
phosphoinositide 3-kinases (PI3K). P2Y12 and α2-adrenoceptor are the two major Gi-coupled 
proteins on the platelet. However, neither of these receptors mediates activation in washed 
platelets alone, and in platelet rich plasma they both require the presence of feedback mediators 
to fully activate platelets.   
P2Y12 is an ADP receptor that highly expressed in human platelets and to a smaller extent in 
other tissue such as neurones. In response to activation, P2Y12 downstream signaling amplifies 
the platelet response induced by ADP and other agonists by inhibiting cAMP synthesis through 







sustainable platelet aggregation (Gurbel et al., 2015). Bleeding disorders associated with 
P2Y12 defect will be discussed in Section 1.3.4. P2Y12 is also an important therapeutic target 
for antiplatelet drugs (e.g. Clopidogrel, ticagrelor, prasugrel and cangrelor) that are used in the 
treatment and prevention of cardiovascular disease (Falcao et al., 2013).  
1.2.1.2 Gq proteins 
Two forms of the Gq protein has been identified (Gq and G11), however, only Gq is expressed 
in platelets (Offermanns, 2006). Gq protein coupled receptors activate platelets through 
regulation of phospholipase C-β (PLCβ) isoforms to generate inositol-1,4,5-trisphosphate and 
1,2 diacylglycerol. These second messengers cause calcium mobilization from intracellular 
stores and activation of protein kinase C (Offermanns et al., 1997, Zhang and Shi, 2016). The 
receptors in human platelets that are coupled through Gq protein are the P2Y1 ADP receptor, 
the TXA2 receptor and the two thrombin receptors, PAR-1 and PAR-4. 
The P2Y1 receptor is expressed on human platelets in relatively low levels of approximately 
150 copies per platelet (Gachet, 2012). When activated by ADP, P2Y1 plays a critical role in 
synergising with the P2Y12 receptor to mediate full aggregation of platelets. No patients have 
so far been reported with excessive bleeding associated with mutations within the P2Y1 
receptor. On the other hand, Leon et al performed studies on mouse platelets and showed that 
P2Y1 receptor plays an essential role in mediating thrombus formation. This finding suggests 
that a drug that targeting P2Y1 receptor could prevent thrombotic events without bleeding 
complications (Leon et al., 1999). 
The thromboxane receptor consists of two isoforms, α and β, although the α form is the only 







specific G protein-coupled receptors to mediate the stimulation of phospholipase C and an 
increase in intracellular concentrations of inositol 1,4,5-triphosphate and diacylglycerol. The 
formation of inositol 1,4,5-triphosphate results in an increase in the cytosolic concentration of 
Ca2+ whereas release of diacylglycerol leads to PKC activation. Moreover the signalling of 
thromboxane receptor α stimulates the formation of cAMP (Paul et al., 1999). The physiological 
ligand for thromboxane receptor is thromboxane A2 (TxA2). It is synthesized by the action of 
enzyme cyclooxygenase 1 (COX-1). COX-1 converts arachidonic acid released within 
activated platelets to form TxA2 which acts as a positive feedback mediator in platelet 
recruitment and aggregation (Caughey et al., 2001). When activated, the thromboxane receptor 
also synergises with the P2Y12 receptor that enables it to play such a critical role as a feedback 
receptor in the control of platelet activation. Targeting the TxA2 pathway using aspirin has 
also proven to be an effective method in preventing platelet activation.  Aspirin prevents 
platelet activation by irreversibly inhibiting platelet COX-1 and thus inhibits thrombus 
formation. As such, aspirin is widely used in the treatment and prevention of cardiovascular 
disease. Studies on both human (Kamae et al., 2011, Mumford et al., 2010) and animal models 
(Thomas et al., 1998) showed that defects in the thromboxane receptor are associated with 
bleeding tendencies. 
PAR-1 and PAR-4 are two protease-activated receptors that are also expressed on human 
platelets. PAR-1 is not expressed on mouse platelets; instead, PAR-3 is expressed in addition 
to the PAR-4 (Sokolova and Reiser, 2008). PAR receptors are activated by thrombin, a soluble 
protease that cleaves the N-terminus of these receptors exposing a tethered peptide ligand that 
mediates receptor activation. Once activated, the thrombin receptors activate Gq and G13 







thrombin plays an essential role in platelet activation; moreover it also provides a feedback via 
the coagulation system through promotion of the surface expression of negatively charged 
phospholipids. The thrombin receptors can also be activated using short thrombin receptor 
activating peptides (TRAPs) that mimic thrombin action without the need for receptor cleavage. 
TRAP is a useful agonist as it makes it possible to activate platelets in platelet rich plasma 
(PRP) independent of coagulation (Coughlin, 2000). No patients have so far being identified 
with mutation in the PAR receptors that are associated with excess bleeding. However, 
evidence suggests that polymorphisms on PAR receptors could affect platelet responses to 
thrombin (Muehlschlegel et al., 2012, Patel et al., 2014). 
1.2.2 Glycoprotein receptors 
Platelets express also a wide range of membrane glycoproteins (GP) receptors that play 
essential role in the activation and aggregation of platelets. Among these are GPIb-IX-V that 
tethers VWF, the GPVI-FcR-γ chain complex which is the major signalling receptor for 
collagen and the platelet integrin αIIbβ3 a receptor for a number of adhesive proteins include 
fibrinogen and VWF.   
GPVI is a membrane glycoprotein receptor of the immunoglobulin (Ig) family which has two 
extracellular Ig domains. In 1989, Moroi et al were the first to propose GPVI as a major collagen 
receptor on platelets when they showed that GPVI autoantibody from patient with autoimmune 
thrombocytopenia caused abnormal platelet aggregation to collagen (Moroi et al., 1989). Seven 
years later, GPVI became widely recognised as a major signalling receptor for collagen when 
Gibbins et al. demonstrated the association of GPVI with FcR-γ in the platelet membrane 
(Gibbins et al., 1996). The FcR-γ chain contains an immunotyrosine-based activation motif 







(Gibbins et al., 1998). The expression of GPVI on platelet surface is tightly regulated with 
around 4,000-6,000 copies per platelet (Best et al., 2003). Collagen interacts with GPVI with 
relative low affinity; however, the interaction is strengthened by binding to α2β1 in a two step 
process (Nieswandt and Watson, 2003). GPVI can also be activated specifically without the 
association with α2β1 using a synthetic Collagen-related peptide (CRP). Moreover, the CRP is 
able to induce shape change and aggregation even in the absence of ADP and TxA2 (Jarvis et 
al., 2002).  Deficiency of GPVI and FcR-γ is associated with a prolonged bleeding phenotype 
in mice (Kalia et al., 2008, Kato et al., 2003). Mice injected with GPVI antibody are also 
protected from lethal thrombogenic injections of adrenaline and collagen (Nieswandt et al., 
2001). Bleeding diatheses have also been reported in a number of patients with inherited or 
acquired defects of GPVI receptor (Moroi et al., 1989, Hermans et al., 2009, Dumont et al., 
2009, Boylan et al., 2004).  
The GPIb-IX-V complex is a VWF receptor that exclusively expressed on platelets and MK. It 
is the second most abundant receptor complex on human platelets composed of two subunits of 
GPIbα, GPIbβ, and GPIX and one subunit of GPV (Li and Emsley, 2013).The GP Ib-IX-V 
complex plays two essential roles in platelet function; firstly, when it binds to immobilized 
VWF it mediates tethering of platelets at intermediate and high shear rate and also induces weak 
signalling leading to activation of the integrin αIIbβ3. Secondly, it also facilitates high affinity 
binding and promotes the ability of thrombin to activate platelets (Dormann et al., 2000). 
Qualitative and quantitative defects of GPIbα, GPIbβ, and GPIX subunits causes  Bernard-
Soulier syndrome (BSS) a severe bleeding disorder characterized by thrombocytopenia and 







The integrin αIIbβ3 is a fibrinogen receptor that is exclusively expressed on platelets and MK. It 
is the most abundant receptor on platelets and consists of α and β subunits (Bussel et al., 2000). 
In circulating platelets the αIIbβ3 is maintained in a resting state but transforms into high affinity 
form (activated) following platelet activation. When activated, αIIbβ3 binds to a number of 
adhesive proteins such as fibrinogen and VWF to promote platelet aggregation and thrombus 
formation (Li et al., 2010). Defects of either subunit of αIIbβ3 causes Glanzmann thrombasthenia 
(GT) a bleeding disorder characterized by severe bleeding with a normal platelet count (Nurden 
and Caen, 1974).  (GT is described in details in section 1.3.2). 
1.2.3 Other platelet receptors 
Platelets are found to express a number of other receptors that have been shown to induce 
platelet activation, although in some cases their physiological role is not understood. Some 
examples of these are shown below 
C-type lectin-like receptor-2 (CLEC-2): is a transmembrane platelet receptor that activates 
platelet through a hemi-immunoreceptor tyrosine-based activation motif (hemITAM). CLEC2 
can be activated by either its physiological ligand podoplanin or by a snake venom rhodocytin 
(Suzuki-Inoue et al., 2011). 
Platelet P2X1 receptor: is  a ligand-gated ion channel, when activated by ATP, P2X1 increases  
intracellular Ca2+  levels to mediate platelet activation (Mahaut-Smith et al., 2011). 
cMpl: is a receptor for TPO, a cytokine that regulates the differentiation and maturation of MK. 
Defects within the cMpl receptor cause congenital amegakaryocytic thrombocytopenia (Ihara, 
2000). Mutations in JAK2, a cMpl signalling molecule also lead to myeloproliferative disorders 







1.3 Platelet disorders 
Defects within platelets can impair platelet function resulting in bleeding symptoms of varying 
severity ranging from mild to excessive bleeding which can be life threatening (Watson et al., 
2013). Inherited platelet function disorders are catagorised depending on the type of 
abnormality as described below. An additional list of platelet disorders is summarized in table 
1.2.  
1.3.1 Defects in platelet adhesion 
BSS and Platelet-type von Willebrand disease (PT-VWD) are two inherited disorders resulting 
in impaired platelet interaction with subendothelium.  BSS was first described in 1948 by two 
French haematologists Jean Bernard and Jean Pierre Soulier (Bernard and Soulier, 1948). It is 
characterized by either complete absence of or a dysfunctional GPIb-IX-V receptor complex 
resulting in defective adhesion of platelets to the subendothelium (Nurden and Caen, 1975). 
BSS is a very rare disorder which is transmitted in an autosomal recessive manner. A variety 
of mutations of the GPIb-α, GPIb-β, or GPIX genes have been described which is most likely 
to be responsible for its heterogeneity (Sumitha et al., 2011).  The disease classically presents 
with a severe phenotype characterized by severe bleeding episodes, thrombocytopenia, and very 
large platelets. The bleeding symptoms of BSS may range from mild to life-threatening, most 
commonly epistaxis, ecchymosis, cutaneous and gingival bleeding, menorrhagia and 
gastrointestinal bleeding (Berndt and Andrews, 2011). A number of laboratory tests can be used 
to identify BSS. Full blood counting reveals macrothrombocytopenia and evaluation of the 
peripheral blood smears often confirms the presence of large platelets. Platelet aggregation 
studies will show a defective response to ristocetin which cannot be corrected by addition of 







Aggregometry will also reveal a slow response with low doses of thrombin but normal 
aggregation to all other agonists. A confirmatory test is normally performed using flow 
cytometry to demonstrate a specific deficiency of GPIbα on platelet surface (Pham and Wang, 
2007).  
PT-VWD or pseudo VWD was first described in 1982 by Weiss and Miller (Weiss et al., 1982, 
Miller and Castella, 1982). It is a rare autosomal dominant bleeding disorder characterized by 
gain-of-function mutations within the platelet membrane glycoprotein Ibα (GPIbα) receptor. 
As a consequence enhanced binding of VWF to GpIb not only causes  thrombocytopenia but a 
loss of high molecular weight (HMW) VWF multimers (Favaloro, 2008). Glycoprotein Ibα 
which contains the binding domain of VWF is the largest component of the platelet membrane 
receptor complex GPIb/IX/V, which consists of four subunits (GPIbα, GPIbβ, GPIX, GPV) 
(Berndt and Andrews, 2011). Mutations such as missense (Gly233Val, Met239Val and 
Gly233Ser) and various gene deletions in the Glycoprotein Ibα gene that give rise to PT-VWD 
have been described.  Bleeding symptoms of individuals with PT-VWD include mild-to-
moderate mucocutaneous bleeding and haemorrhage after surgical procedures. Diagnosis of 
PT-VWD is challenging because laboratory features such as a prolonged bleeding time and 
mild macrothrombocytopenia are very similar to those of type 2B VWD (Othman, 2007). Other 
findings include the presence of platelet clumps on blood smears, enhanced platelet aggregation 
in response to low dose of ristocetin and loss of HMW VWF multimers in plasma. 
1.3.2 Defects in platelet aggregation 
GT is a rare autosomal recessive bleeding disorder. It is characterized by a deficiency or 







interaction with plasma fibrinogen (Nurden, 2006). GT was first described in 1918 by 
Glanzmann as “hereditary haemorrhagic thrombasthenia” due  to a prolonged bleeding time 
and an isolated, rather than clumped, appearance of platelets on a peripheral blood smear 
(Glanzmann, 1918). Then in 1956 the disease was reviewed by Braunsteiner and Pakesch who 
described GT as “platelets of normal size that failed to spread onto a surface and did not support 
clot retraction” (Braunsteiner and Pakesch, 1956). In 1964, Caen et al, established the current 
diagnostic features of GT including the absence of platelet aggregation (Caen et al., 1966).  In 
a recent study of a large group of patients with GT, Nurden et al. found 78 genetic variants on 
ITGA2B and ITGB3 genes that associated with GT (Nurden et al., 2015). 
1.3.3 Defects in platelet secretion  
Storage pool disease (SPD) and release defects are heterogeneous group of disorders resulting 
from a deficiency of platelet granules or a dysfunction in the release of granules upon platelet 
activation. SPD is associated with a defect of α or δ granules but in rarely both (Bolton-Maggs 
et al., 2006b).   
 
Dense granule defects: Inherited disorders of dense granules are also referred to as δ-storage 
pool deficiencies. They may occur as isolated disorders or in combination with other genetic 
conditions. The pathogenesis of SPD is variable associated with bleeding of various severities. 
SPD can be diagnosed using platelet aggregation, measurement of dense granules content and 
electron microscopy (Fitch-Tewfik and Flaumenhaft, 2013). The following two conditions have 








Hermansky-Pudlak syndrome (HPS): is a rare heterogeneous group of autosomal 
recessive disorders. It was first described in Czechoslovakia in 1959 (Hermansky and 
Pudlak, 1959) but large numbers of patients are now found in Puerto Rico. Eight different 
mutations associated with HPS have so far been identified in nine human genes. These are 
HPS1, AP3B1/HPS2, HPS3, HPS4, HPS5, HPS6, HPS7 (Di Pietro and Dell'Angelica, 2005), 
HPS8 (Morgan et al., 2006) and HPS9 (Wei, 2006). There is a marked phenotype of 
oculocutaneous albinism associated with a bleeding diathesis and pulmonary disease. In 
addition, some forms of HPS can cause dysfunction in the lungs, heart, intestine or kidneys 
(Pierson et al., 2006). The bleeding diatheses in patients with HPS are caused by a lack of 
dense granules in platelets resulting in impaired platelet aggregation and secretion.   
Chediak-Higashi syndrome (CHS): is a rare childhood disorder inherited as autosomal 
recessive. Patients with CHS are characterized by variable degrees of oculocutaneous albinism 
due to defects in the melanosomes and a tendency for mild bleeding due to a defect in platelet 
dense granules and recurrent infection due to impaired neutrophil function (Maaloul et al., 
2016). In most cases CHS is identified in early childhood and is fatal if not treated. In human, 
63 mutations have so far been descried on CHS1/LYST gene that are involved in lysosomal 
trafficking (Lozano et al., 2014).  
α granular defects  
α–granule deficiency can be caused by mutations or deletions of specific transcription factors 
involved in vesicular trafficking resulting in markedly decreased or absent α–granules and their 







haemostasis resulting in a variable severity of bleeding (Blair and Flaumenhaft, 2009). The 
following conditions have been described to be associated with α–granule deficiencies.  
Grey platelet syndrome (GPS): It is an inherited disorder initially described in 
1971(Raccuglia, 1971). The name GPS comes from the gray appearance of the platelets in the 
peripheral blood smear as a result of the absence of α-granules and their constituents. Lack of 
α-granular constituents in GPS is caused by abnormal formation of the granule membranes. 
Patients with GPS present with bleeding symptoms due to a defect in platelet α-granules, and 
thrombocytopenia due to a reduction in platelet survival. The key laboratory finding in patients 
with GPS is the presence of macrothrombocytopenia and appearance of grey platelets on the 
blood smear. Clot retraction can also be abnormal with variable platelet function (Nurden and 
Nurden, 2007). The genetic defect causing GPS has only recently been identified where 
different mutations in the neurobeachin-like 2 (NBEAL2) gene were detected in patients with 
GPS (Albers et al., 2011). Several other causative mutations related to GPS have also been 
identified within the NBEAL2 gene that encodes a BEACH domain (Gunay-Aygun et al., 2011, 
Kahr et al., 2011). In 2007, Tubman et al reported an X-linked pattern of inheritance in GATA1 
gene on a family with GPS (Tubman et al., 2007).   
Paris-Trousseau and Jacobsen syndromes: Paris-Trousseau thrombocytopenia and Jacobsen 
syndrome are two closely related disorders associated with an increased bleeding tendency, 
thrombocytopenia, heart defects, skeletal abnormalities and mental retardation. The syndrome 
is inherited as autosomal dominant/recessive due to a deletion of a variable region on 
chromosome 11q that including the FLI1 (Jones et al., 1994). Although the two conditions are 







Jacobsen syndrome present with marked dense body deficiency indicating a storage pool defect 
(White, 2007). 
Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: is a rare but fatal autosomal 
recessive inherited disorder associated with arthrogryposis, renal tubular dysfunction and 
cholestasis. It is normally diagnosed early in life presenting with impaired liver and kidney 
function, muscular and bone deformities, and bleeding problems. The syndrome is caused by 
mutations in the VPS33B or VIPAR gene (Gissen et al., 2006). Peripheral blood smears and 
electron microscopy are valuable tools for diagnosis of ARC where platelets appear large, pale 
and agranulated (Kim et al., 2010). 
Quebec platelet disorder (QPD) is a unique platelet function defect which differs from most 
platelet disorders.  It is associated with a gain of function mutation resulting in enhanced 
fibrinolysis due to increased expression and storage of urokinase plasminogen activator (uPA) 
in platelet alpha granules.  QPD is autosomal dominant resulting from duplicate mutation of 
PLAU gene (Diamandis et al., 2009). Patients with QPD present with spontaneous haematuria 
and delayed-onset bleeding, following trauma or dental procedures which responds only to 
treatment with fibrinolytic inhibitors (McKay et al., 2004). Laboratory tests may often but not 
always show a reduced platelet count and variable responses to different platelet agonist 
typically in response to epinephrine (Hayward and Rivard, 2011).  
α, δ – storage pool deficiency: is described as a rare inherited platelet abnormality where both 
α and δ granules are deficient. It was first described by Weiss and his colleagues when they 
found patients with variable deficiency of α and δ granules (Weiss et al., 1979). Patients may 







deficient in α and δ granules. However a severe decrease in both granules has also been reported 
in four members of the same family (White et al., 2007).  
1.3.4 Defects in agonist receptors  
Interaction between platelet membrane receptors and various agonists promote platelet 
activation and function. Deficiency or dysfunction of these receptors can also result in impaired 
platelet function resulting in bleeding of variable severities. 
Defects in ADP receptors  
ADP was the first known aggregating agent and was identified in 1961. Although itself a weak 
agonist, ADP plays a key role in haemostasis and thrombosis. There are three distinct receptors 
expressed on human platelets known to interact with adenine nucleotides; P2Y1 and P2Y12 bind 
ADP while P2X1 binds ATP. No human mutation of the P2Y1 has so far been identified. 
However, a patient with a history of bleeding following surgery and three members of his family 
were described to be associated with low levels of P2Y1 mRNA suggestive of deficiency in 
P2Y1 gene transcription (Cattaneo, 2011a). In contrast the pathology associated with platelet 
P2Y12 receptor has been well-characterized. Patients with either congenital 
deficiency/dysfunction of P2Y12 have so far been described. Congenital deficiencies are 
typically autosomal recessive and were first described in 1992 in a patient with a lifelong history 
of excessive bleeding. The genetic defect of this patient displayed homozygous base pair 
deletions in the coding sequence resulting in frameshifts leading to introduction of premature 
stop codons and a lack of demonstrable P2Y12 expression (Cattaneo et al., 1992, Cattaneo et 
al., 2003). Subsequently, similar patients were later described worldwide (Shiraga et al., 2005, 







aggregation, a failure of ADP to inhibit PGE-stimulated adenylyl cyclase and a reduction in the 
number of binding sites for radiolabelled ADP analogues. As a result patients present with 
lifelong history of mucosal bleeding, easy bruising, and excessive bleeding following 
haemostatic challenge.  
Patients with heterozygous mutations of P2Y12 demonstrate mild bleeding with abnormal 
aggregation only to low dose ADP and borderline ATP secretion.  Hollopeter et al., reported a 
patient with a heterozygous mutation of P2Y12. Although the coding sequence on the second 
allele appeared to be normal the patient’s platelets demonstrate a complete absence of P2Y12 
receptors (Nurden et al., 1995, Hollopeter et al., 2001).  
A congenital bleeding disorder associated with expression of dysfunction P2Y12 was also 
reported in a patient with a lifelong history of easy bruising and excessive blood loss in response 
to surgery and trauma (Cattaneo et al., 2003). Platelets from this patient display reduced and 
reversible aggregation in response to 20 μM ADP. Genetic analysis demonstrated a mutation in 
two different allies (G256A and C265T) resulting in normal expression of P2Y12 but with 
altered functionality (Cattaneo, 2011b). A heterozygous mutation in P2Y12 was also detected in 
a patient diagnosed with type 1 VWD disease.  This finding suggests that platelet function 
defects can also be found in conjunction with other bleeding disorders (Daly et al., 2009). A 
mutation within the platelet P2X1 receptor was also described in a patient with a severe bleeding 
disorder. The mutation was caused by a deletion of three nucleotides resulting in the loss of one 
leucine residue located between residues 351–353 of the P2X channel (Oury et al., 2000).   
Defects in collagen receptor (α2β1) 
Integrin α2β1 is also known as platelet glycoprotein GP) Ia/IIa and is expressed on various types 







platelet collagen receptor that initiates the platelet adhesion to collagen and contribute 
synergistically to platelet function (Jung and Moroi, 2001). Defects in α2β1 have been reported 
in several unrelated patients with mucocutaneous bleeding symptoms. Platelets from a patient 
reported by Nieuwenhuis et al failed to aggregate in response to collagen. These platelets only 
expressed 15-25% of GP Ia and adhesion to subendothelial surfaces was impaired at both low 
and high shear rates (Nieuwenhuis et al., 1985, Nieuwenhuis et al., 1986). Kehrel et al. reported 
a defect of both thrombospondin and GP Ia in a patient with a severe lifelong bleeding tendency. 
Platelets from this patient demonstrate a markedly reduced aggregation in response to collagen 
(Kehrel et al., 1988). In an animal model, Habart et al also reported that platelets from α2β1 
deficient mice fail to respond to collagen but no haemostatic defects were observed (Habart et 
al., 2013) 
Defects in collagen receptor (GPVI) 
A number of cases of inherited GPVI deficiencies have also been reported. The majority of 
these patients present with mild mucocutaneous bleeding and are characterised by platelets that 
fail to respond to collagen stimulation. A non-functional form of GPVI was described in a 13 
year old female presenting with ecchymosis and a life long history of bleeding. Her platelets 
failed to response to collagen, convulxin and the CRP but aggregated normally in response to 
all standard agonists. Genetic analysis showed a compound heterozygous 16bp deletion and a 
missense mutation S175N (Hermans et al., 2009). A hereditary disorder in GPVI signalling was 
also reported on a 60 year old female presenting with a history of excessive bleeding since 
childhood, a life-threatening post traumatic haemorrhage and impaired immune function. Her 
platelets showed normal expression of GPVI/FcRγ receptors but failed to response to collagen, 







In contrast, several patients with acquired dysfunction of GPVI have been reported. Most of 
these cases are also associated with autoimmune disorders such as systemic lupus 
erythematosus (SLE) and immune thrombocytopenic purpura (ITP) (Arthur et al., 2007). One 
patient however with severe deficiency of GPVI was also diagnosed with GPS but a genetic 
defect of GPVI was not detected (Nurden et al., 2004). A list of platelet disorders is summarized 










Disease Inheritance Defective gene Laboratory and other findings 
Platelet adhesion Platelet-type von 
Willebrand’s disease 
Autosomal dominant GP1BA (17p13.2) Thrombocytopenia                         
Diminished or absent large vWF 
multimers Enhanced ristocetin 
agglutination (occurs at low 
concentrations), which is corrected when 
donor platelets and patient plasma are used 
in mixing studies 




Thrombocytopenia with increased MPV 
Anomalies in components of the GPIb–V–
IX complex                                          




P2Y12 ADP receptor Autosomal recessive 
(mild phenotype in 
heterozygotes) 
P2Y12 (3q25.1) Platelet count normal                            
Platelet aggregation: normal P2Y1 
receptor-driven responses; shape change 
and transient aggregation 
GPVI collagen receptor Autosomal recessive GP6 (19q13.42) Platelet count normal                            
Platelet aggregation: absent with GPVI-
specific agonists, e.g. convulxin and 
collagen-related peptide; and marked 









 Thromboxane A2 receptor Autosomal recessive 
(mild phenotype in 
heterozygotes) 
TBXA2R (19p13.3) Platelet count normal                            
Platelet aggregation in response to 
arachidonic acid and U44619 reduced in 
heterozygotes to and presumed to be 





Autosomal recessive ITGA2B (17q21.32) 
ITGB3 (17q21.32) 
 
Normal platelet count, size, and 
morphology. Presents with severe bleeding 
symptoms in early life                                                
Absent platelet aggregation with all 
agonists; agglutination in response to 
ristocetin is normal. Flow cytometry with 
CD41 and CD61 antibodies may show 
reduced levels of either GPIIb or GPIIIa 
Platelet secretion Hermansky–Pudlak 
syndrome 
Autosomal recessive HPS1 (10q24.2) 
HPS2/AP3B1 
(5q14.1) 
HPS3 (3q24),   
HPS4 (22q12.1) 
HPS5 (11p14)  
HPS6 (10q24.32) 
HPS7/dysbindin 
(6p22.3)            
HPS8 (19q13.32) 
HPS9 (15q21.1) 
Platelet count normal                                
Skin and hair hypopigmentation    
Reduced/absent δ-granules on electron 
microscopy                       












Autosomal recessive CHS1/LYST (1q42) Platelet count normal                               
Skin and hair hypopigmentation 
Immunodeficiency                                   
Giant inclusions in granulocytes and their 
precursors                                           
Reduced or irregular α-granules 
Lumiaggregometry: reduced/absent ATP 
release 
Gray platelet syndrome Autosomal recessive NBEAL2 (3p21.31) Thrombocytopenia                            
Increased MPV with platelet anisocytosis 





 X-linked  GATA1 (Xp11.23) Thrombocytopenia with increased MPV 





Autosomal recessive VPS33B (15q261) 
VIPAS39 (14q24.3) 
 
Thrombocytopenia with increased MPV 
Severe multisystem syndrome, leading to 




Autosomal dominant FLI1 (11q24.1-24.3) Thrombocytopenia with increased MPV 
Developmental delay and facial 
abnormalities 
Quebec platelet disorder Autosomal dominant PLAU (10q22.2) Platelet count at low end of normal range    
α-Granule protein degradation         
Increased urokinase-type plasminogen 













also known as 
Sebastian/Fechtner/Epstein 
syndrome) 
Autosomal dominant MYH9 (22q12-13) Thrombocytopenia with increased MPV 
Döhle-like inclusions in neutrophils 





X-linked WAS (Xp11.23)  
 
Thrombocytopenia with small platelets 
Immunodeficiency and eczema (in 
Wiskott–Aldrich syndrome) 




X-linked FLNa (Xq28) Thrombocytopenia with raised MPV and 
abnormal platelet morphology       
Abnormal distribution of platelet filamin 
on confocal microscopy 
Actin disorders  Autosomal dominant ACTIN1  (14q2401) Thrombocytopenia with raised MPV and 
platelet anisocytosis                           
Patients either have moderate bleeding 




Scott syndrome Autosomal recessive TMEM16F (12q12-
13.11) 
Platelet count normal                              
Anomalies in scramblases translocating 
negatively charged phospholipids on the 
plasma membranes                                       









Table 1.2: Brief reference guide on inherited platelet disorders. Adopted from (Watson et al., 2013). ADP: Adenosine diphosphate; ATP: 









Autosomal recessive MPL (1p34) Severe thrombocytopenia         
Pancytopenia                                       
Absent megakaryocytes in bone marrow  
Increased plasma thrombopoietin levels  
Thrombocytopenia with 
absent radius syndrome 
Autosomal recessive MASTL, ACBD5, 
ANKRD26 (all 
10p12.1) 
Severe thrombocytopenia                  
Normal platelet morphology 
Shortened/absent radii in forearm 
THC2 Autosomal dominant MASTL, ACBD5, 
ANKRD26 (all 
10p12.1) 
Mild to moderate thrombocytopenia with 
normal MPV                                      
Platelets deficient in GPIa and α-granules 
Platelet aggregation normal               
Possible dysmegakaryopoiesis  
Familial platelet disorder 
with predisposition to 
acute myelogenous 
leukemia (FPD/AML) 
Autosomal dominant RUNX1 (21q22.12) Mild thrombocytopenia, with possible 
raised MPV                                    
Abnormal aggregation in response to 
multiple agonists  
GFI1B mutation  Autosomal dominant GFI1B (single 
nucleotide insertion 
in exon 7, c880-
881insC – results in 
frameshift mutation)  
Red cell anisopoikilocytosis           
Moderate thrombocytopenia, raised MPV 
Decrease in platelet alpha granules    
Absent aggregation with collagen, +/- 






1.4 Diagnosis of Platelet Function disorders 
Characterisation of individual platelet function defects (PFD) is crucial for optimal treatment 
and management as frequent minor bleeding episodes can have a significant impact on quality 
of life. Diagnosis of severe forms of PFD such as GT and BSS is less challenging because 
bleeding symptoms are not only usually identified early in life, but the laboratory tests are often 
straightforward due to the absence of aggregation and ristocetin induced agglutination, 
respectively, and lack of expression of the glycoproteins by flow cytometry (Daly et al., 2014).   
In contrast, diagnosis of the milder forms of PFD is complex and challenging for several 
reasons. Firstly, bleeding symptoms are often not recognised in early age as patients are not 
usually exposed to severe haemostatic challenges e.g. surgery, injury, and childbirth. In 
addition, similarities of bleeding patterns are often observed in other haemostatic disorders 
including type 1 VWD (Watson et al., 2013).   
Individuals with inherited PFD normally present with a history of prolonged bleeding during 
injury, unexplained bruising, excessive mucocutaneous bleeding such as epistaxis and 
menorrhagia, bleeding after dental extraction and post-partum bleeding (Daly et al., 2014). A 
proper assessment of this clinical history is therefore very important to exclude acquired platelet 
disorders or any other haemostatic abnormalities. This is now commonly performed by using 
the Bleeding Assessment Tool (BAT), a standardised questionnaire which assesses the bleeding 
symptoms of the patient which are then recorded as a single bleeding score (Rodeghiero et al., 
2010b).  Additional investigations such as platelet count and morphology with screening tests 
to evaluate coagulation abnormalities and VWD are also performed to rule out non-platelet 








1.4.1 Phenotyping of platelet function disorders  
 
The history of platelet function testing (PFT) started in 1910 with the development of the 
bleeding time (BT) by the Duke procedure. The BT was designed to evaluate in vivo primary 
hemostasis by assessing the platelets ability to form a hemostatic plug by recording the time 
taken for a small skin wound to stop bleeding.  The test was once considered as an important 
tool used to test platelet function. The use of BT however has dramatically reduced due to lack 
of sensitivity and poor reproducibility, and it is no longer recommended (Harrison et al., 2011). 
The in vitro bleeding time or PFA-100 is another screening test which measures high shear 
dependent platelet function and it is currently used in many laboratories to investigate PFD. 
Similarly to the BT, the PFA-100 has poor sensitivity and can also be significantly affected by 
number of factors such as platelet count, haematocrit and VWF levels (Bolton-Maggs et al., 
2006a).  
Over the years a wide range of platelet function assays have been developed, some of which 
focus on response to specific agonist and some of which measure a global output of platelet 
activation.  Light transmission aggregometry (LTA) is the most widely used methodology for 
assessing platelet function disorders. It simply measures the change in light transmission in real 
time when agonists are added to platelet-rich plasma or washed platelets. The basic principle of 
LTA has not changed in over 50 years since it was first described by Born in early1960s (Born, 
1962),  even though modern day aggregometers are much smaller and easy to use (Harrison, 
2009). In addition, the secretion of platelet ATP from the dense granules can also be 
simultaneously monitored using luminescence by addition of luciferin–luciferase reagents 
during the aggregation process (Dawood et al., 2007, Miller, 1984). An example trace of lumi-






important in diagnosis of HPS and other dense granule secretory and release disorders. 
However, a defect in ATP secretion cannot discriminate between abnormal granule formation 
or defects in platelet signalling, so additional investigations are usually necessary for 
confirmation including e.g. electron microscopy, serotonin uptake and measurement of total 
platelet ATP/ADP content (Watson et al., 2013). LTA is also time consuming, requires large 
blood volumes for preparation of PRP, needs to be performed on fresh samples and requires 
expertise for correct performance and interpretation. Furthermore, platelet responses can also 
be transiently affected by diet and intake of certain medications which may also inhibit various 
activation pathways (Daly et al., 2014). 
In an attempt to improve platelet function testing and overcome the major drawbacks of LTA, 
a number of alternative platelet function techniques have been developed in the past few 
decades. Each places a differing emphasis on the role of platelet aggregation and feedback 
pathways, which explains the subtle distinction in their results. Impedance platelet 
aggregometry (IPA) is designed to evaluate platelet function in whole blood to avoid further 
platelet processing before analysis (Toth et al., 2006). The technique measures the changes in 
resistance or impedance between two electrodes as platelets adhere and aggregate in response 
to platelet agonists (Cardinal and Flower, 1980). The use of whole blood also offers an 
advantage of rapid testing of platelets within physiological conditions without centrifugation 
and lower blood volume requirements. The use of IPA has regained popularity in the last decade 
after the development of Multiple Electrode Aggregometry (MEA) and has been widely used 
for the monitoring of anti-platelet therapy (Lenk and Spannagl, 2013). (MEA will be discussed 






A number of platelet function instruments have now become available that are simple to use and 
can be utilized at patient’s bedside as point of care tests to be used as perioperative tools or for 
monitoring the efficacy of anti-platelet therapies. The experience of these techniques in 
identifying inherited platelet function defects however is limited (Harrison, 2009). The impact 
cone and plate(let) analyser (CPA) is a fully automated, simple and rapid to use device that 
monitors platelet adhesion to a polystyrene plate. The platelet adhesion is dependent on VWF, 
fibrinogen binding, and the platelet receptors GPIb and integrin αIIbβ3 (Pakala and Waksman, 
2011). Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) measure real 
time clot formation using an oscillating cup and oscillating pin (respectively) that holds whole 
blood samples. The assays provide a complete profile of clot formation by measuring fibrin 
formation, clot development, clot stability and fibrinolysis (Choi et al., 2014). Platelets can also 
be pre activated using arachidonic acid and ADP, thus, making the techniques theoretically 
suitable to monitor antiplatelet therapy (Sambu and Curzen, 2011, Lordkipanidze et al., 2013).  
The drawback of these techniques is their lack of sensitivity and they are time consuming, and 
their utility is currently limited to the monitoring of surgical haemostasis (Choi et al., 2014). 
The VerifyNow is a rapid fully automated device which monitors the platelets interaction with 
the fibrinogen-coated beads in whole blood, resulting in agglutination. Currently, three types of 
cartridges are available for use with VerifyNow for the monitoring of the effect of aspirin, P2Y12 
inhibitors and αIIbβ3 antagonists (Pakala and Waksman, 2011). The Total Thrombus-formation 
Analysis System (T-TAS) is another whole blood platelet function test that has recently being 
developed. It is a microchip-based analytical system that evaluates total thrombus formation 
under flow conditions using two types of microchips with thrombogenic surfaces (Hosokawa et 






Flow cytometry is now increasingly used in assessing patients with suspected platelet function 
defects. It is mainly used to measure the levels of glycoproteins and activation markers on the 
platelet surface. For example, measurement of the levels of glycoprotein receptors GPIb and 
αIIbβ3 integrin can confirm or exclude BSS and GT respectively, while measurement of the 
levels of P-selectin and CD63 can verify platelet activation (Harrison et al., 2011). Flow 
cytometry is also used to assess platelet procoagulant function by measuring PS expression, 
which facilitates thrombin generation. Following stimulation with strong agonists such collagen 
or calcium ionophore, platelets expose PS which can be measured using specialized probes such 
as Annexin V or  lactadherin (Presseizen et al., 2002). 
The main advantage of flow cytometry is that is only requires a small volume of whole blood.  
However, the technique is restricted to specialized laboratories and can only be performed on a 
fresh blood sample. This drawback can now be potentially overcome by using remote activation 
and fixing solutions (Platelet Solutions, Nottingham UK) which can activate and then stabilize 
whole blood samples for up to 9 days (Dovlatova, 2015). Samples are taken and stimulated at 
point of blood collection, fixed and sent to a central laboratory for analysis. This approach of 
platelet function disorder diagnosis has recently being evaluated and has demonstrated a good 
agreement with lumiaggregometry (Dovlatova et al., 2014). However, the test has yet to be 
evaluated as a potential clinical screening test in clinics. (Platelet solutions will be discussed in 












Figure 1.2: Example of an aggregation trace obtained with Lumi-LTA. Aggregation traces after 
addition of a high concentration of ADP (30 μM) from a healthy individual (control) and a 
patient with a suspected homozygous P2Y12 mutation. Control aggregation is shown in red, and 
the patient aggregation shown in blue. Control ATP secretion is shown in green, patient ATP 
secretion shown in black. The patient shows reversible aggregation with absent ATP secretion. 








1.4.2 Genotyping of Platelet Function disorders  
Genetic testing has contributed greatly to the understanding of cellular and molecular 
mechanisms that facilitate the identification and confirmation of heritable disorders. The utility 
of genetic testing increased after the invention of Sanger sequencing by Edward Sanger (Sanger 
et al., 1977). The technique was developed in 1975 and was considered the gold standard for 
genetic testing for more than two decades. Sanger sequencing was utilised within the 13-year-
long Human Genome Project (HGP) that was completed in 2003 (Lander et al., 2001, 
Sachidanandam et al., 2001). Following the HGP, other genetic projects such as the 1000 
Genomes Project were designed with goal of providing a valuable resource to the research 
community on human genetic variation (Bunimov et al., 2013).  
Due to the drawbacks of Sanger sequencing related to cost and low throughput, demand for 
new sequencing methods that are cheaper and faster increased rapidly. This demand led to the 
development of next-generation sequencing (NGS) that was first introduced in 2005 (Shendure 
and Ji, 2008).  Several NGS platforms are now available which perform high throughput 
sequencing that allows an entire genome to be sequenced in less than a day. The two most 
commonly used platforms in research and clinical labs today are the Life Technologies Ion 
Torrent Personal Genome Machine (PGM) and the illumina MiSeq. Despite that the sequencing 
technique of each of NGS platform is unique, the basic methodology applied in these two 
techniques are similar which includes template preparation, sequencing and imaging, and data 
analysis (Metzker, 2010). The inventions of NGS platforms with high-throughput and low cost 
made sequencing accessible to more laboratories and has resulted  in the rapidly increasing 







Two analytic strategies are applied in NGS to identify genetic variants, whole-genome 
sequencing (WGS) and whole-exome sequencing (WES). Despite that the WGS is the most 
straightforward and comprehensive strategy, its application is still limited due to the relatively 
high cost. Moreover, about 85% of disease-related mutations that underlie Mendelian disorders 
found within the exons only constitute approximately 1% of the human genome (Majewski et 
al., 2011). As such, the WES approach alone can therefore provide sufficient data to uncover 
the majority of rare and potential genetic disorders. In 2009, Ng et al published the first report 
of selectively sequencing the whole exome (Ng et al., 2009). In the same year Choi et al used 
WES to correct the diagnosis of a patient who was previously misdiagnosed with Bartter 
syndrome (Choi et al., 2009). In another case, a patient with oculocutaneous albinism (OCA) 
and neutropenia was misdiagnosed with HPS type 2. WES however identified two disease 
causative mutations, one (SLC45A2) related to OCA and the other (G6PC3) related to 
neutropenia (Cullinane et al., 2011). 
There are several drawbacks of WES that still limits its global application; the most obvious is 
the inability of WES to assess the impact of non-coding regions since the method is only limited 
to coding and splice site variants (Rabbani et al., 2014). In addition, the method remains time 
consuming and the coverage of regions of interest is still limited despite recent improvements. 
Furthermore, due to the difficulty of WES in identifying repeat mutations and copy number 
variants, any possible disease-causing variants need to be confirmed and validated by Sanger 
sequencing, thus making WES less cost effective (Sanger et al., 1977, Majewski et al., 2011).  
WGS and WES are becoming increasingly popular and widely used in the diagnosis of PFD for 
the aim of identifying variants that are responsible for the clinical presentation of patients. 
However, phenotypic variants among individuals with PFD makes it difficult to generate 






individuals. A number of research groups now use NSG each with different approaches to 
identify the causes of unexplained bleeding. The Genotyping and Phenotyping of Platelets 
(GAPP) study run from the University of Birmingham aims to categorise a patient’s disease 
through a combination of extensive platelet phenotyping and WES to determine their genotype 
(Watson et al., 2010) (The GAPP study is described in details in section 1.5). The BRIDGE 
Consortium-Bleeding and Platelet Disorders (BPDs) study (B20) takes an alternative approach 
to identify novel and known variants in a large patient cohort (>1000 donors) by combining 
WGS and WES with annotation with Human Phenotype Ontology (HPO) terms 
(https://bridgestudy.medschl.cam.ac.uk/bpd.shtml). Other smaller groups in Italy and USA also 
use WES in diagnosis of patients with inherited thrombocytopenia.   
The first successful study of NGS in patients with PFDs was published in 2011 when Albers 
CA et al identified NBEAL2 as the causative gene for GPS (Albers et al., 2011). Several other 
causative mutations within the NBEAL2 gene that encodes a BEACH domain have been 
identified in individuals with GPS (Gunay-Aygun et al., 2011). With a collaboration of several 
research groups more novel variants have recently being discovered in patients with an 
unexplained bleeding (Maclachlan et al., 2017b).    
The power of NGS has led to major advances in the ability to sequence large amounts of genetic 
material that facilitate the identification and confirmation of PFD. One of the main challenges 
arises however, is the analysis of huge amount of data generated by NGS.  This often requires 
expert interpretation of bioinformatics data and comparison to datasets to identify the causal 
gene and variants among multiple possible variants and link it to disease and function. More 
over the terminologies that are used by bioinformatics datasets to name the identified variants 
often lead to confusion. Standards and guidelines have recently been published by the American 






consensus terminology to describe variants identified in possible disease-causing genes 
(Richards et al., 2015). Another potential challenge is when discovery of incidental or 
secondary findings of genetic variants that are not related to the disease state in question. The 
question is whether clinicians should disclose any secondary findings with potential clinical 
relevance to patients. The ACMG has recently published a statement suggesting that reporting 
of incidental findings to patients should be proceed with caution in related to ethical and social 
concern which could require education and genetic counseling (Green et al., 2013). 
1.5 The Genotyping and Phenotyping of Platelets (GAPP) study 
The United Kingdom Genotyping and Phenotyping of Platelets (GAPP) study was established 
in 2009 with the aim of investigating populations of patients who present with excessive 
bleeding (Watson et al., 2010). Patients with suspected PFD have been recruited from 28 
haemophilia referral centres in the UK which accounts for more than 66% of the overall number 
of Haemophilia Comprehensive care centres (Figure 1.3). The study uses a combination of 
platelet phenotyping and gene sequencing approach to identify candidate mutations underlying 
platelet dysfunction. The ultimate goal is to identify novel gene defects that would provide 
information on genes and proteins involved in normal platelet physiology and would extend 
our understanding of disease pathogenesis.  These findings may lead us to the development of 
new methods in diagnosis and treatment strategies that would minimize risk of bleeding. The 
GAPP study has so far identified several patients with functional disrupting mutations in the 
TxA2 receptor (Mumford et al., 2010) and the P2Y12 ADP receptor (Dawood et al., 2012). 
Furthermore, a novel mutation in the P2Y12 ADP receptor has been reported in a family with 
type 1 VWD (Daly et al., 2009). More recently, mutations in SLFN14, RUNX1 and FLI1 genes 
in patients with thrombocytopenia have been identified through the GAPP study (Fletcher et 






Figure 1.3 Map showing the UK-GAPP study collaboration network. Blue star shows the 
coordinating and central laboratory for measuring phenotypes (Birmingham Platelet Group), Blue 
squares show other central laboratories for measuring phenotypes (Royal Hallamshire Hospital 
[Sheffield] and Bristol Royal Infirmary), Red pins indicate all referring Haemophilia 






1.6 Aims of PhD study 
1. To identify defects in platelet function using Lumi-LTA in patients who exhibit 
abnormal bleeding but have normal platelet counts included in the GAPP study. 
2. To perform genotyping of selected patients found to have an abnormal phenotype 
searching for mutations within specific genes involved in platelet function and 
megakaryopoiesis using Sanger sequencing and whole exome sequencing. 
3. To evaluate the ability of MEA in diagnosing patients with mild bleeding disorders by 
comparison with lumi-LTA  
4. To perform a prospective study using a new remote platelet function test (RPFT) as a 
screening tool for patients with inherited platelet function disorders in comparison with 
lumi-LTA.  
5. To evaluate the utility of the Total Thrombus-formation System (T-TAS) for assessing 
thrombus formation within human and mouse blood.  





CHAPTER TWO: MATERIALS AND METHODS 
2.1 Study approval 
The UK-GAPP study was approved by the National Research Ethics Service Committee of 
West Midlands–Edgbaston (REC reference: 06/MRE07/36) and participants gave written 
informed consent in accordance with the Declaration of Helsinki. This study was registered at 
www.isrctn.org as #ISRCTN 77951167. The GAPP study is also included in the National 
Institute of Health Research Non-Malignant Haematology study portfolio (ID9858). The GAPP 
study approach used in this thesis is summarised in figure 2.1 
  





    
Figure 2.1 GAPP approach to investigate patients with platelet disorders showing initial sample 
collection and lumi-LTA study, in addition to examples of further testing methods Modified 
from (Watson et al., 2010). 





2.2 Materials  
ADP, adrenaline, PGI2, Trisodium citrate, ristocetin and U46619 were purchased from Sigma-
Aldrich (Poole, UK). Arachidonic acid was purchased from Cayman Chemical Company 
(Michigan, USA). The PAR-1 peptide (SFLLRN) was purchased from Severn Biotech 
(Kidderminster, UK) and Collagen was purchased from Takeda (Linz, Austria), CRP from Dr. 
Richard Farndale (Cambridge, UK), and Luciferin Luciferase reagent (Chrono-lume) and ATP 
standard were purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents 
were dissolved in phosphate-buffered saline (PBS) at PH 7.4 and stored as frozen aliquots at 
the concentrations shown in supplementary tables (1 and 2), thawed and diluted in PBS when 
required and kept on ice. Collagen was stored as a concentrated stock at 1 mg/ml as supplied 
by the manufacturer at 4°C and diluted with the special buffer provided. Platelet solution kits 
were purchased from Platelet solutions Ltd (Nottingham, UK). Monoclonal mouse anti-human 
CD61 (Pre CP) antibody and a Mouse IgG1 fluorescence isotype control were purchased from 
Becton, Dickinson and Company (BD Biosciences, Oxford, UK). Monoclonal mouse anti-
human CD63 (FITC) antibody was purchased from Beckman Coulter (High Wycombe, UK) 
and monoclonal mouse anti-human CD62P (FITC) antibody were purchased from Bio-Rad 
Company (Watford, UK). AR chip TC0101, PL chip TC0201, CaCTI TR0101and 3.2% sodium 
citrate were provided by Quadratech Diagnostics Limited (Epsom, UK). 25 μg/ml hirudin blood 
tubes were purchased from Roche Diagnostics (Munich, Germany). 
  






Table 2.1 Panel of agonists and concentrations used to perform Light Transmission 
Aggregometry within the GAPP study  
 
 
Table 2.2 Panel of agonists and concentrations used to perform Platelet Aggregation using 

















3 µM, 10 µM, 30 µM 
and 100 µM 
Sigma-Aldrich A2754 
Adrenaline 100mM 3µM, 10µM  and 30µM Sigma-Aldrich E-4375 




Collagen 1mg/ml 1 µg/ml, 3µg/ml and 10 
µg/ml 
Takeda-Austria  
PAR-1 peptide  
(TRAP-SFLLRN) 
10mM 30 µM and 100 µM Severn Biotech, 
Kidderminster, UK  
Ristocetin 50mg/ml 1.5mg/ml and 2.0mg/ml Sigma-Aldrich R7752 
Secondary Reagents 





















2.5µM and 10µM Sigma-Aldrich A2754 
Arachidonic acid 15mM 0.5mM Cayman Chemical 
10006607 
Collagen 1mg/ml 1 µg/ml and 3µg/ml  Takeda-Austria 
PAR-1 peptide  
(TRAP-SFLLRN) 
10mM 100µM Severn Biotech, 
Kidderminster, UK 





2.3 Patient recruitments and blood sample collection 
2.3.1 Patient recruitment  
Patient recruitment processes for this study were either through regional Comprehensive Care 
Haemophilia centres across the UK or by referring haematologists specialising in bleeding 
disorders. Patients were recruited following a clinical history and subsequent diagnosis of a 
suspected platelet based bleeding disorder. Potential candidates were invited to participant 
dependent upon following specific inclusion and exclusion criteria as set out by the study.  
Inclusion criteria 
a. Aged 0 – 85 years  
b. Abnormal bleeding symptoms compatible with an inherited platelet function disorder  
c. Results from coagulation factors and VWD assays all within local laboratory reference 
interval   
d. Willing to participate and able to provide informed consent 
Exclusion criteria 
a. Patients with existing diagnosis of Glanzmann thrombasthenia, Bernard-Soulier 
syndrome, May Hegglin anomaly or Hermansky-Pudlak syndrome  
b. Patients taking drugs that are known to influence platelet function, including 
nonsteroidal anti-inflammatory drugs, aspirin, clopidogrel, dipyridamole, within 7 days 
of enrolment 
c. Patients having undergone a major surgical procedure within 1 month of enrolment 
d. Patients with chronic renal failure requiring dialysis 
e. Patients with severe anaemia (Haemoglobin < 8g/dl) 





Healthy volunteers were aged 18 years or older and considered healthy if they did not have a 
history of bleeding symptoms or did not require long-term medical therapy. All healthy 
volunteers denied taking drugs known to influence platelet function and had not donated blood 
in the previous two weeks  
All healthy volunteers and patients or their parents gave written informed consent in accordance 
with the GAPP project ethical approval (GAPP, ISRCTN 77951167). Bleeding history of adult 
participants was assessed using the International Society on Thrombosis and Hemostasis 
bleeding assessment tool (ISTH BAT) (The full questionnaire is included in Appendix 2.). This 
score can range from 0-56 in women and 0-48 in men, based on a maximal score of 4 in fourteen 
separate categories assessing different types and severity of bleeding.  
2.3.2 Blood sample collection 
Blood samples (40 ml from adults or 20 ml from children) was obtained from patients and 
anticoagulated with one tenth volume of 0.109 mol/L buffered trisodium citrate in vacutainer 
plastic tubes (Becton Dickinson, Plymouth, UK). An additional 2-3ml blood was also 
anticoagulated within EDTA vacutainer plastic tubes (Becton Dickinson, Plymouth, UK). The 
same volume of blood was also collected from a healthy control at the same time in each centre. 
In the majority of cases, blood samples were then transported by courier to Birmingham and 









2.4 Blood sample preparation and processing 
2.4.1 Whole Blood Platelet Counting using the Sysmex XN-1000 Analyser  
EDTA blood samples from patients and controls were analysed using the XN-1000 whole blood 
counter (Sysmex UK, Milton Keynes). The XN-1000 is a state of the art whole blood analyser 
that is capable of rapidly producing a full blood differential cell count from 88 µl of human 
blood. The analyser has a set of unique platelet parameters including three platelet counts: 
platelet impedance (PLT-I), platelet optical (PLT-O) and platelet fluorescence (PLT-F) counts, 
mean platelet volume (MPV) and the immature platelet fraction (IPF). Platelet counts and MPV 
were recorded for each patient while IPF were recorded for patients with low platelet counts. 
The platelet parameters were compared against reference ranges established from 40 healthy 
normal controls. Daily quality control of the instrument was checked using commercial fixed 
samples with known cell counts (Xn Check, Sysmex, Milton Keynes, UK.). The analyser was 
also enrolled into an External Quality control scheme (UKNEQAS, Watford, UK). 
2.4.2 Preparation of PRP and PPP 
Platelet Rich Plasma (PRP) was prepared by centrifuging the citrated blood samples at 200g for 
20 minutes. PRP was transferred carefully into a separate clean 15 ml falcon tube, capped and 
stored upright at room temperature. Platelet-poor plasma (PPP) was then prepared by further 
centrifugation at 1,000g for 10 minutes and transferred into a separate clean 15 ml falcon tube, 
capped and stored upright at room temperature. About 2-3ml of the buffy coat layer was also 
taken from the same tubes and stored at -80oC for DNA analysis.  
 
 





2.4.3 Platelet counting of PRP 
An impedance analyser (Coulter Z2 Beckman Coulter, High Wycombe, Bucks, UK) was 
utilised to count the platelets within the PRP by diluting 5 µl of PRP into 10 ml of fresh isoton 
II diluent (Beckman Coulter, Bucks, UK). The platelets were counted in triplicate and the mean 
was calculated and recorded as x108/ml along with the MPV.  
2.4.4 Storage of platelets for protein analysis  
Patient and control samples were diluted to platelet counts of 3 x 108/ml. 1 µl of 1 µg/mL 
prostacyclin (Cayman Chemical Company, Michigan, USA) was then added and the samples 
were centrifuged at 1000 g for 10 minutes. The supernatants were then removed and the pellets 
re-suspended in 1 ml PBS. 1 µl of 1 µg/mL prostacyclin was again added and the platelets 
centrifuged at 13,000 rpm for 2 minutes. The supernatant was again removed and the pellets 
were re-suspended into 600 µl of 10% sample buffer (or 300 µl 20% sample buffer + 300 µl 
tyrodes buffer) and then boiled at 100˚C for 5 minutes. The samples were then centrifuged for 
a short time at 5000 rpm and then stored at -80˚C. All samples were coded and dated.  
2.5 Platelet function assay in whole blood 
Whole blood impedance aggregometry was performed on citrated blood using Multiple 
Electrode aggregometry (MEA) (Multiplate, Roche Diagnostics Munich, Germany) consisting 
of 5 reaction channels, an integrated computer, and guided automatic pipetting. The tests were 
performed in disposable ready-to-use test cells with 2 independent sensor units consisting of 2 
silver-coated highly conductive copper electrodes. In each test cuvette, mixed whole citrated 
blood (300 μl) was diluted, 1:1 vol/vol, with 0.9% Saline solution and incubated at 37°C for 3 
minutes before addition of 30 μl of each agonist. Platelets were stimulated with ADP (10 and 





2.5 µM), PAR-1 peptide (100 µM), Arachidonic acid (0.5 mM) and collagen (1 and 3 µg/mL).  
During the test platelets adhere and aggregate upon the sensor electrode surfaces resulting in an 
increase in the electrical resistance (impedance) and the signals arerecorded and plotted as an 
aggregometry trace. The total aggregation measured with this device is quantified as area under 
the curve (AUC) or AU*min. 
2.6 Platelet function assay in platelet-rich plasma 
Light transmission aggregometry (LTA) was carried out in all patients and controls within 6 
hours of preparation of the PRP, as described previously (Dawood et al., 2007). Aggregation 
studies were performed by using a dual Chrono-log lumiaggregometer (model 460 VS, 
Havertown, PA, USA) in 400 μl mini cuvettes and stirred at 1,000 rpm at 37°C. The 100% line 
was set using autologous platelet-poor plasma (PPP) and the 0% baseline established with 
native undiluted PRP.   After one minute incubation and stirring to set the baseline,  platelets 
were stimulated with either ADP (10, 30, and 100 µM), adrenaline (10, 30, and 100 µM), 
arachidonic acid (0.5, 1, and 1.5 mM), U46619 (1 and 3 mM), collagen (1 and 3 µg/mL), CRP 
(1, 3, and 10 µg/mL), PAR-1 peptide (10, 30 and 100 µM), or ristocetin (1.5 and 2 mg/mL).  
Platelet aggregation was monitored by measuring the change in optical density (or light 
transmittance) over 5 minutes after addition of the agonists and the maximal percentage of 
aggregation was recorded. Traces were monitored for longer times if required depending upon 
the responses observed. 
2.7 Measurement of platelet ATP secretion 
ATP secretion from platelet dense granules was also assessed simultaneously by 
Lumiaggregometry using the luciferase reagent (Chronolume). 30 µl of Luciferin reagent was 





added to the PRP and incubated for 1 minute. Platelets were then stimulated with the agonists 
listed above and monitored for 5 minutes followed by addition of 4 l of ATP standard (2 µM) 
to facilitate internal calibration. Secreted ATP levels were calculated by measuring the maximal 
amplitude of luminescence during the aggregation to PAR-1 peptide and comparing to the 
standard. A cut-off point of 0.65 nmol ATP / 1x108 platelets was established from previously 
studied healthy volunteers as the 5th percentile for secretion in response to maximal stimulation 
with PAR-1 peptide. 
2.8 Evaluation of platelet function using RPFT 
For the RPFT measurements, whole blood samples were collected and processed locally by a 
trained member of staff at each haemophilia centre. Briefly, sodium citrate blood samples were 
pre-warmed and stimulated at 37°C for 5 minutes using four  vials containing either (A) 
arachidonic acid and epinephrine (AA 0.5 mM/Epi 100 μM), (B) saline alone to provide a 
baseline test, (C) adenosine diphosphate with U46619 (ADP 10 μM/U4 1 μM) and (T) thrombin 
receptor activating peptide (TRAP [SFLLRN] 20 μM). Stimulated samples were then fixed 
using 1 ml PAMFix (Platelet Solutions Ltd, Nottingham, UK) and transported at room 
temperature to University of Birmingham by courier and processed within 5 days.  In all cases 
the flow cytometry analysis were performed at the University of Birmingham. 5 μl of the fixed 
whole blood was incubated with 10 μl of diluted antibodies anti-CD61- PerCP (1/8 dilution) 
(BD Biosciences, Oxford, UK) and CD62p-FITC (1/20 dilution) (Bio-Rad, Watford, UK) and 
CD63-FITC (1/20 dilution) (Beckman Coulter, High Wycombe, UK) for 20-30 minutes in the 
dark at room temperature. After incubation, 200 μl of filtered PBS was added and analyzed 
within one hour using an Accuri C6 flow cytometer (BD Biosciences, Oxford, UK). For platelet 
identification a gating was initially setup on the Accuri C6 flow cytometer based on platelet 





size (FSC) and expression of CD61 (SSC). 10,000 events were then acquired on each sample 
and the results of platelet markers expression (p-selectin/CD63) from unstimulated platelets 
were first quantified to set up the baseline reading. The expression of platelet markers (p-
selectin/CD63) after platelet stimulation using specific agonists were then quantified in 
comparison to the baseline reading  and reported as median fluorescence intensity (MFI). 
Platelets stained with FITC mouse IgG (Bio-Rad, Watford, UK) were used as isotype controls 
for nonspecific staining. 
2.9 Evaluation of thrombus formation under flow conditions on human blood 
In vitro thrombus formation was analysed on the T-TAS instrument (Zacros, Fujimori Kogyo 
Co. Ltd., Tokyo, Japan) using two types of microchips, the PL chip (width 40 μm × depth 40 
μm) (containing 25 capillary channels coated with type 1 collagen) and the AR chip (width 300 
µm, depth 60 or 120 µm, length 15 mm) (consisting of a single capillary channel coated with 
collagen and thromboplastin). The PL chip was used to analyse platelet thrombus formation 
(PTF). Briefly, hirudin anticoagulated whole blood (320 µL) was pipetted in the reservoir then 
perfused at 37°C through the PL chip by a pneumatic pump.  After the perfusion of blood was 
initiated, platelets were then activated by the collagen coated on the capillary. The AR chip was 
used to analyse white thrombus formation (WTF). Briefly, citrated whole blood (480 µl) was 
mixed with 20 µl of 0.3 M CaCl2 containing 1.25 mg/mL of Corn Trypsin Inhibitor (CTI) 
immediately before it was pipetted in the reservoir. The re-calcified blood was then perfused at 
37°C through the AR chip by a pneumatic pump.  After the perfusion of blood through the 
capillary was initiated, platelets and the extrinsic coagulation pathway were simultaneously 
activated by collagen and tissue thromboplastin. To prevent the outlet port from clotting, the 
blood is mixed with 25 mM EDTA (pH 10.5). The process of thrombus formation in both chips 





was monitored by flow pressure changes in the capillary using the pressure sensor located 
between the pump and the reservoir.  As thrombus formation proceeded on the coated surface, 
the capillary is gradually occluded, increasing the flow pressure. Based on the flow pressure 
pattern, The following four parameters are used to analyse the results (i) T10 (time to reach 10 
kPa) was defined as the onset of thrombus formation and represents the duration (sec) for the 
flow pressure to increase to 10 kPa from baseline due to partial occlusion of microcapillaries. 
(ii) OT (occlusion time) was defined as the complete occlusion of the capillary, which coincides 
with a pressure of 60 and 80 kPa for the PL and AR chips respectively. (iii) T10–60 for PL chip 
and T10–80 for AR chip were defined as the interval between T10 and OT, representing the 
rate of thrombus growth; (iv) AUC (area under curve) is an area under the flow pressure curve 
(under 60/80 kPa) for 10/30 min after the start of assay for the PL and AR chips respectively. 
AUC is used to quantify a decrease in WTF when OT is not achieved during the time period of 
assay. 
2.9.1 Antithrombotic effects of ticagrelor and rivaroxaban under flow conditions 
Ticagrelor (10 mM) and Rivaroxaban (10 mM) were kindly provided by University of Leeds 
(Leeds, UK). Ticagrelor (final concentration, 10 µM) was incubated either in hirudin or citrate 
anticoagulated blood for 10 min at room temperature. Rivaroxaban (final concentration, 1 µM) 
was incubated in citrate anticoagulated blood for 3-5 min at room temperature. After incubation 
blood were perfused through either the PL chip and/or AR chip within the T-TAS instrument 
as described above.   
2.9.2 Evaluation of thrombus formation under flow conditions on mouse blood 
Mouse blood was tested in the T-TAS in collaboration with the Birmingham platelet signalling 
group led by Professor Yotis A. Senis.  CSK and/or CD148 conditional knockout (KO) mouse 





models were generated by crossing CSKfl/fl (Schmedt et al., 1998) and/or CD148fl/fl (Katsumoto 
et al., 2013) mice with Pf4-Cre (Tiedt et al., 2007) transgenic mice to obtain 
megakaryocyte/platelet-specific knockout mice.  Deletion of loxP-flanked genes in 
megakaryocytes and platelets was achieved by crossing the Pf4-Cre mice to obtain animals 
with homozygous loxP-flanked alleles either without or hemizgous for Cre.  All mice were 
previously backcrossed over ten generations to the C57BL/6 background.  All procedures were 
undertaken with United Kingdom Home Office approval in accordance with the Animals 
(Scientific Procedures) Act of 1986.  Blood sampling was performed by puncture of the inferior 
vena cava in isoflurane-anaesthetized mice and 0.5 and 1.0 mL of blood was collected into 
tubes containing either 3.2% sodium citrate (9 vol blood to 1 vol citrate) or hirudin (final 
concentration, 25 μg/ml).  Haematological parameters were obtained using ABX Pentra 60 
Haematology Analyzer (Horiba ABX, Montpellier, France).  Blood samples were perfused 
through either the PL chip or AR chip on the T-TAS instrument as described above.   
2.10 Genetic analysis 
2.10.1 DNA extraction 
Following separation of PPP, the buffy coats from patients’ blood samples were collected and 
stored at -80°C. Genomic DNA was then isolated from the buffy coat samples and purified as 
recommended by the manufacturer using a Gentra Puregene kit (Qiagen Sciences, Maryland, 
USA). The concentration of the isolated DNA was measured using the Qubit 3.0 Fluorometer 
(Fisher Scientific, Loughborough, UK).  
 
 





2.10.2 Polymerase Chain Reaction (PCR) 
Prior to gene sequencing the patient’s DNA was first amplified by PCR. Oligonucleotide 
primers used for PCR were designed using the online exon primer tool available on Helmholtz 
Center Munich institute of human genetic website (http://ihg.helmholtz-
muenchen.de/ihg/ExonPrimer.html).  The primers were then stored at -20°C at working 
concentration of 10µM. For each PCR reaction, 20µl of master mix was prepared as shown 
below: 
 12.5µl RedTaq 
 0.5µl forward primer 
 0.5µl reverse primer 
 6.5µl DNA/RNA free water 
The master mix was then vortexed and centrifuged before 20µl was dispensed to a well of a 96-
well plate. 100ng of patient DNA was added to the well and mixed by pipetting.  One well 
containing ddH2O was run in parallel to act as a negative control. The plate was then centrifuged 
using a plate centrifuge and the PCR reaction was performed on the DNA Engine Tetrad®2 
Peltier thermal Cycler (BIO-RAD, California, USA). 30 cycles of PCR were carried out as per 
standard cycle conditions (denaturing, annealing and hybridisation) as shown below:  
 94°C for 3 minutes 
 94°C for 1 minute 
 60°C for 1 minute 
 72°C for 1 minute 
 72°C for 5 minutes  
 





DNA amplification was verified by electrophoresis using a ethidium stained 1% Agarose TAE 
gel. 10µl of the PCR product was loaded on the gel next to a 1kb DNA ladder (BioLabs, 
Ipswich, UK) and run for 30-40 minutes at 100V. To visualize the electrophoresis fragments 
the gel was imaged under the ultraviolet trans-illuminator system (Syngen, Gene Genius Bio 
imaging system) using GeneSnap software (Synoptics, GeneSnap running version 6.03.00). 
The DNA amplification was confirmed by correct sizing and alignment of the bands of the PCR 
fragments to the DNA ladder.  
2.10.3 Sanger Sequencing  
Preparation of PCR products for Sanger sequencing involved a four-step procedure of 
microclean, amplification, washing and denaturation. For sequencing, the forward and reverse 
primers were tested separately, so two sets of PCR product were required for each test  
Microclean: 2.4µl of each PCR product for each sample was pipetted into two separate wells. 
2.4µl of miroCLEAN solution (Microzone, Haywards Heath, UK) was then added to each 
well and the plate was spun in a Hettich Universal 320 (Hettich,Tuttlingen, Germany) plate 
centrifuge for 40 minutes at 2200g.  To remove the microclean solution, the plate was 
centrifuged by inverting for 30 seconds at 250g.   
Amplification: For each PCR reaction, 10µl of master mix was prepared as shown below: 
 0.5µl BigDye reaction Mix (ThermoFisher,  Loughborough, UK)  
 2µl BigDye sequencing Buffer 
 2µl forward/reverse primer 
 5.5µl ddH2O  





10µl of master mix was added to each well containing the dried PCR product, mixed by 
pipetting and briefly centrifuged in a plate centrifuge. The plate was then placed on the DNA 
Engine Tetrad®2 Peltier thermal Cycler (Bio-Rad, California, USA) and 30 cycles of the 
sequencing were carried out as shown below:  
 96°C for 30 seconds 
 50°C for 15 seconds  
 60°C for 4 minutes 
 
Washing: Two steps of ethanol washes were carried out to wash the sequencing reaction 
products. Firstly, 2 µl of 0.125M EDTA was dispensed into the wells and 30 µl of 100% ethanol 
was added. The plate was centrifuged at 1100g in a balanced plate centrifuge for 20 minutes 
and then centrifuged with the plate inverted for 30 seconds at 250 g to remove the washing 
solution. The second wash involved addition of 90 µl of freshly prepared 70% ethanol followed 
by 10 minutes spin at 1100 g. The plate was again inverted and centrifuged to remove the 
ethanol and the plate was allowed to air dry.  
Denaturation: For denaturation, 10 µl of Hi Di Formamide was first added to each well and 
pipetted mixed to re-suspend the pellet. The plate was then heated on the PCR thermocycler for 
2 minutes at 94°C. To avoid re-annealing of single stranded DNA, the plate was immediately 
snap chilled on ice.  
Sequencing: All DNA sequencing runs were carried out by the Functional Genomics 
laboratory, University of Birmingham, using the ABI 3730 DNA sequencer (Applied 
Biosystems, California, USA). For data analysis, the Sanger DNA sequencing was viewed 
using Chromas and/or analysed using MutationSurveyor® DNA Variant Analysis Software 





(BioLabs, Ipswich, UK). A variant can be identified by comparing the patient’s result with an 
online reference data within the software. 
2.10.4 Whole exome sequencing using NGS 
Whole exome sequencing of candidate PFD genes was undertaken externally by collaborators 
in Kings College London headed by Prof Michael Simpson. Genomic DNA was isolated from 
buffy coat samples and purified as recommended by the manufacturer using a Gentra Puregene 
kit (Qiagen Sciences, Maryland, USA). <1µg of quantified genomic DNA was sent to the 
assigned laboratory at ambient room temperature. DNA enrichment of coding regions and 
intron/exon boundaries was undertaken using the SureSelect Human All Exon 50Mb Kit 
(Agilent Technologies, UK) following the manufacturer’s instructions. Subsequently, DNA 
Sequencing was performed on an Illumina HiSeq 2500 (Illumina, Chesterford, UK) with 100bp 
paired-end reads. Sequence reads were aligned based upon the reference genome (hg19) using 
Novoalign (Novocraft technologies, Selangor, Malaysia). Duplicate reads and reads that 
mapped to multiple locations in the exome were excluded from further analysis. Small 
insertions/deletions and single nucleotide variations were identified and filtered for quality 
using the SAM tools software package and in-house software tools (Li et al., 2009). All calls 
with a read coverage of <4 were excluded from downstream analysis. The variants were then 
filtered to determine for novelty by comparison to known variants present within dbSNP139, 
EVS (evs.gs.washington.edu/EVS/), the 1000 Genomes Project and the results from over 1200 
in house control exomes analysed using the same protocol. Variants found with a minor allele 
frequency (MAF) > 0.01 were excluded and novelty was confirmed by comparison to 
dbSNP138. A bioinformatics filtering pipeline used to analysis WES data is shown on figure 
2.2. 





2.10.5 Conservation and pathogenicity prediction 
The pathogenicity of a candidate variant was predicted using different pathogenicity prediction 
software to identify a variant that may affect protein function. These included: Polymorphism 
Phenotyping v2 (PolyPhen-2) which uses two pairs of datasets to predict the pathogenic effect 
of a variant on protein structure and function (Adzhubei et al., 2010). MutationTaster (Schwarz 
et al., 2014) which is designed to evaluate the disease potential of an alteration and can predict 
functional consequences of different classes of sequence variations, including substitutions, 
insertions, deletions, intronic and synonymous alterations.  Sorting Intolerant from Tolerant 
(SIFT) assesses the effect of a substitution by using sequence homology to predict the effects 
of all possible substitutions at each position in the protein sequence (Kumar et al., 2009). Protein 
Variation Effect Analyzer (PROVEAN) uses alignment-based score to predict the damaging 
effects of single or multiple amino acid substitutions by measuring the change in sequence 
similarity between the reference and variant versions in comparison to sequence homologs 
(Choi et al., 2012). 
  






Figure 2.2:  Bioinformatics pipeline used to analysis WES data. It comprises of two main arms, 
the left arm which focused upon comparison to a panel of 357 genes that known to affect platelet 
phenotype, and the right arm focused upon novel variants that are significant and shared within 
affected family members.  





2.11 Statistical analysis  
Statistical analysis was carried out using Microsoft Excel 2010, Graph Pad Prism version 7.0 
and IBM SPSS statistics version 20, with testing methodologies as specified in figure legends 
(dependent upon the data being interrogated). P-values of ≤0.05 were considered to be 
significant. 
  





CHAPTER THREE: PHENOTYPE OF INDIVIDUALS SUSPECTED 
WITH MILD BLEEDING DISORDERS USING LIGHT TRANSMISION 
AGGREGOMETRY  
3.1 Introduction 
Characterisation of individual platelet function defects (PFD) is crucial for optimal treatment 
and management as frequent minor bleeding episodes can have a significant impact on quality 
of life. Diagnosis of milder forms of PFDs is complex and challenging due to their variable 
bleeding phenotype, which often only manifests after haemostaic challenges, and the absence 
of a gold standard laboratory technique. Moreover, similarities of bleeding patterns are often 
observed in other haemostatic disorders including type 1 VWD (Watson et al., 2013).  As such, 
a proper assessment of clinical history is therefore very important to exclude acquired platelet 
disorders or any other haemostatic abnormalities. In 2010, the International Society on 
Thrombosis and Haemostasis developed a Bleeding Assessment Tool (ISTH BAT), a 
standardised questionnaire which assesses the recurrent milder bleeding symptoms of patients 
which can also be applicable for individual of inherited PFDs (Rodeghiero et al., 2010b).  
The most widely used methodology for assessing PFD is light transmission aggregometry 
(LTA). A recent worldwide survey showed that 73.4% of laboratories use this for the diagnosis 
of inherited PFD (Gresele et al., 2014). The technique simply measures the change in light 
transmission in real time when agonists are added to platelet-rich plasma or washed platelets. A 
typical panel of agonists includes ADP, collagen, arachidonic acid, adrenaline, PAR-1 peptide, 
U46619 and ristocetin (Gresele, 2015). The nature of the response is dependent on the agonist 
used, its concentration and the role of the feedback agonists ADP and thromboxane A2 (TxA2). 
During aggregation the platelet response may demonstrate an initial increase in optical density 
as a result of shape change, followed by a primary, biphasic, sustained or reversible increase in 





light transmission (Dawood et al., 2007). An example of a typical aggregation and secretion 
trace is shown in figure 1.2. 
In an attempt to improve platelet function testing, some modern aggregometers (lumi-LTA) can 
simultaneously monitor the secretion of platelet ATP from the dense granules using 
luminescence by addition of luciferin–luciferase reagents during the aggregation process 
(Dawood et al., 2007, Miller, 1984). Measuring the secretion of dense granules is important for 
diagnosis of HPS and other dense granule secretory and release disorders. However, the 
availability of this technique is limited to specialized laboratories. The 2014 survey showed that 
only 40.7% of laboratories have access to lumi-LTA (Gresele et al., 2014).   
Although LTA is considered to be the gold standard method for the investigation of PFD, the 
technique is time consuming, requires large blood volumes for preparation of PRP, needs to be 
performed on fresh samples and requires expertise for correct performance and interpretation 
(Daly et al., 2014). Furthermore, platelet responses can also be transiently affected by diet and 
intake of certain medications which may also inhibit various activation pathways (Daly et al., 
2014). 
3.2 Aim  
To test and classify patients with a suspected platelet function defect using lumi-aggregometry 
(lumi-LTA).  






3.3.1 Overall patient recruitments 
Between September 2014 and April 2017, 318 participants (112 healthy controls and 206 
patients) were recruited into the GAPP study from 10 haemophilia centers for evaluation of 
platelet function disorders (figure 3.1). The healthy control population (n=112) were recruited 
as per the GAPP study criteria. The age range of the healthy controls was between 18 to 57 
years (other data e.g. demographic information is unavailable). Out of 206 patients, 25% (n=51) 
were males and 75% (n=155) were females (figure 3.2) with a median age of 34, range between 
2 to 80 years (figure 3.3). The highest number of patients came from Lincoln (n=72) followed 
by Nottingham (n=45), Birmingham (n=43) and Canterbury (n=21). Only one patient was 
recruited from Oxford over the 32 month period.  More details are shown in figure 3.4. 
Abnormal results were detected in 13/21 (69%) of patients from Canterbury, 26/45 (58%) from 
Nottingham and 21/43 (49%) from Birmingham. Surprisingly, despite the highest number of 
patients came from Lincoln, only 15/72 (21%) were found to have platelet defects. More details 
are shown in figure 3.5 






Figure 3.1 Overall number of participants recruited in the GAPP study between September 
2014 and April 2017 showing healthy controls (n=112) and patients (n=206) 






Figure 3.2 Number of males (n=51(25%) and females (n=155(75%) recruited to the GAPP 
study 
  






Figure 3.3 Age distribution amongst patients (n=206) recruited into the GAPP study. For panel 
A, horizontal bars represent a mean age.  For panel B, the box represents median and 
interquartile range and the whiskers represent 5th and 95th percentiles. Outlying points are 
represented by dots. 
 
 





     
Figure 3.4 Summary of blood samples recruited to the GAPP study from different haemophilia 
centres. Healthy controls (blue) and patients (red).  
 
  





         
Figure 3.5 Summary of platelet function results for samples received from each haemophilia 
centre. Numbers are divided into those with (red) and without (blue) detectable platelet function 
defects. 
 





3.3.2 Platelet parameters and ATP secretion values 
The overall platelet parameters and ATP secretion values of healthy controls (n=112) and 
patients (n=206) are shown in table 3.1. In patients, the values (mean ± SD) of whole blood 
platelet counts and MPV were 226.0 ± 84 x 109/L and 11.2 ± 1.3fL respectively. The PRP count 
(mean ± SD) was 3.52 ± 1.58 x 108/ml. ATP secretion values (mean ± SD) were 0.89 ± 0.49 
nmol/1 x 108/ml platelets. The patients’ platelet counts in whole blood (figure 3.6) and PRP 
(figure 3.7) were not different compared to that of healthy controls. In contrast, the MPV (figure 
3.8) and ATP secretion values (figure 3.9) of patients were significantly different when 
compared to healthy controls.





Table 3.1 Summary of platelet parameters and ATP secretion values obtained from healthy controls (n=112) and patients (n=206): Data are 
presented as mean, +/- standard deviation and ranges. Statistical analysis performed by the Mann Whitney U test. Significance was compared 
to healthy controls (***p <0.001, **p<0.01 and *p<0.05).






Figure 3.6 Measurement of platelet counts in whole blood from healthy controls (n=112) and 
patients (n=206) as analysed by the Sysmex XN-1000. For panel A, horizontal bars represent 
mean values, statistical analysis performed by the Mann Whitney U test. For panel B, Boxes 
represent median and interquartile ranges, whiskers represent 5th and 95th percentiles and 









    
Figure 3.7 Measurement of platelet counts in PRP from healthy controls (n=112) and patients 
(n=206) as analysed by the Coulter Z2 analyser. For panel A, horizontal bars represent mean 
values and statistical analysis performed by the Mann Whitney U test. For panel B, the boxes 
represent median and interquartile ranges, whiskers represent 5th and 95th percentiles and 
outlying points are represented by dots. 
 





   
Figure 3.8 Measurement of MPV values in whole blood from healthy controls (n=112) and 
patients (n=206) as analysed by the Sysmex XN-1000. For panel A, horizontal bars represent 
mean values, statistical analysis performed by the Mann Whitney U test. Significance was 
compared to healthy controls (**p<0.01).  For panel B, Box represents median and interquartile 
ranges, whiskers represent 5th and 95th percentiles and outlying points are represented by dots. 
 
 





   
Figure 3.9 ATP secretion values in PRP in response to 100µM PAR-1 TRAP peptide from 
healthy controls (n=112) and patients (n=206). For panel A, horizontal bars represent mean 
values and horizontal dotted line represents the 95th percentile (cut off value) used to determine 
abnormal results. Statistical analysis performed by the Mann Whitney U test. Significance was 
compared to healthy controls (***p<0.001).  For panel B, the Boxes represent median and 
interquartile ranges, whiskers represent 5th and 95th percentiles and outlying points are 
represented by dots. 





3.3.3 Overall aggregation results and platelet defect classification 
Out of 206 patients tested, 90(44%) patients gave abnormal responses to one or more agonists, 
however, a significant proportion of patients (56%) were also found to exhibit normal platelet 
function (figure 3.10). As shown in figure 3.11B, the functional defects were classified into five 
main groups (Gi signalling defects, Gq signalling defecst, dense granular secretion defects, 
cyclooxygenase pathway defects, and other defects) according to their pattern of responses to 
specific agonists as previously described (Dawood et al., 2012). The distribution of defects 
amongst 90 patients is shown in figure 3.11A. A high proportion of patients were identified to 
have dense granular secretion defects (16%), followed by Gi signalling defects (11%). Defects 
within the cyclooxygenase pathway, Gq signalling, multiple defects and other defects were 














      
Figure 3.10 Comparison between overall normal and abnormal lumi-LTA results identified 










    
 
             
Figure 3.11 Distribution of platelet function defects among 206 patients recruited into the 
GAPP study. (A) Pie chart segments showing the percentage of each defect (B) Bar chart 
showing the absolute number of patients in each defect. Cox = cyclooxygenase, Gi = Gi 
signalling pathway, Gq= Gq signalling pathway 
 





3.3.4 Analysis of patients with thrombocytopenia  
Out of 206 patients tested, 39 (19%) were found to have mild to moderate thrombocytopenia as 
characterized by low platelet counts (<150 x109/L) in whole blood (Figure 3.12). There was a 
small but significant difference in age between patients with thrombocytopenia and those with 
normal platelet counts (figure 3.13). The age (mean ± SD) of patients with thrombocytopenia 
was 27 ± 22 years and that of patients with normal platelet count was 35 ± 20 years. The 
proportion of males was higher among patients with thrombocytopenia than those with normal 
counts (35% and 22% respectively) (figure 3.14). The overall platelet parameters and ATP 
secretion of patients with thrombocytopenia and those with normal platelet counts are shown 
in table 3.2. The values (mean ± SD) of whole blood platelet count and MPV were 261 ± 68 x 
109/L and 11.0 ± 1.1fL for patients with normal count and 106 ± 32 x 109/L and 12.2 ± 1.8fL 
for patients with thrombocytopenia, respectively. The PRP count (mean ± SD) was 3.9 ± 0.84 
x 108/ml in patients with normal counts and 1.87 ± 0.77 x 108/ml in thrombocytopenia. The 
platelet counts in whole blood (figure 3.15) and in PRP (figure 3.16) were significant lower in 
patients with thrombocytopenia than patients with normal platelet count. In contrast, the MPV 
was higher in patients with thrombocytopenia than patients with normal platelet counts (figure 
3.17). ATP secretion values (mean ± SD) were 0.89 ± 0.42 nmol/1 x 108  and 0.87 ± 0.71 nmol/1 












Figure 3.12 Overall number of participants recruited in the GAPP study between 
September 2014 and April 2017 showing healthy controls (n=112), patients with normal 










Figure 3.13 Age distribution amongst patients with normal platelet counts (n=167) and 
thrombocytopenia (n=39) recruited into the GAPP study. For panel A, horizontal bars represent 
a mean age.  Statistical analysis performed by the Mann Whitney U test. Significance as 
compared to patients with normal platelet count (*p<0.05). For panel B, Boxes represent 
median and interquartile range, whiskers represent 5th and 95th percentiles and outlying points 
are represented by dots. 
  






Figure 3.14 Distribution between male (blue) and female (red) among patients with normal 









       
     
 
Table 3.2 Comparison of platelet parameters and ATP secretion values between patients with 
normal platelet counts (n=167) and thrombocytopenia (n=39): Data are presented as mean, +/- 











Figure 3.15 Measurement of platelet counts in whole blood among healthy controls (n=116), 
patients with normal platelet counts (n=167) and thrombocytopenia (n=39). For panel A, 
horizontal bars represent mean values. Statistical analysis performed by the Kruskal-Wallis test 
with Dunn's adjustment for multiple comparisons. Significance as compared to healthy controls 
(***p<0.001).  For panel B, Boxes represents median and interquartile range, whiskers 
represent 5th and 95th percentiles and outlying points are represented by dots. 
 





       
Figure 3.16 Measurement of PRP platelet counts among healthy controls (n=116), patients with 
normal platelet counts (n=167) and thrombocytopenia (n=39) as analysed by the Coulter Z2 
analyser.  For panel A, horizontal bars represent mean values. Statistical analysis performed by 
the Kruskal-Wallis test with Dunn's adjustment for multiple comparisons. Significance was 
compared to healthy controls (***p<0.001).  For panel B, Boxes represent median and 
interquartile ranges, whiskers represent 5th and 95th percentiles and outlying points are 
represented by dots. 






Figure 3.17 Measurement of MPV in whole blood among healthy controls (n=116), patients 
with normal platelet counts (n=167) and thrombocytopenia (n=39). For panel A, horizontal bars 
represent mean values. Statistical analysis performed by the Kruskal-Wallis test with Dunn's 
adjustment for multiple comparisons (**p<0.01).  For panel B, Boxes represent median and 
interquartile range, whiskers represent 5th and 95th percentiles and outlying points are 
represented by dots. 
 





75% of patients with thrombocytopenia were also found to have secondary defects in platelet 
function. In contrast, only 36% of patients with normal platelet counts were found to have a 
platelet function defect (figure 3.18). Interestingly, dense granular secretion defects were the 
most common functional defects (58%) among patients with thrombocytopenia compared to 
normal platelet counts (33%) (figure 3.19). Surprisingly, however, there was no significant 











Figure 3.18 Overall comparison between the number of samples found to have platelet defects 
(red) in patients with normal platelet counts (n=167) and  thrombocytopenia (n=39). 
  







Figure 3.19 Classification of platelet function defects among patients with normal platelet 
counts (blue) and patients with thrombocytopenia (red). Cox = cyclooxygenase, Gi = Gi 











Figure 3.20 Measurement of ATP secretion values among healthy controls (n=116), patients 
with normal platelet counts (n=167) and thrombocytopenia (n=39) as determined by lumi-LTA 
measuring ATP secretion in response to 100µM PAR-1 TRAP stimulation. For panel A, 
horizontal bars represent mean values. Statistical analysis performed by the Kruskal-Wallis test 
with Dunn's adjustment for multiple comparisons (**p<0.01).  For panel B, Boxes represent 
median and interquartile ranges, whiskers represent 5th and 95th percentiles, and outlying points 
are represented by dots. 
  
 





3.3.5 Assessment of ISTH Bleeding score among patients with normal platelet counts 
The ISTH BAT was used for assessment of the bleeding history in 122 of patients with normal 
platelet counts. The age of patients (median ± SD) was 40±17 and the majority were female 
(84%). I also included the BAT score of 21 healthy controls that were previously assessed 
within the GAPP study (Lowe et al., 2013). A platelet function defect was identified by lumi-
LTA in 32% of patients. The BAT score (median ± SD) of patients was significantly higher 
than that of healthy controls (11 ± 5.7 and 0.6 ± 1.5 respectively) (figure 3.21). Similarly, female 
patients had higher BAT scores than males (12 ± 6 and 8 ± 5 respectively) (figure 3.22). 
However, there was no significant difference between the BAT score of patients with no 
detectable platelet defect and those with platelet defects detected by lumi-LTA (figure 3.21). 
Furthermore no association was found between the BAT score and the type of platelet defect 
detected by lumi-LTA (figure 3.23). Surprisingly, the BAT score of patients with 
thrombocytopenia (10 ± 5) were similar to that of patients with normal platelet counts (11 ± 6) 
(figure 3.24). 
 






Figure 3.21 Association between the ISTH BAT score and the presence of a platelet function 
defect on lumi-LTA. For panel A, horizontal bars represent a mean values, horizontal dotted 
line represents 95th percentile (score of 4) calculated from healthy controls. Statistical analysis 
performed by the non-parametric Kruskal-Wallis test, with Dunn's adjustment for multiple 
comparisons (***p<0.001).  For panel B, Boxes represent median and interquartile ranges, 
whiskers represent 5th and 95th percentiles and outlying points are represented by dots. 
 






Figure 3.22 Comparison of ISTH BAT scores between male and female patients. For panel A, 
horizontal bars represent a mean values, horizontal dotted line represents 95th percentile (score 
of 4) calculated from healthy controls. Statistical analysis performed by the non-parametric 
Kruskal-Wallis test, with Dunn's adjustment for multiple comparisons (***p<0.001 and 
**p<0.01).  For panel B, Boxes represent median and interquartile ranges, whiskers represent 
5th and 95th percentiles and outlying points are represented by dots. 
 
  






Figure 3.23 Association between the ISTH BAT scores and the type of platelet function defect 
on lumi-LTA. For panel A, horizontal bars represent a mean values, horizontal dotted line 
represents 95th percentile (score of 4) calculated from healthy controls. Statistical analysis 
performed by the non-parametric Kruskal-Wallis test, with Dunn's adjustment for multiple 
comparisons (***p<0.001).  For panel B, Boxes represent median and interquartile ranges, 
whiskers represent 5th and 95th percentiles and outlying points are represented by dots. 
 






Figure 3.24 Comparison of ISTH BAT scores between patients with normal counts and 
thrombocytopenia. For panel A, horizontal bars represent a mean values, horizontal dotted line 
represents 95th percentile (score of 4) calculated from healthy controls (n=21). Statistical 
analysis performed by the non-parametric Kruskal-Wallis test, with Dunn's adjustment for 
multiple comparisons (***p<0.001).  For panel B, Boxes represent median and interquartile 
ranges, whiskers represent 5th and 95th percentiles and outlying points are represented by dots. 
 





A receiver-operator curve (ROC) analyse was used to investigate the ability of the ISTH BAT 
score to discriminate between patients with and without a demonstrable platelet function defect 
by lumi-LTA (figure 3.25). The area under the curve (AUC) was 0.54 (95% CI 0.43 to 0.65) 
thus indicating a lack of discriminative ability. Furthermore a comparison study was also 
performed to analyse the ability of the ISTH BAT score to predict the presence of a platelet 
defect on lumi-LTA. A score of 11 was used as a cut off value for the ISTH BAT as this 
presented the 50th centile of the ISTH BAT score in all patients. The agreement between the 
ISTH BAT score and the presence/absence of platelet defect by lumi-LTA is shown in table 
3.3. Overall, there was a concordance in 53% of patients, with a positive predictive value of 
only 35%. This finding demonstrates a lack of association between the high ISTH BAT score 
and the likelihood of having a platelet defect.    






Figure 3.25 ROC analysis for the presence of a platelet function defect by lumi-LTA and the 
ISTH BAT score. Area under the curve: 0.54(95% CI 0.43 to 0.65).  
  






Table 3.3 A comparison study to analyse the ISTH BAT score of 11 and over in predicting the 
presence of a platelet defect by lumi-LTA. ISTH BAT score of 11 represents the 50th centile in 
all patients studied. Sensitivity, specificity, positive predictive value and negative predictive 
value are shown.  





3.3.6 Investigation of families with a history of excessive bleeding 
10 families with a history of excessive bleeding were recruited into the GAPP study for the 
investigation of potential platelet function defects. Families were categorised into three groups 
based on their platelet count in whole blood. (1) Family with normal platelet counts, (2) family 
with thrombocytopenia and (3) family with variable platelet counts (only families with normal 
platelet counts are fully analysed including NSG). All family members had platelet aggregation 
performed by lumi-LTA. Overall demographic characteristic and summary of platelet 
phenotyping of all ten families are shown in figure 3.26 (families with normal platelet count 
and with thrombocytopenia) and figure 3.27 (families with variable platelet count). The two 










Figure 3.26 Demographic characteristics and summary of platelet phenotyping of family 
members indicating the patients’ age, gender, platelet parameters, ATP secretion values, type 
of platelet defect identified and the ISTH BAT score. For panel A family with normal platelet 
count and panel B families with thrombocytopenia. 
 






Figure 3.27 Demographics and summary of platelet phenotyping of family members with 
various platelet counts indicating the patients’ age, gender, platelet parameters, ATP secretion 
values, type of platelet defect identified and the ISTH BAT score.  
  





3.3.7 Case presentations from patients with various categories of platelet defects   
3.3.7.1 Index case No.1 - A patient with a Gi signalling defect 
A 17 year old girl with a bleeding history includes epistaxis, bruising, bleeding from minor 
wounds, oral cavity bleeding and menorrhagia since menarche. Her whole blood platelet count, 
MPV, PRP count and ATP secretion level were normal (214 x 109/L, 10.5 fL, 2.96 x 108/ml 
and 1.10 nmol ATP/1x108 platelets, respectively) and the aggregation traces are shown in figure 
3.28. The platelet abnormality was characterized by transient aggregation to ADP and absent 
primary wave of aggregation to adrenaline and impaired ATP secretion to both agonists. A 
reduced response to collagen is also consistent with impairment of the feedback role of ADP.  
A robust response to low dose arachidonic acid helps to exclude a defect in the TxA2 pathway. 
The level of ATP secretion was within the normal range, indicating that the participant did not 
have a secretion defect. 






Figure 3.28 Representative traces from a patient with Gi signalling defect. Left Y axes show 
percentage aggregation and right Y axes show ATP secretion levels. For panels A, D, F and G 
control aggregation is shown in blue and patient aggregation is shown in black. For panels B, 
C and E control aggregation is shown in blue and patient aggregation is shown in red, control 
secretion is shown in black and patients secretion is shown in green. Reversible aggreagtion is 
seen in response to low and high doses of ADP, with no secondary wave of aggregation with 
high dose of adrenaline suggesting a lost of the Gi signalling. Reduced aggregation is seen with 
a low dose of collagen, although this normalises at a higher concetration. Response to low doses 
of arachidonic acid and PAR-1 peptide are normal.  Normalised secretion to PAR-1 peptide is 
within the normal range at 1.10nmol ATP / 1x108 platelets (5th centile in healthy controls =0.68 
nmol ATP / 1x108 platelets) 





3.3.7.2 Index case No.2 - A patient with cyclooxygenase pathway defet 
A 42 year old lady presented with a bleeding history of epistaxis, bruising and bleeding from 
minor wounds, muscle haematomas, oral cavity bleeding, bleeding after tooth extractions, 
bleeding after surgical operation and menorrhagia. All of her platelet parameters were normal 
including platelet count in whole blood (239 x 10
9
/L), MPV  (11.5fL), PRP count (3.36 x 
10
8
/ml) and ATP secretion level (0.71/0.68 nmol ATP/1x10
8
 platelets) with the aggregation 
traces  shown in figure 3.29. A platelet abnormality was characterized by a marked defect in 
aggregation and secretion in response to arachidonic acid. The normal aggregation in response 
to U46619 however, indicated a defect in conversion of arachidonic acid to TxA2 because the 
response to U46619 is insensitive to cyclooxygenase blockade. A reduced response to low dose 
of collagen is consistent with impairment of the feedback role of TxA2. Normal sustained 
responses to ADP exclude a defect in the ADP pathway. The level of ATP secretion was within 
the normal range, indicating that there was no secretion defect. 
 






Figure 3.29 Representative traces from a patient with a potential cyclooxygenase pathway 
defect. Left Y axes show percentage aggregation and right Y axes show ATP secretion levels. 
For panel A control aggregation is shown in blue and patient aggregation is shown in black. For 
panels B, C, D, E, F, G and H control aggregation is shown in blue and patient aggregation is 
shown in red, control secretion is shown in black and patient secretion is shown in green.  No 
aggreagtion is seen in response to low and high doses of arachidonic acid. Response to U46619 
is normal suggesting that the thromboxane receptor  is normal. Reduced aggregation is seen 
with low dose of collagen, although this normalises at a higher concetration. Responses to low 
and high doses of ADP and to PAR-1 peptide are normal.  Normalised secretion to PAR-1 
peptide is within the normal range at 0.71nmol ATP / 1x108 platelets (5th centile in healthy 
controls =0.68nmol ATP / 1x108 platelets) 





3.3.7.3 Index case No.3 - A patient with a possible dual platelet defect (cyclooxygenase 
pathway and Gi signalling) 
A 47 year old male presented with a clinical history of gum bleeding after dental cleaning which 
lasted for five days. His WB platelet count, MPV and PRP count were with normal ranges (262 
x 109/L, 8.7fL and 4.72 x 108/ml, respectively). His ATP secretion value (0.66 nmol ATP/1x108 
platelets) was  borderline and aggregation traces are shown in figure 3.30. A transient 
aggregation to ADP and absent primary wave of aggregation to adrenaline as well as an 
impaired ATP secretion to both agonists indicated a defect in Gi signalling pathway. There was 
also a marked defect in aggregation and secretion to arachidonic acid even at the higher 
concentration, however, a normal aggregation response to U46619 indicated normal receptor 
function. A marked defect in response to collagen is consistent with impairment of the feedback 
mediators as collagen response is markedly dependent on the feedback actions of ADP and 
TxA2. 






Figure 3.30 Representative traces from a patient with a possible dual defect (cyclooxygenase 
pathway and Gi signalling defects). Left Y axes show percentage aggregation and right Y axes 
show ATP secretion levels. For panels A and I control aggregation is shown in blue and patient 
aggregation is shown in black. For panels B, C, D, E, F, G, H and J control aggregation is shown 
in blue and patient aggregation is shown in red, control secretion is shown in black and patient 
secretion is shown in green. Reversed aggregation is seen in response to low and high doses of 
ADP, with no secondary wave of aggregation with a high dose of adrenaline suggeting a lost 
of the Gi signalling. No aggregation is seen in response to low and high doses of arachidonic 
acid. Response to U46619 is normal suggesting normal thromboxane receptor function. Only 
shape change is seen in response to a high dose of collagen. Response to CRP is normal  
suggesting a normal function of the GPVI collagen receptor. Reversable aggregation is seen in 
response to low PAR-1 peptide although this normalises at a higher concetration. Normalised 
secretion to PAR-1 peptide is borderline range at 0.66 nmol ATP / 1x108 platelets (5th centile 
in healthy controls =0.68 nmol ATP / 1x108 platelets) 





3.3.7.4 Index case No.4 - A patient with a suspected  dense granule secretion defect 
 A 5 year old boy presented with history of excessive bleeding and mild thrombocytopenia. His 
platelet count in whole blood was 139 x 10
9
/L but the PRP count was 2.02 x 10
8
/ml which was 
within the accepted range (≥1.00 x 10
8
/ml) for aggregation study. MPV was within normal 
range at 12.1fL. The ATP secretion level was markedly reduced (0.22 nmol ATP/1x10
8
 platelets) 
and aggregation traces are shown in figure 3.31. A platelet abnormality was characterized by 
decrease in ATP secretion in response to all agonists even though maximal aggregation was 
sustained at high concentrations. A reduction in aggregation to low concentrations of almost all 
platelets agonists is consistent with impairment of the feedback role of ADP and TxA2. The 
participant was confirmed to have a dense granular secretion defect with low ATP secretion. 






Figure 3.31 Representative traces from a patient with a potential dense granular secretion 
defect. Left Y axes show percentage aggregation and right Y axes show ATP secretion levels. 
For panel A control aggregation is shown in blue and patient aggregation is shown in black. For 
panels B, C, D, E, F, G, H and I control aggregation is shown in blue and patient aggregation 
is shown in red, control secretion is shown in black and patient secretion is shown in green. 
Aggregation responses to low doses of ADP and collagen were reduced, although this 
normalised at higher concentrations. reduced aggregation is also seen in response to low and 
high doses of arachidonic acid, but full response is seen to U46619. Response to PAR-1 peptide 
is normal. There is a reduced secretion level in response to all agonists. Secretion to PAR-1 
TRAP peptide is markedly reduced at 0.22 nmol ATP / 1x108 platelets (5th centile in healthy 
controls =0.68nmol ATP / 1x108 platelets 






   
Figure 3.32 Summary of the overall 206 patients tested by lumi-LTA during the study period 
presenting the number of normal, abnormal and their four groups of classification according 
the phenotypic pattern of response. WES was further analyzed on 22 selected cases with genetic 
defects identified in 13 patients.  
 
  






This chapter reveals the overall recruitment, patients’ characteristics and platelet phenotyping 
by lumi-LTA. The cohort includes a total of 318 participants (112 healthy controls and 206 
patients) recruited into the GAPP study from 10 haemophilia centres across the UK. The healthy 
control population recruited in this cohort were adults with an age range of 18 to 57 years.  
However, due to the GAPP study criteria and ethical issues, other details and additional 
demographic information from healthy controls group were not provided. The number of 
patients recruited from each centre varies with larger numbers of patients referred from Lincoln, 
Nottingham, Birmingham and Canterbury. It might be possible that due to the geographical 
location, some of these centres had access to more patients than others. On the other hand, the 
number of defects identified from each center also varied considerably and were not consistent 
to the number of patients recruited. This might explain the importance of taking a proper clinical 
history and applying an appropriate screening test to exclude non platelet disorders. 
Patient age varied considerably among all consenting patients, this is probably due to the 
inclusion criterial of <85 years of age and enrolment of patients from both paediatric and adults 
haemophilia centres. However, the average age of patients included in this cohort is 
significantly into adulthood at 33 years. On the other hand, female patients were by far more 
than male accounts for 75% of all participants. Both, the variation in age towards the adulthood 
and gender to towards female are in line with previous studies within the GAPP project 
(Dawood et al., 2012, Lowe et al., 2013, Johnson et al., 2016).  This is because, individuals 
with mild bleeding disorders may not be recognised during their childhood as they have not yet 
experienced severe haemostatic challenges such as trauma or a major surgical procedure. 
Similarly, women with bleeding disorders are also more readily identified than men because of 
menorrhagia and increased potential for bleeding after child birth (Watson et al., 2010). It has 





been reported that approximately 5 – 10% of women do seek medical attention at some point 
during their reproductive life due to prolonged menorrhagia and that about 15% of them do 
have underlying bleeding diatheses (Rydz and James, 2012). 
Analysis of platelet parameters (whole blood count, PRP count and MPV values) are important 
while diagnosing patients with PFDs. Firstly, they provide a practical guidance as approach of 
investigating patients with normal count within the GAPP study is different to that of patients 
with thrombocytopenia. Secondly, platelet parameters along with aggregation trends are 
essential for result interpretation as some form of platelet defects are associated with low 
platelet counts of either normal size or macrothrombocytopenia.  
Abnormal lumi-LTA results were defined based upon the cut-off values that were calculated as 
5th percentile from the healthy volunteers as well as both the magnitude and time course of 
response. However, applying of the 5th percentile cut-off values may resulted in miss diagnosis 
on a small degree of patients due to an overlap in platelet responsiveness between patients and 
healthy population. This small degree of overlapping however has also been reported in other 
laboratory methods (Quiroga et al., 2007). 
A qualitative defect in platelet function was observed in 44% of patients (90/206) that were 
tested by lumi-LTA. This is slightly lower than a previously reported higher frequency of 58% 
platelet defects within the early stages of the GAPP study (Dawood et al., 2012). The platelet 
defects reported here were categorised into four main groups (dense granular defects, Gi and 
Gq signalling defects, and cyclooxygenase pathway defects) based on the aggregation patterns 
as previously described (Dawood et al., 2012). However, the current cohort identified more 
patients with dense granular defects than Gi signalling defects (16% and 11% respectively). 
Although, an accurate classification of an inherited platelet function defect does not necessary 
change patient treatment and haemostatic management, the correct identification of platelet 





function defect is important to minimise bleeding risk and ensures the appropriate family 
counselling.  A number of reasons could be considered for the excessive bleeding in 56% of 
patients in whom a platelet defect was not identified. For example, the testing undertaken within 
the GAPP study are not comprehensive enough to detect all platelet defects such as alpha 
granular function and platelet procoagulant activity (e.g. Scott syndrome). Patients may also 
possibly have abnormalities in another part of haemostatic system that are not easily tested e.g. 
structural defects in collagen, vessel wall abnormalities and abnormal fibrinolysis. One example 
within the GAPP study is the recently reported genetic defect in the thrombomodulin gene in 
family members with excessive bleeding but normal platelet function (Maclachlan et al., 
2017a).   
In this cohort, 19% (39/206) of patients were also identified to have a low platelet count (<150 
x109/L) in their whole blood.  The GAPP study has a different approach for patients with 
thrombocytopenia and normally they are recruited into another arm of the GAPP project 
(Johnson et al., 2016). However, if the PRP count of these patients is within the accepted 
analytical range (≥1.0 x108/ml), the phenotyping are still performed by lumi-LTA. Patient’s 
characteristics showed that the proportion of males in patients with thrombocytopenia was 
slightly higher than those with normal platelet count. Furthermore, the average age was younger 
in patients with thrombocytopenia than those with normal platelet count. This is of no surprise 
as the patients with thrombocytopenia can be equally identified in all age and both gender due 
to their low platelet count. It was also noted that the proportion of patients detected to have 
platelet functional defect was significant higher among patients with thrombocytopenia than 
those with normal count. In addition the majority of these were found to have dense granules 
defect.  





In this cohort of patients, the ISTH BAT score was recorded on 122/167 of patients with 
excessive bleeding but normal platelet counts (Rodeghiero et al., 2010b). Analysis of the 
association between the ISTH BAT score and platelet function defects was performed in these 
patients. It was found that the high ISTH BAT score could not predict the presence of platelet 
function defect among patients with excessive bleeding. Furthermore, there was no association 
found between the BAT score and the sub-type of platelet defect detected by lumi-LTA. Similar 
findings were previously reported within the GAPP study (Lowe et al., 2013). Interestingly, the 
negative predictive value in this study was higher than that previously reported (71% and 54% 
respectively). This is more likely due to the increase number of patients found to have no 
platelet defect. Surprisingly, there was no increase in the ISTH BAT score among patients with 
thrombocytopenia despite their low platelet count and the presence of secondary functional 
defects. However, the number of patients with thrombocytopenia in this group was small 
(n=21).  
4 index cases discussed in this chapter were selected to represent the 3 major diagnostic groups 
of platelet function defects (Gi signalling, TxA2 pathway and dense granule secretion) based on 
the patterns of response. This also demonstrated the importance of using a standard panel of 
agonists at a range of different concentrations alongside measurement of ATP secretion level 
for correct interpretation and classification. For example, a Gi signalling defect in case No. 1 
was diagnosed based on defect in aggregation and secretion in response to the 2 Gi-coupled 
heterotrimeric receptors agonists ADP and adrenaline. A key diagnostic feature of Gi defects is 
the presence of transient aggregation to ADP with a reduced or absent primary wave and no 
secondary wave of aggregation to adrenaline (Dawood et al., 2012). In contrast, in  case No. 2 
an individual with TxA2 pathway defect exhibited a marked defect in aggregation and secretion 
in response to arachidonic acid but normal response to U46619. Because the U46619 is a TxA2-





mimetic agonist it is insensitive to cyclooxygenase blockade, and therefore a normal response 
indicates normal functioning of the TxA2 receptor. A normal level of ATP secretion in this 
patient also excluded a secretion defect. In  case No. 4 the participant was diagnosed to have a 
defect in secretion because of the reduced level of ATP secretion. In patients with secretion 
defect a decrease in ATP secretion is normally observed in response to all agonists (Dawood et 
al., 2012). They also may exhibit a reduction in aggregation to low concentrations of most 
platelet agonists in particular to collagen due to impairment of the feedback role of ADP and 
ATP.  
In summary, this chapter demonstrates that lumi-LTA using a streamlined panel of key platelet 
agonists and specified concentrations can reliably diagnose the majority of PFDs. In many cases 
the patterns of response were consistent with a specified defect. In some cases however, the 
interpretation remained unclear mainly due to the feedback effects of ADP and thromboxane 
A2 (TxA2) and by the overlap with the response of healthy volunteers. Furthermore, the 
phenotyping of platelets described in this chapter have also been used to direct genotyping of 
selective cases for the purpose of identifying a causative gene defect that may contribute to 
bleeding diathesis of these patients. The genetic analyses of selective cases will be discussed in 
the next chapter.   
 





CHAPTER FOUR: GENOTYPING OF PATIENTS IDENTIFIED TO 
HAVE A PLATELET DEFECT  
4.1 Introduction 
Genetic testing has long been used to facilitate the identification and confirmation of heritable 
disorders. This approach however has progressed rapidly since the invention of Sanger 
sequencing and has led to major advances in the ability to sequence large amounts of genetic 
material due to high-throughput sequencing techniques and the decrease in cost (Rabbani et al., 
2014, Rizzo and Buck, 2012). In the diagnosis of PFD, genetic testing is widely applied for the 
aim of identifying variants that are responsible for the clinical presentation of patients and 
possible screening of other family members. So far, genetic testing has helped in identifying 
causative mutations behind a number of previously phenotypically well classified disorders 
such as grey platelet syndrome (GPS) (Albers et al., 2011) and the discovery of novel causative 
genes not previously implicated in disease (Johnson et al., 2016). 
In the GAPP study a combination of a platelet phenotyping and gene sequencing approach is 
used to identify candidate mutations underlying platelet dysfunction (Watson et al., 2010). This 
approach has so far identified several patients with functional disrupting mutations in the TxA2 
receptor (Mumford et al., 2010) and the P2Y12 ADP receptor (Dawood et al., 2012). 
Furthermore, a novel mutation in the P2Y12 ADP receptor has been reported in a family with 
type 1 VWD (Daly et al., 2009). Other mutations in SLFN14, RUNX1 and FLI1 have been 
identified in patients with thrombocytopenia (Fletcher et al., 2015, Johnson et al., 2016). More 
recently,  a genetic variant in thrombomodulin (THBD) has been identified in a family with an 
unexplained bleeding (Maclachlan et al., 2017b). 
 





4.2 Aim  
This chapter aims to perform genotyping (using WES and Sanger sequencing) of selected 
patients found to have an abnormal phenotype upon platelet function testing to try to uncover a 
genetic variant which is likely to be causative of disease 






4.3.1 Overall patients’ demographics and platelet parameters  
Genetic analysis was performed on 25 patients with platelet function defects including 2 
extended families (9 male and 15 female) with a median age of 33 years (range 4-53).  The 
overall patients’ demographic, platelet parameters and Lumi-LTA finding are shown in table 
4.1. Phenotyping of one of the patients (P10) was done at a local referral centre and so no details 
are available. All patients had a normal platelet count and two (P8 and P9) had increased MPV 
(14fl and 13.8fL, respectively). ISTH BAT score varied between patients (range 4-20). All 19 
index cases and 4 family members presented with abnormal platelet function (table 4.1).   
WES was performed on genomic DNA. Overall, WES revealed between 26,000 and 36,000 
variants (including single nucleotide variants, splice variants, frameshifts and small scale 
insertions/deletions) in the DNA from each patient. The variants were first subjected to filtering 
using a variant frequency cut off value of ≤0.01. Any variant with a minor allele frequency 
(MAF) of >0.01 or synonymous variants not known to change the amino acid were excluded. 
On average, 3396 variants with a MAF of ≤0.01 excluding synonymous variants were noted 
per individual. The variants from each individual were then compared to a database of 357 
known platelet related genes (the list is outlined on appendix 3). An average of 44 (range, 14-
58) variants were observed per individual, and of these variants about 7 (range, 2-10) variants 
were deemed plausible candidates.  
A total of 89 variants within 71 genes, were identified among the 19 index cases presented with 
a platelet function defect, of which 90% (80/89) were missense alterations and 23 were 
previously unreported. In addition to the missense variants, 3 potential splicing, and two each 





of frameshift, stopgain and nonframeshift variations were identified. All the variants identified 
in this cohort were inherited in a heterozygous fashion.   
 








Table 4.1 Summary of 25 patients that were analysed by genetic test, the table displays patient demographic, platelet parameters, ISTH BAT score 
and Lumi-LTA finding: Data are presented as an absolute number. 





 4.3.2 Variants found in patients suspected to have Gi defects  
Genetic testing was analysed on 10 index cases and one family member that presented with a 
Gi defect by lumi-LTA (table 4.1). Prior to WES, Sanger sequencing was initially analysed on 
4 cases (P1:F1:I, P8, P11 and P13) searching for a mutation on the P2Y12 receptor gene, 
however, no abnormal variant was identified. The results of WES of 9 index cases are presented 
in the table 4.2. The results of one of the index cases (P1:F1:I) and his related family members 
will be discussed  in section 4.3.6 of  this chapter. Of 9 of the index cases (table 4.2) two patients 
were presented with two variants in genes known to be involved in Gi signalling pathway.  In 
patient P2, a missense variant (c.169C>T, p.Arg57Trp) causing single nucleotide variant (SNV) 
in the PRKACG gene is a novel variant and was not found in all databases searched. In patient 
P10, a missense variant (c.424G>T, p.Val142Phe) causing an SNV in the PLA2G4C gene. The 
variant (rs00115932) was previously found in other databases with a MAF of 0.0089. Both of 
these variants were predicted to be damaging by 5 in silico prediction softwares which include 
Mutation Taster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar, Provean Score and Sift Score.  
5 out of 9 patients (P4, P7, P10, P12 and P13) were identified with variants in genes (JMJD1C, 
VWF, VPS16 and VPS41) known to be involved in both Gi signalling pathway and platelet 
secretion (table 4.2) (Leo C V et al 2015). Interestingly, two of these patients (P4 and P13) 
presented with low ATP secretion in addition to their Gi defect (table 4.1).  All of the five 
variants (JMJD1C; c.3634A>T, VWF; c.817C>T, VWF; c.4751A>G, VPS16; c.1037G>C and 
VPS41; c.622C>T) were missense variant causing SNVs and four of which (c.3634A>T, 
c.817C>T, c.4751A>G, and c.622C>T) were previously found in other databases with a MAF 
of 0.000704, 2.50E-05, 0.002942 and 0.0001568 respectively. Two variants within the VWF 
gene were identified in two different patients. One of the variants in patient P7 occurred within 





VWF; c.817C>T, p.Arg273Trp with MAF of 2.50E-05 and the other in patient P10 occurred 
within VWF; c.4751A>G, p.Tyr1584Cys with a MAF of 0.002942. The variant (c.1037G>C, 
p.Cys346Ser) within the VPS16 gene identified in P12 was the only novel variant and was not 
found in all databases. All of these variants were predicted to be disease causing by using 
Mutation Taster and damaging by at least three of other prediction software (PolyPhen-2 
HumDiv, PolyPhen-2 HumVar, Provean Score or Sift Score).  
Seven other variants were identified within 6 genes (VPS33B, LYST, VPS4B, TRPM7, MYH13 
and ANKRD26) known to be involved in secretion (Leo et al., 2015). Three of these (TRPM7, 
MYH13 and ANKRD26) were noted in a single patient (P13).  One variant within ANKRD26 
was found in this patient which introduced a premature stop codon at the point of variation 
(c.105C>G, p.Tyr35*). This variant was previously found in other databases with a MAF of 
0.0002. The other variant within the TRPM7 gene, a missense variant (c.2033C>T, 
p.Ala678Val) is a novel variant and was not found in all databases. The third variant is within 
the MYH13 gene consisting of a missense variant (c.5101C>G, p.Arg1701Gly). It was 
previously found in other databases with a MAF of 0.002563. Interestingly, the ATP secretion 
value of this patient was reduced, suggesting that one or more of these genes could be the cause 
of her bleeding symptoms. 2 out of 7 variants were identified in P11, one of which (c.2806C>A, 
p.Pro936Thr) in LYST was novel and the other (c.40C>G, p.Leu14Val) in VPS4B was 
previously found with a MAF of 0.001519. The last two variants in VPS33B (c.1453G>A, 
p.Val485Ile) and LYST (c.8913T>G, p.Asn2971Lys) were observed in two patients (P2 and 
P12, respectively). Both variants were consisting of a missense change and were previously 
found in other databases with a MAF of 0.0000825 and 0.002159 respectively. All of the 7 
variants were predicted to be disease causing by Mutation Taster and damaging by at least two 





of other prediction software (PolyPhen-2 HumDiv, PolyPhen-2 HumVar, Provean Score or Sift 
Score). However, all the other 3 patients (P2, P11 and P12) gave normal ATP secretion value. 





         





           
Table 4.2 Summary of pathogenicity prediction and variant classification of the variants identifed in patients with Gi defects. The table dispays the nucleotide 
changes and effect of the resulting protein, the type of variantion and the prevelance among the population, PhyloP and PhastCons measure the prediction and 
probability of conservation at each individual base, Mutationtaster, SIFT, Provean and PolyPhen-2 are used to predict the pathogenicity a mutation. The ACMG 
provides supporting evidence for variants classification.   





4.3.3 Variants found in two patients with dual defects and one patient suspected with a 
defect on the PAR-1 receptor.  
WES analysis of three patients (P3, P6 and P9) is outlined in table 4.3.  The platelet function 
test of P3 and P6 revealed a dual defect in Gi signalling and cyclooxygenase pathways (table 
4.1).  The WES of these two patients identified a total of 14 significant variants in known 
platelet related genes. Patient P3 presented with 6 variants (table 4.3), two of which are within 
the genes (VWF and PLCB3) known to be involved in both Gi signalling and secretion, and one 
variant in RAI1 known to be a secretion related gene. Interestingly, the ATP secretion level of 
this patient was reduced (table 4.1).  All three variants consisted of missense changes 
(c.6187C>T, p.Pro2063Ser, c.2558C>A, p.Pro853His and c.5590G>A, p.Gly1864Arg, 
respectively) and they were previously found in other databases with a MAF of (0.01273, 
0.002786 and 3.32E-05, respectively). P6 presented with 8 variants, one variant is within 
PTPRC which is known to be involved in both Gi signalling and secretion. This variant was a 
missense change (c.2293C>T, p.His765Tyr), and is a novel variant not found in all databases 
screened. Two other variants in P6 were within MYH13 and ANKRD26 which are known to be 
involved in platelet secretion. However, the ATP secretion level of the patient was normal (table 
4.1). The platelet function test of P9 suggested a defect on the PAR-1 receptor.  However, the 
analysis of the PAR-1 receptor gene by Sanger sequencing did not identified any variant. WES 
identified four variations (table 4.3), two of which were within the genes (MPL and STX2) 
known to be involved in platelet secretion. Interestingly, the ATP secretion value of this patient 
was reduced (table 4.1). Both variants were missense changes. The variant (c.1652C>T, 
p.Pro551Leu) in the MPL gene was a novel variant, and the variant (c.845T>C, p.Leu282Pro) 
in STX2 was previously found in other databases with a MAF of 0.000651. 






          
Table 4.3 Summary of pathogenicity prediction and variant classification of the variants identifed in two patients with dual defects and one patient with PAR-
1 receptor defect. The table dispays the nucleotide changes and effect of the resulting protein, the type of variantion and the prevelance among the population, 
PhyloP and PhastCons measure the prediction and probability of conservation at each individual base, Mutationtaster, SIFT, Provean and PolyPhen-2 are used 
to predict the pathogenicity of a mutation. The ACMG provides supporting evidence for variants classification.   





4.3.4 Variants found in patients suspected to have a cyclooxygenase pathway defect 
A total of 25 variants were identified by WES analysis in 5 patients suspected with 
cyclooxygenase pathway defects (table 4.4). Overall, no variant was noted in genes related to 
the thromboxane receptor or cyclooxygenase 1 enzyme in any of the 5 patients analysed. 
Interestingly however, 5 variants observed in 3 of the patients (P14, P17 and P18) were found 
in genes (MYLK, SELP, CTTN and ITGA2B), and have previously been reported to be 
associated in platelet function in individuals with aspirin resistance (Voora et al., 2013). Two 
of these variants were found in patient P14 (MYLK and SELP), both missense changes 
(c.3338C>T, p.Ser1113Phe and c.2180G>A, p.Gly727Glu, respectively) and were previously 
found in other databases with a MAF of (0.00001648 and 0.001213, respectively). Two other 
missense variants were noted in P17; one variant (c.1019T>G, p.Val340Gly) in CTTN and the 
second variant (c.439C>G, p.Leu147Val) in ITGA2B, both of which were previously found in 
other databases with a MAF of (0.003746 and 0.009465, respectively). The fifth variant was 
found in patient P18, a missense change (c.2503A>G, p.Ser835Gly) in ITGA2B and was 
previously found in other databases with a MAF of 0.00004954. All of these variants were 
predicted to be disease causing and damaging by at least two of prediction software including 
Mutation Taster.  
On the other hand, there are 12 additional variants presented in these 5 patients which are found 
in genes known to be involved in either the Gi signalling pathway, secretion pathway or in both. 
In P15, three variants were observed in genes known to be involved in both Gi signalling and 
secretion. Interestingly, the ATP secretion value of this patient (P15) was moderately reduced 
(table 4.1). Two of these variants are within PTGIR and LTBP1, a frameshift causing deletion 
(c.48delG, p.Gly17* and c.514delC, p.Arg172*, respectively),   both of which are novel 





variants and were not found in all databases searched. The third variant is in VPS41, consisting 
of a missense change (c.1832G>A, p.Arg611His) and was previously found in other databases 
with a MAF of (0.001055). Two other variants observed in P15 are within two genes (ADRA2B 
and PDE5A) known to be involved in Gi signalling. Both of these variants were missense 
changes (c.1126G>A, p.Val376Ile and c.2207T>C, p.Ile736Thr, respectively) and were 
previously found in other databases with a MAF of 0.002181 and 0.001228, respectively.  
In P16, two variants were observed in genes (STXBP2 and ANKRD12) known to be involved 
in secretion and one variant in VWF known to be involved in both Gi signalling and secretion. 
Interestingly, the ATP secretion value of this patient was also reduced. All of these three 
variants are missense changes (c.115C>T, p.Arg39Cys, c.971C>T, p.Pro324Leu and 
c.1078G>A, p.Gly360Ser, respectively). However, only the variant c.115C>T, p.Arg39Cys was 
a novel variant and was not found in all databases.  
Finally, two patients (P17 and P18) were identified with variants in genes known to be involved 
in platelet secretion (DNAH11 and MYH13, respectively). Both patients however, had normal 
ATP secretion values (table 4.1). Both of these variants were missense changes (c.9011G>A, 
p.Arg3004Gln and c.5354G>A, p.Arg1785Gln) and were previously found in other databases 











          
 





      
Table 4.4 Summary of pathogenicity prediction and variant classification of the variants identifed in patients with cyclooxygenase pathway defects. 
The table dispays the nucleotide changes and effect of the resulting protein, the type of variantion and the prevelance among the population, PhyloP 
and PhastCons measure the prediction and probability of conservation at each individual base, Mutationtaster, SIFT, Provean and PolyPhen-2 are 












4.3.5 Defect in genes that were identified in multiple patients  
A number of gene variants were noted in more than one patient (table 4.5).  Candidates were 
within VWF and identified in four patients, two of which (P7, P10) presented with Gi defect, 
one (P3) with a defect in Gi and cyclooxygenase pathway, and one (P16) with defect in 
cyclooxygenase pathway. ATP secretion values of patient P3 and P16 were also reduced. All 
of these 4 variants were missense changes and were previously reported in other databases 
(table 4.5).  Defects in MYH13 were also found in four different index cases (P1:F1:I, P6, P13 
and P18). MYH13 is a platelet secretion gene, but only one patient (P13) had low ATP secretion 
values. All of the variants were missense changes and were previously reported in other 
databases (table 4.5). 
Variants in NBEAL2 were identified in three patients (P3, P6 and P12). All of the three variants 
were missense changes (c.5866G>A, p.Val1956Met, c.2231C>T, p.Pro744Leu and 
c.6631G>A, p.Asp2211Asn, respectively) and one, found in patient P12 was novel. NBEAL2 is 
a gene involved in platelet secretion however only patient P3 was presented with reduced ATP 
secretion (table 4.5). LYST is another platelet related secretion gene and was found in two 
patients (P11 and P12), both of which however presented with a normal ATP secretion value. 
Both variants (c.2806C>A, p.Pro936Thr and c.8913T>G, p.Asn2971Lys) were missense 
changes and one in patient P11 was novel.  Two candidates in VPS41 were noted in two patients 
(P13 and P15). Both variants (c.622C>T, p.Arg208Trp and c.1832G>A, p.Arg611His) were 
missense changes and were previously reported in other databases. VPS41 is a member of the 
VPS family genes known to function in intracellular trafficking and cell secretion. Interestingly, 
both of patients identified with VPS41 variations have reduced ATP secretion values (table 4.5). 
ANKRD26 is associated with thrombocytopenia but variants were found in two patients (P6 and 





P13) with a normal platelet count. Similarly, ITGA2B is associated with GT but it was identified 
in two patients (P17 and P18) with defects in cyclooxygenase pathways. This indicated that 
both genes (ANKRD26 and ITGA2B) are unlikely to contribute to the bleeding diathesis 
observed in these patients.  
 





Table 4.5 Summary of defects in genes that were identified in more than one patient. The table 
dispays the list of genes idenified and patients involved, platelet phenotypes, the type of gene 










4.3.6 Genetic analysis of an index case presented with a Gi signalling defect and her family 
members  
The index case (P1:F1:I), a 55 year old female was investigated for a platelet function defect 
and was identified to have an abnormal platelet function defect in response to all concentrations 
of ADP. Her initial sequencing analysis did not identify any abnormal variant in the P2Y12 
receptor gene. Her family members, a brother (F1:II) a daughter (F1:III) and a son (F1:IV) were 
later recruited and investigated for a platelet function defect. The clinical manifestations 
presented among family members vary including epistaxis, cutaneous bleeding, oral cavity 
bleeding, gum bleeding and menorrhagia (in female). The ISTH BAT score, overall patients’ 
demographic, platelet parameters and Lumi-LTA findings are shown in table 4.1. A defect in 
platelet function was only identified in the index case (P1:F1:I) and her brother (F1:II), both of 
whom presented with a Gi signalling defect. ATP secretion values were normal in all family 
members (table 4.1). The family pedigree is shown in figure 4.1. 






Figure 4.1 Pedigree from family one investigated for bleeding disorders.  Males are represented 
by squares and females by circles. Individuals with bleeding manifestation are shaded and their 
ISTH BAT sore are in the brackets.  Question mark denotes that the candidate was not tested. 





 Only the index case (P1:F1:I) of family one was analysed by WES which identified 10 
significant variants (table 4.6A). One variant was found in TTC37 which is known to be 
involved in Gi signalling. It is a splice site variant (c.4053+3A>G) located within 3bp of the 
intron-exon boundary. The variant is novel and it was predicted to be a disease causing by 
Mutation Taster. Two other variants presented in this patient are found in genes (PLCB3 and 
APC) known to be involved in both Gi signalling and platelet secretion. Both of these variants 
are missense changes (c.1197G>C, p.Lys399Asn and c.3332T>C, p.Leu1111Ser, respectively), 
the former variant is novel and was not found in any databases. None of the 4 patients in this 
family however were found to have a low ATP secretion value. Three additional variants 
identified in the index case were found in genes (STXBP, MYH13 and HOOK3) known to be 
involved in platelet secretion. Two of these variants are missense changes (STXBP, c.1197G>C 
and MYH13, c.827C>G) and one (HOOK3 c.1945-2delA) consisting of a splice site deletion 
located within 2bp of the intron-exon boundary. All of the three variants are novel and were not 
found in all databases searched. 
Sanger sequencing of selected variants (P2RX1, PLCB3, APC and TTC37) were analysed in all 
family members, firstly to remove potentially false-positive derived results from WES and to 
confirm the presence of the variant in other family members. These four variants were selected 
based on the abnormal platelet function results suggesting a Gi signalling defect in two of the 
family members (the index case and F1:II). The list of three variants identified by Sanger 
sequencing in each family member is presented in table 4.6B.  





              
Table 4.6 Summary of pathogenicity prediction and variant classification of the family one. (A) Variants identifed by WES in index case and (B) 
Variants identifed by Sanger sequencing in other family members.  The tables dispay the nucleotide changes and effect of the resulting protein, 
the type of variation and the prevalance among the population, PhyloP and PhastCons measure the prediction and probability of conservation at 
each individual base, Mutationtaster, SIFT, Provean and PolyPhen-2 are used to predict the pathogenicity of a mutation. The ACMG provides 
supporting evidences for variants classification.  





Sanger sequencing confirmed the presence of all three variants in the index case (figure 4.2). 
None of the variants identified here however, were consistent with the platelet phenotype 
observed in this family. The variant c.101G>A in P2RX1 was also identified in F1:III and 
F1:IV, both of which with normal platelet function (figure 4.2A). The variant c.3332T>C in 
APC was also identified in another two family members (F1:II and F1:IV) one of which (F1:IV) 
however  has normal platelet function (figure 4.2B). In contrast, the variant c.1197G>C in 
PLCB3 was only observed in the index case and not in F1:II, both of which however presented 
with Gi signalling defects (figure 4.2C). 
 
 






Figure 4.2 Electropherograms of sanger analysis from four members of the family one showing 
the nucleotide change in comparison with a control. (A) The variant c.101G>A in P2RX1 gene 
identified in three family members (P1:F1:I, F1:III and F1:IV), (B) the variant c.3332T>C in 
APC gene identified in three family members (P1:F1:I, F1:II and F1:IV) and (C) the variant 
c.1197G>C in PLCB3 gene identified only on the index case (P1:F1:I), arrows indicate a point 
of nucleotide change.   
 





4.3.7 Genetic analysis of a family presenting with a platelet secretion defect 
Four family members (P19:F2:I, F2:II, F2:III and F2:IV) were investigated in family 2. The 
family pedigree for all members is shown in figure 4.3. The index case (P19:F2:I) is a 45 year 
old mother with an ISTH BAT score of 17 (table 4.1). Clinical manifestations including 
bleeding from minor wounds, cutaneous and oral cavity bleeding were shared among all four 
family members in addition to menorrhagia in female members. Platelet function tests presented 
with low ATP secretion value in all family members in addition to cyclooxygenase like defect 
in two members (P19:F2:I and F2:III). WES analysis revealed an average of 36,200 variants 
per individual. However, only two variants were identified to be significant (table 4.7). Only 
one of the two variants was noted to be shared by all four members (table 4.7). Interestingly, 
the variant was found in VPS39 which is known to be associated with platelet secretion. The 
variant is a missense change (c.1723G>T, p.Asp575Tyr) and was previously found in other 
databases with a MAF of 0.003381. The second variant was only shared by two family members 
(F2:II and F2:IV), a missense change (c.622G>C, p.Glu208Gln) in SH2B3 and previously 
found in other databases with a MAF of 0.0009879. 






Figure 4.3 Pedigree from family 2 presenting the inheritance of VPS39 mutation. Males are 
represented by squares and females by circles. Affected individuals are shaded. Question mark 
denotes that the candidate was not tested. The ISTH BAT sore are in the brackets.   
 






        
Table 4.7 Summary of pathogenicity prediction and variant classification of the variants identifed in family two with secretion defect. The table dispays the 
nucleotide changes and effect of the resulting protein, the type of variantion and the prevelance among the population, PhyloP and PhastCons measure the 
prediction and probability of conservation at each individual base, Mutationtaster, SIFT, Provean and PolyPhen-2 are used to predict the pathogenicity of a 









Sanger sequencing of SH2B3 and VPS39 was analysed for all four members of family two in 
order to remove potentially false-positive derived results from WES and to confirm the presence 
of these variants within the family members. The c.1723G>T is the only candidate noted to be 
shared by all four members. Interestingly, the variant is found in VPS39 which is predicted to 
be a platelet secretion gene. Analysis using the Blueprint epigenome data (Chen et al., 2014) 
revealed a full expression of VPS39 throughout the haematopoietic progenitors leading to 
megakaryocytes (figure 4.4B). Furthermore, the variant is located at highly conserved genetic 
site in many of species (figure 4.4C), suggesting that a mutation at this point is more likely to 
affect the function of resulted protein.  






Figure 4.4 Analysis of VPS39 gene mutation found in all four members of family 2. (A) 
Representative sanger electropherograms confirming the VPS39 variant repoterd by WES to be 
presenet in all family bembers, arrows indicate a poin of nucleotide change. (B) Expression of 
VPS39 gene throughout the progenitors leading to megakaryocytes as determined using 
Blueprint epigenome data (HSC–Haematopoietic stem cell, MPP–Mulitpotent progenitor, 
CMP–Common myeloid progenitor, MEP–Myelo-erythroid progenitor, EB–Erythroblast, and 
MK–Megakaryocyte). (B) Conservation sight of the VPS39 mutation in higher order species.  
 
   






The work in this chapter presents genetic findings analysed in a selected group of patients and 
some family members recruited into the GAPP study. The patients were investigated using the 
GAPP approach which combines platelet phenotyping with whole exome sequencing. All 
selected index cases included in this cohort presented with platelet function defects and a 
normal platelet count (table 4.1). The cohort mainly focused on individuals with a defect in Gi 
signalling and cyclooxygenase pathways as these are the two major feedback pathways 
underlying platelet activation, however one candidate suspected with a defect on PAR-1 
receptor and a family with secretion defect were also included.  
To exclude variants that are unlikely to contribute to the phenotype observed in the patients and 
to identify a potential causative gene defect following WES, a combination of strategies were 
applied. Firstly, the data was filtered by excluding synonymous variants not known to change 
the amino acid, and restricting the analysis of variants with a MAF of less than 0.01. The 
variants were then compared to a database of 357 known platelet related genes and were 
predicted to be deleterious using a selection of bioinformatic tools. A further reduction of 
variants was also achieved in some index cases by comparing candidate variants within related 
family members. 
WES has identified candidate genetic variations that could explain the platelet function defect 
in 59% (13/22) of the cases. The majority of variants identified in this cohort were missense. 
This was not of surprise as missense variants are most common due to relative impact on the 
expressed protein. In general, missense variants are tolerated by retaining expression and partial 
function of the affected allele.   





23 (26%) candidate genes identified in this cohort were consistence with patients’ phenotypes. 
Four of the variants within genes (TTC37, PRKACG, PLA2G4C and PTPRC) are known to be 
associated with Gi signalling (Leo et al., 2015). The variants were observed in four patients, all 
of which presented with a defect in Gi signalling. The variant in PRKACG was novel and the 
one in TTC37 was a splicing defect causing a loss of the donor site. Nine other variants within 
genes (PTGIR, LTBP1, TRPM7, MYH13, RAI1, MPL, STX2, STXBP2 and ANKRD12) known 
to be associated with platelet secretion defects (Leo et al., 2015) were found in 5 patients 
presenting with low ATP values. 3 out of these 5 patients were presented with two missense 
variants each, one of which was novel. P15 however, showed two frameshift variants (PTGIR 
and LTBP1) both of which were novel. Two other genes (JMJD1C and PLCB3) previously 
reported in patients with defect Gi signalling and platelet secretion defects (Leo et al., 2015) 
were noted in two patients (P4 and P3).  Interestingly, both patients are presented with a defect 
in Gi signalling and reduction in ATP secretion. 
Defects in the VWF gene is responsible for VWD, however, a number of studies have previously 
suggested a possible genetic link associated between VWD and platelet function defects 
(Goodeve et al., 2007, James et al., 2007). Several genetic variants in genes associated in 
platelet function including two with P2RY12 gene have been reported in patients diagnosed with 
VWD (Stockley et al., 2015, Daly et al., 2009).  Recently, genetic variations in VWF gene have 
been observed in patients with Gi signalling and platelet secretion defects (Leo et al., 2015).  In 
this study, candidates within the VWF gene were identified in four patients (table 4.5). 
Interestingly, two of these four patients (P7 and P10) presented with Gi signalling defects, one 
patient (P16) with a reduced ATP value and one patient (P3) with both defects. Two of these 
four VWF candidates genes mutations identified in this cohort (Pro2063Ser and Tyr1584Cys) 
were previously reported in patients with type 1 VWD (Kasatkar et al., 2013, Daidone et al., 





2017). The harmful consequences of the former mutation (Pro2063Ser) however, remains 
controversial (Hampshire and Goodeve, 2014). 
Two missense variants in VPS41 were noted in two patients (P13 and P15), both of which 
presented with a reduced ATP value. VPS proteins are known to function in intracellular 
trafficking and therefore a defect in this gene can result in secretion defects (Balderhaar and 
Ungermann, 2013).  Recently, a defect in the VPS41 gene was identified in patients with a 
secretion defect (Leo et al., 2015). As both of the patients described are presented with reduced 
ATP values, it is possible that the defect in VPS41 identified here could have contributed to 
their bleeding diathesis.  Functional confirmation however will still be required to confirm this.  
WES detected 5 genes in 12 patients that were not consistence with patients’ phenotypes. 
MYH13 has previously been noted in patients with secretion defects (Leo et al., 2015). In this 
study, variants with MYH13 were identified in four cases, three of which however presented 
with normal ATP values (table 4.5). The NBEAL2 protein is known to be involved in vesicular 
trafficking and so is critical for the development of α-granules (Rensing-Ehl et al., 2015). 
Defects in NBEAL2 have been reported to be associated with GPS (Gunay-Aygun et al., 2011). 
In this cohort, candidate variations in NBEAL2 were found in three patients, none of which 
presented with clinical features of GPS. One of these four patients (P6) was analysed by flow 
cytometry as a part of RPFT and was found to have normal expression of P-selectin in response 
to number of agonists. Defect in LYST is also known to be associated with CHS (Sepulveda et 
al., 2015).  In this study, two variants within LYST were identified in two index cases, both of 
which have no clinical features of CHS and their ATP values were normal. Interestingly, one 
of the patients (P12) presented with a defect in both NBEAL2 and LYST (table 4.5). ANKRD26 
is a gene responsible for THC2 which is associated with thrombocytopenia and haematologic 





malignancies (Noris et al., 2013). Two variants in ANKRD26 were identified in two cases. One 
of the variants was a premature stop codon and it was detected in a patient (P13) presenting 
with a low ATP value. Both of the two patients however have normal platelet counts, therefore 
these variants are unlikely to be the cause of their bleeding symptoms. Two patients were 
identified with variants in ITGA2B, a gene known to be associated with GT (Nurden et al., 
2011). Platelet phenotyping of these two patients however were not consistence with GT 
indicating that variants are unlikely to be the cause of bleeding diathesis.  
Individual with an ‘aspirin-like’ defect have been diagnosed in laboratories for almost 50 years 
now. Many of them were found with a defect in platelet cyclooxygenase (Rao, 2003) and some 
with thromboxane synthase deficiency (Rolf et al., 2009). However, only few mutations in 
thromboxane pathway have so far been reported (Hirata et al., 1994, Adler et al., 2008, 
Mumford et al., 2010). In this study, WES was analysed on 7 patients presented with a defect 
in cyclooxygenase pathway. However, no causative mutation was noted in genes related to 
thromboxane receptor or the cyclooxygenase 1 enzyme in any of the 7 patients. Interestingly 
however, 5 variants observed in 3 of the patients (P14, P17 and P18) were found in genes 
(MYLK, SELP, CTTN and ITGA2B) previously reported to be associated in platelet function in 
individuals with aspirin resistance (Voora et al., 2013). These variants may or may not have 
contributed to the aspirin-like’ defect observed in these patients, but further work would be 
needed to determine this. 
Two families were investigated in this cohort. Family one is a complex case of four related 
individuals. A mother (index case) and her two siblings all of which were presented with 
bleeding diathesis and ISTH BAT score of 5 and above (Figure 4.1). Surprisingly, only the 
mother was presented with abnormal platelet phenotype. In contrast, the brother of the index 





case has almost no bleeding symptoms (ISTH BAT score of 1). However, his platelet function 
analysis presented with a Gi signalling defect similar to his sister (table 4.1). Four genes 
(P2RX1, APC, PLCB3 and TTC37) were identified in P1:F1:I to be consistence with her 
phenotype and were further investigated in all four family members using Sanger sequencing. 
APC and PLCB3 have previously been reported in patients with a defect in Gi signalling (Leo 
et al., 2015). In this family, the variant in APC was also detected in F1:IV who has no platelet 
defect suggesting that the variant  is unlikely to contribute to the platelet phenotype observed 
in other two family members. On the other hand, the PLCB3 gene was identified only in 
P1:F1:I.  Absence of this variant in F1:II who also presented with platelet defect has ruled out 
the likelihood of this variant to be the cause of the abnormal platelet function observed. P2X1 
is an ATP receptor when binds to its ligand and evokes Ca2+ influx to contribute to platelet 
function (Mahaut-Smith et al., 2011). A mutation within the platelet P2RX1 has been reported 
in a patient with a severe bleeding and abnormal platelet function (Oury et al., 2000). In this 
family the variant on P2RX1 gene was observed in three family members, two of which have 
normal platelet function. Furthermore, the variant was absent on the family member F1:II who 
also presented with abnormal platelet function indicating that the variant is unlikely to cause 
the platelet defect in this family. The TTC37 is the causative gene of Trichohepatoenteric 
syndrome (THES) characterised by life-threatening diarrhea in infancy, immunodeficiency, 
liver disease, trichorrhexis nodosa, facial dysmorphism, hypopigmentation and cardiac defects 
(Hartley et al., 2010). The TTC37 gene has also been reported in individuals with defect in Gi 
signalling (Leo et al., 2015). This raises the possibility that, if the TTC37 variant is proven to 
be present in both (P1:F1:I and F1:II) it could then explain the abnormal platelet function 
observed in this family.  However, further functional work would still be required to confirm 
this.  





 Family two is an interesting case of four affected related individuals of a mother and her three 
siblings all of which presented with bleeding diathesis and abnormal platelet function. The 
phenotypic presentation however, varies between the family members. All four present with a 
secretion defect, but the ATP values in patients F2:II and F2:IV was markedly reduced 
compared to the index case (P19:F2:I) and patient F2:III. In contrast, the index case and patient 
F2:III were identified with an additional defect in the cyclooxygenase pathway that was not 
observed in the other two members (table 4.1). WES identified only one variant within the 
VPS39 gene that was present in all 4 individuals which was also confirmed by Sanger 
sequencing (figure 4.4A). No variant was noted to be common in both, the index case and F2:III, 
which could explain their additional defect on cyclooxygenase pathway observed. In contrast, 
one variant in SH2B3 was identified by WES to be present only in F2:II and F2:IV.  
The molecular function of the rare VPS39 gene variant observed in this family is currently 
unknown. However, it has been reported that in human cells the gene is involved for the delivery 
of endocytosed cargo to enzymatically active lysosomes (Pols et al., 2013).  Furthermore, the 
other VPS family genes including VPS33B is known to be a genetic cause of ARC syndrome 
and is related to an alpha granule secretion defect (Urban et al., 2012).  Interestingly, the VPS39 
gene is highly expressed in hematopoietic cells. Furthermore, the amino acid position of this 
gene variant is found to be highly conserved suggesting a possible role for this region in 
regulating VPS39 expression that could be disrupted by the mutation. Overall, it highly 
suggestive that the variant found in VPS39 gene could be the cause of the clinical presentation 
observed in this family. It is also possible that, the presence of other genetic variants may have 
contributed to the variation of platelet phenotype among family members. Functional 
confirmation of the variant c.1723G>T in VPS39 would be of interest to determine whether this 
variant is the true contributor of the phenotype observed in this family.     





In summary, WES in this study has identified the possible genetic variant candidates in 10 
(53%) patients presented with bleeding symptoms and abnormal platelets function. Further 
work however is still needed to confirm the real contribution of these variants to the phenotype 
observed in these patients.   
4.4.1 Limitation and suggestions 
Genetic analysis of this study focused only to those genes known to be platelet related genes. It 
is therefore suggestive in the future to reanalyse the novel genes not previously known to affect 
platelet function for the aim of identifying the genetic mutation of the remaining 47% of 
patients, most importantly the family one which includes family members with both normal and 
abnormal phenotypes. It will also be useful to include family members to further reduce the 
number of possible variants identified within the patients.  
 






CHAPTER FIVE: COMPARISON OF MULTIPLE ELECTRODE 
AGGREGOMETRY WITH LUMI-AGGREGOMETRY FOR THE 
DIAGNOSIS OF PATIENTS WITH MILD BLEEDING DISORDERS 
 
5.1 Introduction 
The Multiple Electrode Aggregometry (MEA) is an impedance aggregometer that has been 
developed for the rapid assessment of platelet function in whole blood. The device is equipped 
with 5 channels that allow simultaneous analysis of platelet responses using different agonists. 
MEA evaluates platelet responses in disposable ready-to-use test cuvettes each containing two 
pairs of electrodes, thus enabling a duplicate measurement. During the test, activated platelets 
adhere onto the electrodes resulting in changes to the electrical resistance which is continuously 
monitored for 6 minutes (Toth et al., 2006). The test results are assessed using the two 
independent sensors in the test cell, calculated and reported as area under the curve (AUC). A 
typical normal aggregation curve and defined endpoint parameters are shown in figure 5.1. 
Although MEA can also measure the kinetic changes in aggregation over time including the 
parameters of lag time, slope and area under the curve and maximal aggregation, the traces are 
not as detailed as LTA which not only measures these but also includes shape change, primary 
(reversible) and secondary aggregation responses.  In addition, MEA does not measure released 
ATP in parallel with aggregation.   
As a whole blood method, MEA has an advantage of assessing platelet function in more 
physiological conditions and avoids the variables associated with the preparation of PRP. In 
addition, this approach is faster, more convenient and is less technically demanding. 
Furthermore, the use of whole blood requires only small volumes making it possible to be used 
as point of care test and for evaluation of platelet function in young children.  






The use of MEA has gained popularity in the last decade and has been widely established for 
the monitoring of anti-platelet therapy. A number of studies have demonstrated the utility of this 
method in assessing inhibition of platelet function in individuals taking antiplatelet agents e.g. 
aspirin and clopidogrel (Paniccia et al., 2009, Velik-Salchner et al., 2008). In assessing acquired 
haemorrhagic conditions,  MEA has been found to be able to predict the risk of bleeding and 
requirement of blood product transfusion in patients before and after cardiac surgery (Rahe-
Meyer et al., 2008, Rahe-Meyer et al., 2009) and to detect impaired hemostasis in patients after 
cardiopulmonary bypass surgery (Mengistu et al., 2009, Steinlechner et al., 2009). Morel-Kopp 
et al. reported a high sensitivity of MEA in identifying patients with heparin-induced 
thrombocytopenia (Morel-Kopp et al., 2010).  Studies on inherited bleeding disorders have 
demonstrated the utility of MEA in identifying patients with von Willebrand disease (Valarche 
et al., 2011) and its potential for the diagnosis of severe platelet disorders (Awidi et al., 2009, 
Albanyan et al., 2015). The use of MEA for the diagnosis of patients with inherited platelet 
disorders however has not been fully investigated.   
5.2 Aim  
To evaluate the ability of MEA in diagnosing patients with mild bleeding disorders by 
comparison with light transmission lumi-aggregometry (Lumi-LTA).  
This work was carried out in conjunction with Sian Drake. 







Figure 5.1 MEA typical normal aggregation curves and the analytical parameters collected (the 
red and blue lines are the results from the two independent sensors in the test cell). A) The 
increase of impedance is measured as arbitrary aggregation units (AU) and plotted against time. 
B) The AUC expressing the overall platelet activity is calculated from the total height of the 
mean aggregation result against the aggregation slope (Toth et al., 2006). 
 







5.3.1 Overall demographics and platelet parameters of patients and healthy controls  
We analysed a total of 109 patients (21 male and 88 female) with a median age 33 (range 3-73) 
and 40 healthy adult volunteers (18 - 57) recruited into the GAPP study and compared MEA 
results with lumi-LTA. The overall platelet parameters and ATP secretion value of patients and 
healthy controls are shown in table 5.1.On healthy control group, the values (mean ± SD) of 
whole blood platelet count and mean platelet volume (MPV) were 234.5 ± 54 x 109/L and 11.7 
± 1.1fL respectively. The PRP count (mean ± SD) was 3.27 ± 1.25 x 108/L with a mean ATP 
secretion value (mean ± SD) of 1.10 ± 0.33nmol/1 x 109/L platelet. On patients, the values 
(mean ± SD) of whole blood platelet count and mean platelet volume (MPV) were 237.9 ± 52.5 
x 109/L and 11.3 ± 1.2fL respectively. The PRP count (mean ± SD) was 3.61 ± 0.95 x 108/L 
with a mean ATP secretion value (mean ± SD) of 1.02 ± 0.43 nmol/1 x 109/L platelet. The cut 
off values for MEA (table 5.2) obtained from healthy controls (n=40) were calculated as the 5th 
percentile of responses of normal of ADP 10 µM, collagen 1µg/ml, collagen 3 µg/ml, PAR-1 
100 µM and arachidonic acid 0.5mM were 19.1, 21, 35.1, 42.3 and 19.7 (AUC), respectively.






Table 5.1 Summary of platelet parameters and ATP secretion values obtained from healthy controls (n=40) and patients (n=109): Data are 
presented as mean, +/- standard deviation and range. Statistical analysis performed by the Mann Whitney U test. Significance was 
compared to healthy controls (**p<0.01 and *p<0.05).






         
Table 5.2 Summary of MEA results with various agonists (mean and SD) obtained from whole 
blood from healthy controls (n=40). The cut-off values were calculated as the 5th percentile of 
the corresponding measurement in healthy control. 






5.3.2 Correlation between platelet counts and aggregation results by MEA and lumi-LTA  
We analyzed the correlation between aggregation results and platelet counts obtained from 
healthy controls (n=40). With MEA we found a significant but weak correlation between 
whole blood platelet counts and aggregation results in response to ADP 10 μM (r=0.321, p = 
0.0434) but not with PAR-1 100 µM (r= 0.1725, p = 0.2871), arachidonic acid (r = 0.3631, p = 
0.1266), collagen 1 µg/ml (r = 0.1452 p = 0.3714) and collagen 3 µg/ml (r = 0.2068 p = 0.2004) 
(figure 5.2).  In contrast, with lumi-LTA, a weak correlation between the PRP counts and 
aggregation was only found in response to collagen 3 μg/ml (r = 0.366, p = 0.0202) but not with 
ADP 10 μM (r = 0.1576, p = 0.3313), PAR-1 100 (r = 0.1607, p= 0.3219), arachidonic acid 
0.5 mM (r = 0.3428 p = 0.1508) and collagen 1 µg/ml (r = 0.1919 p = 0.2354) (figure 5.3). 
 
  







Figure 5.2 Correlation between  MEA (AUC) and whole blood platelet counts (x109/L) in 
samples from healthy controls (n=40) after stimulation with ADP 10 μM, Collagen 3 µg/ml 
PAR-1 activating peptide 100 µM and Arachidonic Acid 0.5 mM. Correlation analysis 
performed on Graph Pad Prism version 7.0 software using linear regression. r = correlation 
coefficient, p = probability value and *p<0.05 







Figure 5.3 Correlation between  Lumi-LTA (aggregation %) and PRP counts (x108/L) in 
samples from healthy controls (n=40) after stimulation with ADP 10 μM, Collagen 3 µg/ml 
PAR-1 activating peptide 100 µM and Arachidonic Acid 0.5 mM. Correlation analysis 
performed on GraphPad Prism version 7.0 software using linear regression. r = correlation 
coefficient, p = probability value and *p<0.05 
 






5.3.3 Overall comparison between MEA and Lumi-LTA 
Overall results of 109 patients tested are shown on figure 5.4. 54 (49%) patients gave abnormal 
responses by lumi-LTA to one or more agonists as defined using previous criteria (Dawood et 
al., 2012). In contrast, only 16 (15%) patients were shown to have abnormal responses to one 
or more agonists by MEA, as defined using the cut off values obtained from healthy controls 
(table 5.2). The overall agreement between the two instruments is shown in table 5.3. 65/109 
samples gave identical results by both tests, with the majority (52) giving normal responses. In 
contrast, there was disagreement in 44/109 samples. MEA gave normal results in 41 patients 
that were abnormal by lumi-LTA. However, 3 samples were abnormal by MEA but normal by 
lumi-LTA.   
  







Figure 5.4 Summary of overall results from patients (n=109) with normal (blue) and abnormal 
(red) results detected by Lumi-LTA or MEA. Abnormal results by Lumi-LTA were determined 
based on our previously published methodology that is based upon the cut-off values that were 
calculated as the 5th percentile from the healthy volunteers as well as both the magnitude and 
time course of response (Dawood et al., 2007, Dawood et al., 2012) and (by MEA) when they 
fall below the cut-off values (5th percentile) calculated from healthy controls as shown in table 
5.2 
  







Table 5.3 Analysis of the overall agreement between MEA and lumi-LTA in patient samples 
(n=109) displaying sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV).  






5.3.4-Analysis and identification of patients with various platelet function defects  
Platelet function defects identified by LTA were classified into 4 main groups (Gi defect, 
secretion defects, COX-like defect and unclassified defects) according to their pattern of 
responses to specific agonists as previously described (Dawood et al., 2012). As shown in figure 
5.5, MEA only detected 4 out of 17 patients with Gi defects and 2 out of 20 with secretion 
defects. MEA only detected 4/7 patients with a COX-like defect and 0/4 patients with 
unclassified defects by LTA. Finally MEA gave abnormal responses to 3 samples out of 6 with 
multiple platelet defects. When functional defects were classified based upon identical 
concentrations/panel of agonists (with no ATP measurements included) used by both tests, this 
also confirmed that MEA was unable to detect some abnormalities detected by LTA (16 (15%) 
versus 41(38%) (figure 5.6).  Overall kappa statistics demonstrated only a fair agreement 
between MEA and lumi-LTA in response to ADP (k = 0.26, CI = 0.11 to 0.40) and collagen (k 
= 0.28, CI = 0.05 to 0.52) and a poor agreement in response to PAR-1 ( k = 0.07, Cl = -0.17 to 
0.32) (figure 5.7). 






       
Figure 5.5 Classification of platelet function defects on patient samples detected by lumi-LTA 
(blue) and MEA (red). Abnormal results by Lumi-LTA were determined based on our 
previously published methodology that is based upon the cut-off values that were calculated as 
the 5th percentile from the healthy volunteers as well as both the magnitude and time course of 
response (Dawood et al., 2007, Dawood et al., 2012) and (by MEA) when they fall below the 
cut-off values (5th percentile) calculated from healthy controls as shown in table 5.2 
  






          
Figure 5.6 Summary of results from patients (n=109) with normal (blue) and abnormal (red) 
result detected by Lumi-LTA and MEA using an identical panel and concentration of agonists 
(with no ATP measurements included). Abnormal results by Lumi-LTA were determined based 
on our previously published methodology that is based upon the cut-off values that were 
calculated as the 5th percentile from the healthy volunteers as well as both the magnitude and 
time course of response (Dawood et al., 2007, Dawood et al., 2012) and (by MEA) when they 
fall below the cut-off values (5th percentile) calculated from healthy controls as shown in table 
5.2 






      
Figure 5.7 Correlations between MEA (AUC) and lumi-LTA (%) in samples from healthy 
controls (n=40, open circles) and patients (n=109, closed circles) after stimulation with, ADP 
10μM, Collagen 3µg/ml, PAR-1 peptide 100µM and arachidonic acid 0.5 mM (healthy 
controls= 19 and patients =36). The vertical black lines indicate the cut-off values of MEA 
determined as the 5th percentile of the normal range established in healthy subjects. The 
horizontal black lines indicate cut-off values of lumi-LTA previously established in the GAPP 
program using samples from healthy controls. Correlation analysis performed on Graph Pad 
Prism version 7.0 software using linear regression, r = correlation coefficient, p = probability 
value. Value were considered significant when p <0.05. 






5.3.5-Analysis of MEA sensitivity in response to specific agonists  
Further analysis of the response of patients to individual agonists is summarised in figure 5.8. 
MEA detected an abnormality within 12 patients in response to 10 µM ADP, the majority of 
which (11) were also abnormal on lumi-LTA. In contrast, lumi-LTA using the same dose of 
ADP detected an abnormality within 45 patients, 33 of which gave normal responses by MEA. 
In response to 3 µg/ml collagen, 5 patients were abnormal by MEA, 1 of these however gave a 
normal response on lumi-LTA. 19 patients gave abnormal responses to 3 µg/ml collagen by 
lumi-LTA but 15 of these were normal by MEA. With 100 µM PAR-1 peptide, 6 patients were 
abnormal on MEA compared to 9 patients by lumi-LTA. Surprisingly, only one patient with an 
abnormal response to 100 µM PAR-1 peptide was detected by both tests. Finally, with 
arachidonic acid (0.5mM), MEA and lumi-LTA detected 8 and 15 abnormalities respectively. 





A         B 
      
Figure 5.8 Summary of platelet function results assessed by MEA (AUC) and lumi-LTA (%) after stimulation with, ADP 10 μM, Collagen 3 
µg/ml, PAR-1 peptide 100 µM and Arachidonic Acid 0.5 mM. A) Number of patients with abnormal responses to specific agonists detected by 
lumi-LTA (blue), MEA (red) and both (green). B) Aggregation responses of samples from healthy controls (n=40) and patients (n=109). The 
horizontal black lines indicate cut-offs determined as 5th percentile of the normal range from healthy controls. In the patient groups: black circles 
indicate individuals with an abnormality detected by lumi-LTA, and red circles indicate an abnormality detected only by MEA.  





5.3.6 Analysis of patients with low ATP secretion levels and thrombocytopenia  
In 20 patients with secretion defects characterized by reduced ATP levels (table 5.4), the lumi-
LTA and MEA aggregation responses were abnormal in only 8 and 3 patients respectively 
(figure 5.9A). MEA is therefore less sensitive than lumi-LTA at detecting secretion defects 
which is not surprising in that MEA does not provide a direct readout of secretion. On the other 
hand, in 12 (11%) patients with mild thrombocytopenia as characterized by low platelet count 
(<150 x109/L) in whole blood (table 5.4), abnormal aggregation responses were detected by 
MEA on 6/12 patients and lumi-LTA on 8/12 patients (figure 5.9B). 
  






Table 5.4 Comparison between MEA and lumi-LTA on overall results, patients with 
thrombocytopenia and patients with reduced ATP secretion by lumi-LTA, the data are 
presented as absolute number and percentage  
 
  





      
Figure 5.9 Number of patients with normal (blue) and abnormal (red) aggregation responses 
detected by lumi-LTA and MEA from patients with (A) low ATP secretion values and (B) 
thrombocytopenia. Abnormal results by Lumi-LTA were determined based on our previously 
published methodology that is based upon the cut-off values that were calculated as the 5th 
percentile from the healthy volunteers as well as both the magnitude and time course of 
response (Dawood et al., 2007, Dawood et al., 2012) and (by MEA) when they fall below the 
cut-off values (5th percentile) calculated from healthy controls as shown in table 5.2 






The Multiple Electrode Aggregometer (MEA) is an impedance aggregometer used for 
performing platelet aggregation in whole blood. This approach offers the advantage of assessing 
platelet function in more physiological conditions and also avoids the variables associated with 
the preparation of PRP (Toth et al., 2006). MEA is popular for measuring antiplatelet therapy 
(Paniccia et al., 2015, Velik-Salchner et al., 2008) and has been shown to be useful for detecting 
severe PFDs (Awidi et al., 2009, Albanyan et al., 2015). However, the use of MEA for the 
potential diagnosis of patients with inherited platelet disorders has yet to be fully investigated. 
Here I assessed the potential utility of MEA for detecting mild PFDs. 
The MEA manufacturer recommends the use of hirudin as anticoagulant of choice to maintain 
physiological calcium levels (Toth et al., 2006). Studies however, have shown that different 
anticoagulants can affect platelet function activities (Wallen et al., 1997). As such, in this study 
we only used citrated blood for both techniques in order to have a similar comparison with 
identical levels of free calcium. Furthermore, a study using citrated blood from healthy 
individuals showed no significant difference between MEA and LTA even at higher citrate 
concentrations (Seyfert et al., 2007). Another crucial factor when testing platelet activity 
particularly on whole blood aggregometry is the storage time between blood collection and 
sample processing. Studies have shown that in citrated whole blood, platelet function activity 
remain stable up to 4 hours from blood collection (Seyfert et al., 2007, Kaiser et al., 2012). As 
such, to avoid variation of results due to time delays, MEA was always tested during PRP/PPP 
preparation for lumi-LTA to ensure that the analysis was always completed rapidly within 4 
hours (Seyfert et al., 2007, Kaiser et al., 2012). 
As MEA dilutes the whole blood 1:1 with saline before testing it was first thought to investigate 
the influence of platelet counts (within normal count) on both MEA and lumi-LTA results. With 





MEA a linear increase in aggregation was only observed with ADP but not collagen, PAR-1 or 
arachidonic acid (figure 5.2). In contrast with lumi-LTA this was only observed with collagen 
but not ADP, PAR-1 or arachidonic acid (figure 5.3). Previous studies with LTA have found no 
correlation between platelet count and aggregation results (Dawood et al., 2007, Seyfert et al., 
2007, Cattaneo et al., 2007, Femia et al., 2013). Seyfert et al. also found a significant correlation 
between platelet count and platelet aggregation on MEA induced by ADP and collagen, but not 
by arachidonic acid (Seyfert et al., 2007). Mengistu et al. and Stissing et al. also demonstrated 
the influence of platelet count on whole blood aggregometry towards low platelet 
concentrations (Mengistu et al., 2009, Stissing et al., 2011). Two more studies also reported 
correlations between platelet count and extent of platelet aggregation on MEA (Femia et al., 
2013, Hanke et al., 2010). However, the latter results are difficult to interpret as the counts were 
adjusted either by addition of PPP (Hanke et al., 2010) which is known to inhibit platelet 
aggregation (Cattaneo et al., 2007), or with dilution with Tyrode's buffer (Femia et al., 2013).   
This study is the first comprehensive comparison of the potential utility of MEA for detecting 
platelet function defects in patients with mild bleeding disorders. The overall patient results 
(figure 5.4/table 5.3) showed a moderate agreement between MEA and lumi-LTA with the 
diagnosis being concordant in 60% of cases.  As many of these gave normal responses, the 
MEA demonstrated a negative predictive value of 56%. In healthy individuals there was good 
agreement between MEA and lumi-LTA with no difference in response between identical 
concentrations of the agonists ADP, collagen, PAR-1 activating peptide and arachidonic acid. 
This findings support a recent study by Seyfert et al., demonstrating equivalent  results of MEA 
and lumi-LTA in healthy samples (Seyfert et al., 2007). In patients’ samples however, we 
observed significant differences between the two techniques in response to all agonists. We  





observed a fair agreement between MEA and lumi-LTA when overall results were analysed 
using kappa statistics (figure 5.7). 
In identification of individuals with platelet function defects we found that MEA detected more 
patients with COX-1 like defects than those with Gi and secretion defects (figure 5.5). This 
suggests that MEA is more sensitive in response to defects in the thromboxane pathway. 
However, the lack of sensitivity of MEA in detecting Gi defects may also be related  to the 
higher ADP concentration (10 µM) used in this study which is slightly higher than the standard 
recommended concentration  (6.5 µM) (Toth et al., 2006). Interestingly, we have also observed 
that MEA showed high consistency in detecting abnormalities in patients with dual defects. 
This findings support the earlier reports suggest that MEA is reliable in detecting more severe 
forms of platelet defects such as GT (Awidi et al., 2009, Albanyan et al., 2015).  
In response to specific agonists we demonstrated reduced sensitivity of MEA to detect platelet 
function defects using all four classes of agonists (figure 5.8A). In particular there was a marked 
decreased sensitivity with ADP, Collagen and arachidonic acid when compared to lumi-LTA. 
A high degree of disagreement between the two techniques was also observed in response to 
PAR-1 activating peptide. Out of 14 abnormal only one (7%) was detected by both techniques 
(figure 5.8B).   
Measurement of secreted ATP levels is an additional but important tool in identifying patients 
with platelet secretion defects (Cattaneo, 2009). Moreover, it is well known that individuals 
with reduced dense granule secretion often demonstrate normal aggregation responses 
(Dawood et al., 2007). In this study MEA and lumi-LTA gave normal responses on 17(85%) 
and 12(60%) patients respectively that were found to have low secreted ATP levels (figure 
5.9A). This is probably unsurprising given that MEA does not directly measure ATP secretion 
and the aggregation responses are probably less sensitive at detecting the feedback loop from 





released ATP/ADP from the dense granules. In related to patients with thrombocytopenia, MEA 
has previously been reported to be unreliable in diagnosing samples with low platelet counts 
(Femia et al., 2013).  In this study however, MPA gave normal responses on 6 (50%) of patients 
with thrombocytopenia. Surprisingly 3 of these have also found to have a functional defect by 
LTA (figure 5.9B). In summary, MEA demonstrates a lack of sensitivity in identifying patients 
with mild bleeding associated with abnormal platelet function and platelet secretion defects. 
More studies are required to further evaluate the role for MEA in the diagnosis of bleeding 
disorders. 
  




CHAPTER SIX: EVALUATION OF THE TOTAL THROMBUS-
FORMATION SYSTEM (T-TAS): APPLICATION TO HUMAN AND 
MOUSE BLOOD ANALYSIS 
6.1 Introduction  
The Total Thrombus-formation Analysis System (T-TAS) is a flow-chamber system designed 
to evaluate the growth of total thrombus-formation (TTF) under variable flow conditions 
(Yamaguchi et al., 2013). The device is equipped with a pneumatic pump, a flow pressure 
sensor, a video microscope and microchips with different thrombogenic surfaces. Two types of 
disposable ready-to-use microchips are available, a platelet (PL) chip coated with collagen for 
assessing platelet thrombus formation and an atherome (AR) chip coated with collagen and 
tissue factor for assessing white thrombus formation mediated by the activation of coagulation 
and platelets (Hosokawa et al., 2011, Hosokawa et al., 2012).  
To evaluate TTF, T-TAS continuously monitors flow pressure within the capillary using a 
sensor that tracks pressure changes in the flow path. When hirudinated blood or re-calcified 
citrated whole blood is perfused through the analytical path of (PL and AR chips respectively) 
the thrombogenic surface of microchip initiates the thrombus formation. This causes an increase 
of flow pressure inside the system and gradually occludes the capillary (Hosokawa et al., 2011). 
The formation of thrombus is analysed using a dual monitoring system, a video microscope that 
continuously records and display the results as video image, and a pressure sensor that monitors 
flow pressure changes and displays the results as wave forms and digital parameters (Hosokawa 
et al., 2012). A typical normal flow pressure curve and defined endpoint parameters are shown 
in figure 6.1 
As a flow based whole blood method, T-TAS has the advantage in evaluating thrombus 
formation in more physiological but variable flow conditions. In addition, the use of whole 




blood only requires small volumes making it possible to be used in young children and studying 
thrombus formation in small animal models. Furthermore the use of microchip coated with 
collagen and tissue factor offer the potential advantage of simultaneous assessment of both 
platelet and hemostasis defects.  
The T-TAS was initially designed to monitor the effectiveness of antithrombotic agents. A 
number of studies have reported its potential utility in assessment of anti-platelet drugs e.g. 
aspirin, clopidogrel, and PAR-1 and PAR-4 antagonists (Hosokawa et al., 2011, Hosokawa et 
al., 2013, Hosokawa et al., 2014a) and anti-thrombotic agents e.g. direct thrombin and factor 
Xa inhibitors (Hosokawa et al., 2014b). T-TAS has also demonstrated high sensitivity in 
detecting coagulation bleeding disorders such as haemophilia (Ogawa et al., 2012), von 
Willebrand disease (Ogiwara et al., 2015) and platelet function defects such as storage pool 
disease (Minami et al., 2015). In assessing acquired haemorrhagic conditions, the T-TAS has 
been found to be able to predict the risk of bleeding in atrial fibrillation patients undergoing 
catheter ablation (Ito et al., 2016). Furthermore, T-TAS has also been demonstrated to be a 
useful tool in the study of thrombus formation in animal models such as micro miniature pigs 
(Miura et al., 2013) and mice (Ogawa et al., 2012, Ono et al., 2012). 
Three mouse models (CSK, CD148 and CSK/CD148) were generated by Senis platelet 
signalling group in the University of Birmingham to study the regulation of Src family kinase 
(SFK) on platelet activity. CSK is a member of family kinases function as a negative regulator 
of SFKs to inhibit platelet activation (Okada, 2012). In contrast, CD148 is a protein tyrosine 
phosphatase receptor which plays essential role as a positive regulator of platelet activation and 
thrombosis (Senis et al., 2009). The deletion of either CSK or CD148, or both together in mice 
resulted in various platelet defects including a reduction in platelet reactivity to collagen 
(manuscript in preparation).  




6.2 Aim  
To evaluate the potential utility  of the T-TAS for assessing thrombus formation in healthy 
individuals, blood spiked with antithrombotic agents, in patients with suspected platelet 
function defects and in genetically modified or wild type (WT) mice. 





Figure 6.1 T-TAS typical normal flow pressure curves and the analytical parameters collected 
for quantification. A) PL chip. T10: time from baseline pressure to reach 10 kPa (PTF starting 
time). T60: time to reach 60 kPa (occlusion time). T10-60: T60 minus T10 (PTF growth rates). 
AUC10: area under the flow pressure curve for 10 min. B) AR chip. T10: time from baseline 
pressure to reach 10 kPa. T80: time to reach 80 kPa. T10-80: T80 minus T10. AUC30: area under 
the flow pressure curve for 30 min (Yamaguchi et al., 2013). 
 





6.3.1 Measurement of T-TAS in healthy subjects 
22 healthy subjects (10 males and 12 females; mean age 31 ± 7 years) were investigated. 
Overall, the T-TAS shows some variation in thrombus formation among healthy subjects on 
both chips (figure 6.2A and 6.3A). Within the PL chip (figure 6.2B and table 6.1), the onset 
(T10) value (mean) and occlusion time (T60) at a shear rate of 1000 s
-1 were greater than at 
1500/2000 s-1 (T10= 03:30, 03:02, 03:29 and T60= 08:10, 06:27, 06:42 respectively). In contrast, 
the AUC10 value (mean) was reduced at a shear rate of 1000 s
-1 than at 1500/2000 s-1 (260, 317 
and 301 respectively). Furthermore, the thrombus growth rates (T10-60) in the PL chip (mean) 
decreased as the shear rate increased (04:40, 03:25 and 03:12 respectively) (figure 6.2B and 
table 6.1). A shear dependent decrease was also observed on the occlusion times (T80) and 
thrombus growth rates (T10-80) on the AR chip (T80=12:1 and 11:30; T10-80= 4:36 and 2:21 
respectively) (figure 6.3B and table 6.2). However, no significant different of the AUC30 values 
(mean) was observed between low and high shear values (1593 and 1591 respectively).  
Surprisingly, the onset (T10) value (mean) on AR chip was greater at high shear (09:19) than at 
the low shear (08:16) (figure 6.3B and table 6.2).  
  




      
Figure 6.2 Measurements of blood from healthy controls (n=22) using the PL chip. For panel 
A, flow pressure curves of all individuals measured at low shear rate (1000 s− 1). For panel B, 
distribution of the T-TAS measurements from three different shear rates (bars represent mean 
values). Statistical analysis performed by the one-way ANOVA test with Sidak’s adjustment 
for multiple comparisons (***p <0.001, **p<0.01 and *p<0.05).  





Figure 6.3 Measurements of blood from healthy controls (n=22) using the AR chip. For panel 
A, flow pressure curves of individuals measured at low shear rate (240 s− 1). For panel B, 
distribution of the T-TAS measurements from two different shear rates (bars represent mean 
values). Statistical analysis performed by the Mann Whitney U test. Significance as compared 
between 240 s− 1 and 600 s− 1 in each parameter (**p<0.01 and *p<0.05).  
     




     
Table 6.1 T-TAS measurements on PL chip using three different shear rates in samples 
obtained from healthy controls (n=22). Data presented as mean and SD.  
 





Table 6.2 T-TAS measurements on AR chip using two different shear rates in samples obtained 
from healthy controls (n=22). Data presented as mean and SD.  
 




Intra-assay coefficients of variation (CV) were calculated from 10 runs of a single sample 
obtained from one healthy subject. Overall, the difference of CV between shear rates was more 
significant on PL chip (figure 6.4) compared to that of AR chip (figure 6.5). On PL chip the CV 
of T60, T10-60 and AUC10 were smaller at 2000 s
− 1 (20000 s-1= 11.4%, 26.4% and 26.9% 
respectively) than at 1000/1500 s− 1 (1000 s-1= 17.9%, 24.4% and 24.4% ;  15000 s-1= 14.3%, 
26.4%  respectively),  whereas the CV of T10 were almost the same at all three share rates 
(14.4%, 15.3% 14.7% respectively) (table 6.3). The statistical analysis of AUC values obtained 
from the first and last 3 replicates from each set showed no significant different, suggesting 
that, the time delay of sample process was not the cause of the high CV values observed (figure 
6.4 B). In AR chip however, the CV of all four parameters were low at 600 s− 1 than that at 
240 s− 1 (T10 7.9%, T80 6.8%, T10-80 20.2%, AUC30 5.0% and T10 8.9%, T80 8.6%, T10-80 22.9%, 
AUC30 5.1% respectively) (table 6.4).  




           
Figure 6.4 Analysis of repeat measurements of a single sample obtained from a healthy 
subject on the PL chip (n=10). Panel A, distribution of the overall T-TAS measurements 
on the PL chip at different shear rates (bars represent mean values), and Panel B, AUC 
obtained from repeat measurements base on sample process order. Statistical analysis 
performed by the Mann Whitney U test. Significance as compared between the first and 
last 3 replicates from each set of parameter (**p<0.01 and *p<0.05). 




     
Figure 6.5 Distribution of repeat measurements of the same sample from a single healthy 
control on the AR chip (n=10). (bars represent mean values). Statistical analysis performed by 








      
Table 6.3 Intra-assay coefficients of variation (CV) in PL chip measurements in a single sample 
obtained from a healthy control (n=10).  





Table 6.4 Intra-assay coefficients of variation (CV) in AR chip measurements in a single 
sample obtained from a healthy control (n=10).  




6.3.2 Measurement of blood from healthy subjects spiked with antithrombotic drugs 
No thrombus formation was observed in the PL chip with both low and high shear rates when 
blood was pre-treated with ticagrelor (10 µM) (figure 6.6). Within the AR chip, thrombus 
formation was not affected by addition of ticagrelor (figure 6.7). In contrast, thrombus 
formation was observed with blood pre-treated with rivaroxaban (1 µM) but varies between 
subjects when perfused through the AR chip at lower shear rates (figure 6.8).  
  





Figure 6.6 Effects of the antiplatelet agent ticagrelor on PL chip measurements. Panel A, flow 
pressure curves and panel B, AUC measurements of blood from healthy controls (n=5) in the 
presence (red) and absence (black) of ticagrelor (10 µM). (bars represent the mean values). 








    
Figure 6.7 Effects of the antiplatelet agent ticagrelor on AR chip measurements. Panel A, flow 
pressure curves and panel B, T10 and AUC measurements of blood from healthy controls (n=4) 
in the presence (red) and absence (black) of ticagrelor (10 µM). (bars represent the mean 
values). Statistical analysis performed by the Mann Whitney U test. 
        




    
Figure 6.8 Effects of rivaroxaban on AR chip measurements. Panel A, flow pressure curves 
and panel B, T10 and AUC measurements of blood from healthy controls (n=5) in the presence 
(blue) and absence (black) of rivaroxaban (1 µM). (bars represent the mean values).Statistical 
analysis performed by the Mann Whitney U test. Significance as compared to control in each 
parameter (*p<0.05).  
 
 




6.3.3 Measurement of T-TAS on samples from patients recruited into the GAPP study 
with suspected platelet function defects. 
We analysed a total of 30 patients (8 male and 22 female) with a median age 35 (range 7-73) 
recruited into the GAPP study and compared T-TAS (PL chip) results with lumi-LTA. All 
patients had normal platelet counts (261 ± 68 x109/L). The waveform of each individual patients 
is presented in figure 6.9A and distribution of the T-TAS measurements in healthy controls 
(n=22) and in patients (n=30) are presented in figure 6.9B. Overall, no significant difference 
was observed between healthy controls and patient group with three parameters (T10, T60 and 
AUC10). With the thrombus growth (T10-60) measurements however, a small but significant 
difference was observed (figure 6.9B). Of 30 patients tested (figure 6.10), 10 (33.3%) patients 
gave abnormal responses by lumi-LTA to one or more agonists as defined using previous 
criteria (Dawood et al., 2012). In contrast, 8 (27%) patients were detected to have abnormal 
thrombus formation by T-TAS, as defined using the cut off values obtained from healthy 
controls (table 6.1). The overall agreement between the two instruments is shown in table 6.5. 
26/30 samples gave identical results by both tests, with the majority (19) giving normal 
responses whereas 7 samples gave abnormal results by both tests. In contrast, there was 
disagreement in 4/30 samples. T-TAS detected an abnormality in 1 patient that was normal by 
lumi-LTA (figure 6.11), whereas 3 samples were normal by T-TAS but abnormal by lumi-LTA 
(figure 6.12). In this study we used AUC10 and the T10 parameters to identify a defect on T-
TAS. 7/8 (88%) samples with an abnormality detected by T-TAS have low values of AUC10. 
One patient however, had normal AUC10 value but a delayed T10 parameter. Interestingly, the 
patient was also found to have a defect by lumi-LTA.   
 
 





Figure 6.9 Measurement of thrombus formation with whole blood from healthy controls 
(n=22) and patients (n=30) in the PL chip (1000 s-1). Panel A, Flow pressure curves observed 
in healthy controls (black) and patients (red). Panel B, Distribution of the T10 and AUC10 
measurements obtained from healthy controls (n=22) and patients (n=30) (bars represent the 
mean values). Statistical analysis performed by the Mann Whitney U test. Significance as 
compared to control in each parameter (*p<0.05).  




                
Figure 6.10 Summary of overall patients results (n=30) analysed by lumi-LTA and T-TAS 
comparing between normal (blue) and abnormal (red). Abnormal results by Lumi-LTA were 
determined based on our previously published methodology that is based upon the cut-off 
values that were calculated as the 5th percentile from the healthy volunteers as well as both the 
magnitude and time course of response (Dawood et al., 2007, Dawood et al., 2012) and (by T-
TAS) when they fall below the cut-off values (5th percentile) calculated from healthy 
individuals as shown in table 6.1 and 6.2 
 
 




            
Table 6.5 Analysis of the agreement between the T-TAS and lumi-LTA in patient samples 
(n=30) displaying sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV).  
 





Figure 6.11 Measurements of thrombus formation in the PL-chip (1000 s−1) within samples 
from patients (n=20) found to have no detectable platelet defects by Lumi-LTA.  Panel A, flow 
pressure curves observed in healthy controls (black), patients with normal (green)  and 
abnormal results respectively (red) by T-TAS (green). Panel B, distribution of the T10 and 
AUC measurements obtained from healthy controls (n=22) and patients (n=20) (bars represent 
mean values). Statistical analysis performed by the Mann Whitney U test.  
 




     
Figure 6.12 Measurement of thrombus formation in the PL-chip (1000 s−1) within samples 
from patients with platelet defects (n = 10) as defined by lumi-LTA.  Panel A, flow pressure 
curves observed in healthy controls (black), patients with normal T-TAS (green) and patients 
with abnormal T-TAS (red). Panel B, distribution of the T10 and AUC measurements obtained 
from healthy controls (n=22) and patients (n=10) (bars represent mean values). Statistical 
analysis performed by Mann Whitney U test. Significance as compared to control each 
parameter (*p<0.05).  




6.3.4 Analysis and identification of patients with various platelet function defects 
Functional defects identified by lumi-LTA were classified into 4 main groups (Gi defects, 
secretion defects, COX-like defect and multiple defects) according to their pattern of responses 
to specific agonists as previously described (Dawood et al., 2012). As shown in figure 6.13, T-
TAS detected all patients classified by lumi-LTA to have either COX-like defect or secretion 
defects (1 and 2 patients respectively).  In contrast, T-TAS only detected 1/3 patients with Gi 
defects but 3 out of 4 with multiple defects.  
 
  






Figure 6.13 Classification of platelet function defects among patients detected by lumi-LTA 
(blue) and T-TAS (red). Abnormal results by Lumi-LTA were determined based on our 
previously published methodology that is based upon the cut-off values that were calculated as 
the 5th percentile from the healthy volunteers as well as both the magnitude and time course of 
response (Dawood et al., 2007, Dawood et al., 2012) and (by T-TAS) when they fall below the 
cut-off values (5th percentile) calculated from healthy individuals as shown in table 6.1 and 6.2 
 




6.3.5 Measurement of T-TAS in sample from GAPP patients with thrombocytopenia 
recruited with suspected platelet function defects  
 
We additionally analysed 7 patients found to have mild to marked thrombocytopenia as 
characterized by low whole blood platelet counts (<150 x109/L) , but  normal PRP counts when 
tested by LTA. The whole blood platelet counts (mean ± SD) were 77 ± 34 (x109/L). The 
waveform of each individual patient is presented in figure 6.14A. AUC10 parameters (figure 
6.14B) showed significant differences between healthy controls (n=22) and patients (n=7). All 
7 patients tested exhibited abnormal thrombus formation within the T-TAS (figure 6.15). 
Interestingly, 4/7 patients were also detected by lumi-LTA to have platelet function defects (3 
secretion and 1 Cox-like defects) in additional to their thrombocytopenia.   




    
 
Figure 6.14 Measurement of thrombus formation in the PL-chip (1000 s−1) within samples 
from patients (n=7) with thrombocytopenia.  Panel A, flow pressure curves observed in healthy 
controls (black) and patients with thrombocytopenia (blue). Panel B, distribution of the AUC 
measurements obtained from normal controls (n=22) and patients (n=7) (bars represent mean 
values). Statistical analysis performed by the Mann Whitney U test. Significance as compared 
to control in each parameter (***p<0.001).  
 




                
Figure 6.15 Summary of an overall comparison between normal (blue) and abnormal (red) 
results detected by lumi-LTA and T-TAS from patients (n=7) with thrombocytopenia. 
Abnormal results by Lumi-LTA were determined based on our previously published 
methodology that is based upon the cut-off values that were calculated as the 5th percentile from 
the healthy volunteers as well as both the magnitude and time course of response (Dawood et 
al., 2007, Dawood et al., 2012) and (by T-TAS) when they fall below the cut-off values (5th 
percentile) calculated from healthy individuals as shown in table 6.1 and 6.2 




6.3.6 Measurement of T-TAS in samples from wild type mice  
 
Blood samples from wild type (WT) mice (n=4) were tested within both PL chips (1000 s-1 and 
2000 s-1) and AR chips (240 s-1). Within the PL chip (figure 6.16), shear enhanced thrombus 
formation was observed with all parameters; however, any differences in measurements 
between shear rates was only significant with the AUC10 parameter. For example, the values 
(mean) at 1000 s-1 (T10 = 02:02, T60 = 04:40 and T10-60 =02:38) were greater than at 2000 s
-1 (T10 
= 01:16, T60 = 03:26 and T10-60 = 02:09). Consequently, the AUC10 at 1000 s
-1 was shorter than 
at 2000 s-1 (405.5 and 463.6 respectively) (table 6.6). The values (mean) of thrombus formation 
within the AR chip (240s-1) are shown in table 6.6. For example, the mean values of T10, T80, 









            
 
Figure 6.16 Distribution of thrombus formation values (T10, T60, T10-60 and AUC10) in blood 
from WT mice (n=4) tested in the PL-chip (1000 s−1 and 2000 s−1) (bars represent mean values). 
Statistical analysis performed by the Mann Whitney U test. Significance as compared between 
1000 s− 1 and 2000 s− 1 in each parameter (*p<0.05).  
 
 




    
Table 6.6 T-TAS measurements in samples from WT mice (n=4) performed on both PL and 
AR chips using different shear rates. Data presented as mean and SD. 




6.3.7 Comparison of T-TAS measurements between blood samples from WT mice and 
human   
 
We compared the difference of thrombus formation between WT mice (n=5) and humans 
(n=22). The whole blood platelet count and MPV of the WT mice is shown in table 6.7. Overall, 
thrombus formation in WT mice was more rapid on both chips (figure 6.17A and figure 6.18A) 
than in humans. With PL chip measurements, the differences between two models were 
significant with all parameters (figure 6.17B). For example, WT mice values (mean) at 1000 s-
1 were T10 = 02:02, T60 = 04:40, T10-60 = 02:38 and AUC10 = 405.5 (table 6.6) whereas the values 
in humans (mean) at the same shear were T10= 03:30, T60= 08:10, T10-60 = 04:40 and AUC10 = 
260 (table 6.1). In contrast, with AR chip measurements the different between two models were 



















Figure 6.17 Measurements of thrombus formation within the PL-chip (1000 s−1) with blood 
from humans and WT mice.  Panel A, flow pressure curves observed in humans (black) and 
WT mice (red). Panel B, distribution of the T-TAS measurements on blood from human (n=22) 
and WT mice (n=5) (bars represent mean values). Statistical analysis performed by the Mann 
Whitney U test. Significance as compared between WT and human blood in each parameter 
(***p<0.001).  
 





Figure 6.18 Measurements of thrombus formation within AR-chip (240 s−1) with blood from 
humans and WT mice.  Panel A, flow pressure curves observed in humans (black) and WT 
mice (red). Panel B, distribution of the T-TAS measurements on blood from humans (n=22) 
and WT mice (n=5) (bars represent mean values). Statistical analysis performed by the Mann 
Whitney U test. Significance as compared between WT and human blood in each parameter 
(***p<0.001). 
  




6.3.8 Measurement of T-TAS with blood from genetically modified mice 
Three types of genetically modified mice (CD148 KO, CSK KO and Double KO mice) were 
analysed on T-TAS using both PL and AR chips. Whole blood platelet count and MPV value 
of all mice is shown in table 6.7. The PL chip detected no thrombus formation in all three types 
of mice with a significant deference of AUC10 parameters in comparison to that of the WT mice 
(Figures 6.19, 6.21 and 6.23). In contrast, full thrombus formation of all mouse models was 
observed on AR chip (Figures 6.20A, 6.22A and 6.24A). However, the T10 and AUC30 
parameters of all three models were significant different when compared to the WT. In addition, 
the T80 parameters of CSK KO and DKO were also different than that of the WT. Interestingly, 
the rate of thrombus growth (T10-80) of all mouse models was similar to that of WT mice.   
 





Table 6.7 Measurements of whole blood platelet count and MPV in samples from WT mice 
(n=22), CSK knock out mice (n=12), CD148 knock out mice (n=12) and double (CSK + 
CD148) knock out mice (n=15). Data presented as median and SD. 
 





Figure 6.19 Measurements of thrombus formation in blood from WT and CD148 knockout 
mice within the PL-chip (1000 s−1). Panel A, flow pressure curves observed in WT (black) and 
CD148 knock out mice (green). Panel B, distribution of the T-TAS (AUC) measurements on 
blood from WT (n=5) and CD148 knock out mice (n=4) (bars represent mean values). 
Statistical analysis performed by the Mann Whitney U test. Significance as compared between 
WT and CD148 KO (***p<0.001). 
 




   
Figure 6.20 Measurements of thrombus formation in blood from WT and CD148 knockout 
mice within the AR-chip (240 s−1)  Panel A, flow pressure curves observed in WT (black) and 
CD148 knock out mice (green). Panel B, distribution of the T-TAS measurements on blood 
from WT (n=5) and CD148 knock out mice (n=5) (bars represent mean values). Statistical 
analysis performed by the Mann Whitney U test. Significance as compared between WT and 
CD148 KO model each parameter (*p<0.05).  
  
  





Figure 6.21 Measurements of thrombus formation in blood samples from WT and CSK KO 
mice within the PL-chip (1000 s−1).  Panel A, flow pressure curves observed in WT (black) 
and CSK KO mice (blue). Panel B, distribution of the T-TAS (AUC) measurements in blood 
from WT mice (n=5) and CSK KO mice (n=4) (bars represent mean values). Statistical analysis 
performed by the Mann Whitney U test. Significance as compared between WT and CSK KO 
(***p<0.001). 
 




   
Figure 6.22 Measurements of thrombus formation with blood from WT and CSK knockout 
mice within the AR-chip (240 s−1 ) Panel A, flow pressure curves observed in WT (black) and 
CSK KO mice (blue). For panel B, distribution of the T-TAS measurements on blood from WT 
(n=5) and CSK KO mice (n=6) (bars represent mean values). Statistical analysis performed by 
the Mann Whitney U test. Significance as compared between WT and CSK KO in each 
parameter (*p<0.05).  
 





Figure 6.23 Measurements of thrombus formation in blood from WT and double KO (CD148 
and CSK) mice within the PL-chip (1000 s−1).  Panel A, flow pressure curves observed in WT 
(black) and double KO mice (red). Panel B, distribution of the T-TAS (AUC) measurements 
on blood from WT (n=5) and double KO mice (n=7) (bars represent mean values). Statistical 
analysis performed by the Mann Whitney U test. Significance as compared between WT and 
DKO (***p<0.001).  
 




    
Figure 6.24 Measurements of thrombus formation in blood samples from WT and double 
(CD148 + CSK) KO mice within the AR-chip (240 s−1) Panel A, flow pressure curves observed 
in WT (black) and DKO mice (red). Panel B, distribution of the T-TAS measurements within 
blood from WT mice (n=5) and double knock out mice (n=7) (bars represent mean values). 
Statistical analysis performed by the Mann Whitney U test. Significance as compared between 
WT and DKO model each parameter (**p<0.01 and *p<0.05).  





The T-TAS is a flow chamber system that evaluates thrombus formation using whole blood 
samples that flow on thrombogenic surfaces under different shear rates. This approach offers 
an advantage for rapidly assessing thrombus formation in more physiological conditions 
involving both whole blood constituents and flow. Furthermore, the use of whole blood only 
requires small blood volumes making it practical for clinical application (Yamaguchi et al., 
2013). We therefore sought to evaluate the potential utility of the T-TAS for assessing thrombus 
formation from GAPP study patients and various mouse platelet receptor knockout models. 
In this study T-TAS was performed using 2 disposable chips.  1) The PL chip where thrombus 
formation is mainly mediated by platelets in the absence of coagulation and fibrinolytic 
pathways. 2) The AR chip where thrombus formation involves both platelet function and 
coagulation pathways.  Testing in the PL chip was performed with hirudin-anticoagulated blood 
to maintain physiological calcium levels as recommended by the manufacturer (Hosokawa et 
al., 2011). In contrast, testing in the AR chip was performed with citrate anticoagulated blood 
but recalcified with a mixture of CaCl2 in the presence of corn trypsin inhibitor (to prevent the 
activation of the intrinsic coagulation pathway). 
In healthy controls, both the start and end points of thrombus formation varied among 
individuals within both chips suggesting that measurements obtained using the T-TAS may 
reflect individual variability of thrombus formation. Within the PL chip, the rate of thrombus 
formation was shorter at higher shear rate which was reflected in all parameters measured 
(figure 6.2B). This supports the evidence that high-shear rates favour the GPIb-IX-V/VWF 
interaction to induce more efficient thrombus formation (Ikeda et al., 1991). In contrast the 
effect of shear rate within the AR chip was variable, in particular the onset (T10) (figure 6.3B) 
where the value at the high shear was greater than at the low shear. With a reason could not be 




explained this finding contradicts with previously publication (Hosokawa et al., 2011, 
Yamaguchi et al., 2013). However, a decreased rate of thrombus growth (T10-80) in accordance 
with an increase in shear rate was observed on AR chip similar to that on PL chip, indicating 
that the shear rates accelerated the growth rate of the thrombus. This Shear rate enhance on T-
TAS parameters were also reported by Hosokawa et al, and Yamaguchi et al, (Hosokawa et al., 
2011, Yamaguchi et al., 2013).  In our study, the T-TAS exhibited high intra-assay coefficients 
of variation (CV) in both chips (table 6.3 and table 6.4).  Typical CV’s obtained were much 
higher than those described by Yamaguchi et al although their sample number (n=5) was 
smaller (Yamaguchi et al., 2013).  
We also evaluated the utility of T-TAS in detecting the effect of antithrombotic therapy on 
haemostasis using two types of drugs. 1) The antiplatelet drug ticagrelor (P2Y12 antagonist) and 
2) The anticoagulant rivaroxaban (factor Xa inhibitor). Ticagrelor (10µM) completely 
suppressed thrombus formation within the PL chip. These findings agree with Hokosawa et al. 
who also previously demonstrated that thrombus formation within the PL chip was inhibited by 
P2Y12 antagonists (Hosokawa et al., 2012, Hosokawa et al., 2013). In contrast, the inhibitory 
effect of ticagrelor on thrombus formation was not observed within the AR chip.  
As thrombus formation within the AR at low shear rate is more dependent upon fibrin formation 
(Hanson and Sakariassen, 1998, Hosokawa et al., 2011), it is possible that P2Y12 inhibitors are 
therefore expected to have no effect in this chip as platelets play little or no role in thrombus 
formation at low shear rates (Leonardi and Becker, 2012, Hosokawa et al., 2014a). Secondary, 
platelets within the AR chip could also be activated via the PAR-1 receptor by thrombin which 
is generated from activation of the coagulation pathways (Leonardi and Becker, 2012). This 
was demonstrated by Hokosawa et al. by demonstrating that PAR-1 antagonism reduced 
thrombus formation within the AR chip (Hosokawa et al., 2014a). In contrast, rivaroxaban (1 




µM) incubation with whole blood within the AR chip displayed considerable variability on 
affecting thrombus formation with a delayed onset despite complete formation of thrombi 
(figure 6.8). This variability might be a result of an individuals’ low responsiveness to the drug. 
Hokosawa et al indeed demonstrated that rivaroxaban (1 µM) only moderately suppressed 
thrombus formation on AR chip (Hosokawa et al., 2014b). 
We also performed a comparative evaluation of the T-TAS using PL chip with GAPP patients 
with suspected platelet function defects and compared the results with the gold standard of 
lumi-LTA. Comparison of the overall results in 30 patients with normal platelet counts (Table 
6.5) demonstrated a good agreement between T-TAS (PL chip) and lumi-LTA with 
concordance in 87% of samples tested. As 73% of samples were defined as normal by lumi-
LTA, T-TAS therefore gave a negative predictive value of 86% suggesting that the test may be 
a potentially novel, reliable and useful tool for the screening of platelet function disorders.  
Interestingly, T-TAS also detected all patients with COX-like defects and secretion defects 
(figure 6.13). This finding is consistent with earlier reports showed that T-TAS was able to 
detect all patients diagnosed with SPD (Minami et al., 2015). T-TAS also showed high 
consistency in detecting abnormalities in patients with multiple defects. This findings also 
support the earlier report suggest that T-TAS is reliable in detecting more severe forms of 
platelet defects such BSS (Minami et al., 2015). In contrast T-TAS failed to detect thrombus 
formation in all patients with thrombocytopenia including three patients that gave normal 
responses by lumi-LTA (figure 6.15). This might suggest that T-TAS is not reliable for testing 
samples with low platelet counts and that thrombus formation is dependent on normal platelet 
number. An earlier study on healthy subjects demonstrated a good correlation between normal 
platelet counts and T-TAS parameters (Yamaguchi et al., 2013). Further studies to evaluate a 




correlation between platelet count and T-TAS on samples with low platelet count would be of 
clinical value.  
T-TAS only requires a small blood volume make it practical in studying thrombus formation in 
small animal models. To evaluate the utility of T-TAS for potentially testing mouse blood we 
then analysed blood from both WT and three knock out mouse models (CD148 KO, CSK KO 
and Double KO mice). As preliminary data (in vivo and in vitro) within these mouse models 
also demonstrated impaired platelet interaction with collagen this suggests they are a suitable 
model to test within the T-TAS (manuscript in preparation).  Indeed testing of normal WT blood 
demonstrated the same influence of shear rates of thrombus formation within the PL-chip as 
with human blood (figure 6.16). Total thrombus formation however was much more rapid 
within mice blood compared to human. Similar results were reported on studies of blood from 
micro minipigs (Miura et al., 2013), suggesting that these animals might exhibit a high 
thrombotic tendency than humans, probable due to high platelet count (table 6.7).  As expected, 
all KO models displayed poor thrombus formation within the PL chip concurring with previous 
in vivo and in vitro findings (manuscript in preparation). In contrast, full thrombus formation 
was observed within the AR chip with all knockouts indicating that the coagulation pathways 
are normal and that platelets probably have no so significant contribution to thrombus formation 
at a shear rate of 240 s−1.  
There is no single parameter that has been described to be more useful in defining haemostatic 
abnormalities within the T-TAS. Almost all studies  evaluating bleeding disorders in the T-TAS 
have used AUC10/30 and to a lesser extent the T10 (Minami et al., 2015, Ito et al., 2016, Nogami 
et al., 2016, Ogiwara et al., 2015).  AUC is particularly useful in quantifying a decrease in 
thrombus formation when occlusion time is not achieved during the time period of assay. In our 
study almost all samples (7/8) with abnormalities detected by T-TAS exhibited low values of 




AUC10. One patient however, gave normal values of AUC10 but with delayed T10 parameters. 
This might therefore suggests that a combination of T10 and AUC parameters are sufficient to 
identify any haemostatic abnormalities on T-TAS.   
Our present study has several limitations. First, the study was performed with only a small 
group of patients suspected of platelet function disorders. Therefore for future studies it would 
be necessary to enrol a larger number of patients with known platelet function defects as well 
as other haemostatic abnormalities such as haemophilia and VWD. Second, the study of 
antithrombotic drugs was performed using a single concentration of either ticagrelor or 
rivaroxaban. It would be of interest in future studies to evaluate the T-TAS with a full range of 
antiplatelet drugs with different molecular targets and at different concentrations. Finally, the 
mouse models were only studied within the AR chip at a low shear rate only. It would be of 
interest to find out if high shear rates would also have detected platelet defects in these mice.    
In summary, T-TAS has demonstrated a good agreement with LTA suggesting that the 
technique could be applied in screening patients with platelet function defects. Moreover, the 
device might be a useful tool in monitoring antithrombotic therapy. Finally, we demonstrated 
that the T-TAS could provide valuable assistance in rapidly studying samples from animal 
models. 
 




CHAPTER SEVEN: PROSPECTIVE STUDY TO EVALUATE THE 
REMOTE PLATELET FUNCTION TEST (RPFT) 
7.1 Introduction 
A range of techniques are now available to test platelet function which are simple, less time 
consuming and require relatively small blood volumes. However, one of the major limitations 
is that the testing needs to be performed with a fresh blood sample (within 4-6 hours) following 
venipuncture (Harrison et al., 2011, Cattaneo et al., 2013). This still limits platelet function 
testing to specialized laboratories where appropriate technique(s) and experienced staff are 
available. These limitations therefore remain significant obstacles for rapid and easy diagnosis 
of platelet function defects and may also contribute to under-estimation of their true prevalence.  
A recently developed Remote Platelet function Test (RPFT, Platelet Solutions) by Professor 
Stan Heptinstall at the University of Nottingham could overcome these limitations and may 
offer a completely new approach to platelet function testing. The kit essentially uses a series of 
vials with lyophilized platelet agonists and fixative solution (PAMFix) that sequentially activate 
and fix platelets in whole blood with proven stability for up to 9 days. Furthermore, the RPFT 
kit is also a closed point of care (POC) system without requiring pipetting or specialized 
laboratory equipment. Fixed samples from remote locations can also then be shipped at ambient 
temperature to a central laboratory for flow cytometric analysis (Dovlatova, 2015).   
For platelet stimulation, anticoagulated whole blood is simply added into 4 vials containing (i) 
saline only as a negative baseline control, (ii) Arachidonic acid/epinephrine, (iii) ADP/U46619 
and (iv) PAR-1 peptide the thrombin receptor agonist. Samples are then mixed and activated 
for 5 mins at 370C within a heat pouch provided in the kit. The samples are then fixed and sent 
in sealed containers via post to the central laboratory. Upon receipt of the samples the degree 




of platelet activation is assessed by measuring the expression of p-selectin (CD62p) and CD63 
as markers of alpha granular and dense granular secretion respectively by using flow cytometry.  
Several studies have assessed the utility of RPFT for monitoring several types of antiplatelet 
therapy and for prediction of the risk of recurrent thrombotic events in patients with acute 
coronary syndromes (Fox et al., 2009, Thomas et al., 2014, Keeler et al., 2015). The RPFT has 
also been evaluated for the diagnosis of mild bleeding disorders and demonstrated a good 
agreement with lumi-LTA (Dovlatova et al., 2014). However, in this study the test was used 
with GAPP samples received at the University of Birmingham and not as a true POC test within 
the clinic. 
7.2 Aim  
To perform a prospective study to evaluate the POC utility of RPFT in the diagnosis of platelet 
function defect in patients with mild bleeding disorders by comparison with the gold standard 
of Light transmission lumi-aggregometry (LTA). Initially, a training session was performed in 
each participating centre to demonstrate how the RPFT test is optimally performed and 
processed.   
 





7.3.1 Sample recruitment and determination of cut off values 
A total of 122 RPFT kits were distributed to 6 haemophilia centres across the UK. Only 63 
(52%) of kits with samples were returned for analysis. 10 of these samples were also rejected 
because of low platelet counts, haemolysis or because of excessive dilution of blood samples. 
The list of kits distributed to each haemophilia centre and number of samples returned for 
analysis is summarised in table 7.1.  The highest number of samples were recruited from 
Lincoln where 76% of the kits were returned for analysis, followed by Nottingham 12(50%), 
Canterbury 10(100%), Leicester (40%) and Manchester 5(23%). Unfortunately no samples 
were recruited from St Thomas’s Hospital in London. 27 healthy volunteers were also recruited 
and measured by RPFT as controls to determine a normal range and to define cut off values for 
classification of normal or abnormal results. As shown within table 7.2, the cut off MFI values 
for P-selectin were 1507 (AA/EPI), 2536 (ADP/U46619) and 2434 (PAR-1), and for CD63 
were 211(AA/EPI), 343 (ADP/U46619) and 440 (PAR-1). When the above cut off values were 
applied to the group of healthy controls only 3/27 participants presented with reduced platelet 
response by the RPFT (figure 7.1). 




   
Table 7.1 List of RPFT kits distributed to 6 haemophilia centres showing the number of kits 
supplied and the number of samples returned for analysis. 




   
Table 7.2 Summary of p-selectin and CD63 expression (MFI) measured with RPFT in samples 
from healthy controls (n=27) after stimulation with various agonists, the data are presented as 
mean and SD. The cut-off values were calculated as the 5th percentile of the corresponding 
measurements in healthy controls. 





Figure 7.1 P-selectin and CD63 (MFI) measured with RPFT in healthy controls (n=27) 
with baseline controls and after stimulation with various platelet agonists. Horizontal 
dotted lines represent the 95th percentile (cut off value) used to determine abnormal results. 
 
 




7.3.2 Overall patient results  
53 patients (15 male and 38 female) with a median age of 37 ± 17 (median ± SD) ranging from 
2-80 years were analysed by the RPFT and results were compared with lumi-LTA. Whole blood 
platelet count and MPV values (mean ± SD) were normal in all participants (250 ± 61x109/L 
and 11.0 ± 0.9fl, respectively). Overall, 30(57%) patients gave an abnormal RPFT with at least 
one parameter falling below the cut off values obtained from healthy controls as shown in table 
7.2. Of these 30, all exhibited low levels of P-selectin expression mainly in response to 
ADP/U46619 and PAR-1 peptide (figure 7.2). In contrast, only 16/30 patients gave low levels 
of CD63 expression (figure 7.3). According to lumi-LTA, 17 out of 53 patients were considered 
to have a platelet defect as defined using previous criteria (Dawood et al., 2012). The overall 
results of all 53 patients tested are shown in figure 7.4. 
  





Figure 7.2 P-selectin (MFI) measured with RPFT in healthy controls (n=27) and patients 
(n=53) after stimulation with various platelet agonists. For panel A, horizontal bars 
represent mean values and horizontal dotted lines represent the 95th percentile (cut off 
value) used to determine abnormal results. Statistical analysis was performed by the Mann 
Whitney U test. Significance was compared to healthy controls (*p<0.05 and ***p<0.001).  
For panel B, the boxes represent median and interquartile ranges, whiskers represent 5th 
and 95th percentiles and outlying points are represented by dots. 
 
 




      
Figure 7.3 CD63 (MFI) measured with RPFT in healthy controls (n=27) and patients 
(n=53) after stimulation with various platelet agonists. For panel A, horizontal bars 
represent mean values and horizontal dotted lines represent the 95th percentile (cut off 
value) used to determine abnormal results. Statistical analysis performed by the Mann 
Whitney U test. Significance was compared to healthy controls (*p<0.05 and ***p<0.001).  
For panel B, the boxes represent median and interquartile ranges, whiskers represent 5th 
and 95th percentiles and outlying points are represented by dots. 
 
  





Figure 7.4 Classification of patients results (n=53) analysed by lumi-LTA and RPFT. Normals 
and abnormals are shown in blue and red respectively.  Abnormal results by Lumi-LTA were 
determined based on our previously published methodology that is based upon the cut-off 
values that were calculated as the 5th percentile from the healthy volunteers as well as both the 
magnitude and time course of response (Dawood et al., 2007, Dawood et al., 2012) and (by 
RPFT) when they fall below the cut-off values (5th percentile) calculated from healthy 
individuals as shown in table 7.2 
 




7.3.3 Overall agreement between lumi-LTA and RPFT 
The overall agreement between the lumi-LTA and RPFT was poor (table 7.3). Only 30/53 
samples gave identical results by both tests. In contrast, there was disagreement in 23/53 
samples. RPFT gave abnormal results in 18 patients that were normal by lumi-LTA. However, 
5 samples were normal by RPFT but abnormal by lumi-LTA.  A similar poor overall agreement 
between the two techniques was also observed when cut off values obtained from a ROC 
analysis were also applied.  A comparison between lumi-LTA and RPFT was then analysed 
using each platelet marker separately. Summary of overall results are shown in figure 7.5. By 
using P-selectin and CD63 individually abnormal platelet function was detected in 30 and 16 
patients respectively, compared to 17 patients detected by lumi-LTA. In contrast, P-selectin and 
CD63 were normal on 23 and 37 samples respectively whereas 36 samples were normal by 
lumi-LTA. Overall, a poor agreement was also observed when lumi-LTA was compared with 
p-selectin expression as there was disagreement in 22(42%) samples (table 7.4A). In contrast a 
better agreement was observed when lumi-LTA was compared with CD63 expression with 
concordance in 43(81%) samples (table 7.4B).  When P-selectin and CD63 where compared to 
one another there was  agreement within 39(74%) samples, In contrast, the two markers 
disagreed on 14 samples, the majority of which (13) exhibited reduced expression of P-selectin 
only (table 7.4C).  





Table 7.3 Overall classification of results by lumi-LTA and RPFT in patient samples (n=53) 
displaying sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV).  





Figure 7.5 Classification of overall patient results (n=53) showing normal and abnormals in 
comparison between samples detected by P-selectin (blue), CD63 (red) and lumi-LTA (green). 
Abnormal results by Lumi-LTA were determined based on our previously published 
methodology that is based upon the cut-off values that were calculated as the 5th percentile from 
the healthy volunteers as well as both the magnitude and time course of response (Dawood et 
al., 2007, Dawood et al., 2012) and (RPFT) when they fall below the cut-off values (5th 
percentile) calculated from healthy controls as shown in table 7.2 




   
Table 7.4 Classification of RPFT results in patient samples (n=53) comparing between  lumi-
LTA and P-selectin (A),  lumi-LTA and CD63 (B) and, P-selectin and CD63 (C),  displaying 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).  




7.3.4 Performance of RPFT in patients with Gi and dense granular secretion defects as 
classified by lumi-LTA 
The 17 patients with platelet defects identified by lumi-LTA were further subdivided into four 
categories based on their patterns of aggregation responses as previously described (Ban et al., 
2012): defects in Gi signalling (n=4), defects in dense granular secretion (n=2), defects in 
cyclooxygenase pathway (n=5) and multiple or complex defects (n=6). All participants who 
presented with Gi signalling defect (figure 7.6) or dense granular secretion defect (figure 7.7) 
on lumi-LTA were also found to give abnormal results by the RPFT. Interestingly, all of these 
patients exhibited a reduced level of both P-selectin and CD63 expression in response to at least 
one agonist. In the Gi defect group, 3/4 patients gave an abnormal result by RPFT in response 
to ADP/U46619, whereas one patient gave an abnormal response to PAR-1 peptide. In dense 
granular secretion defects however, both patients gave abnormal levels of both platelet markers 
in response to PAR-1 peptide.  
  






Figure 7.6 P-selectin and CD63 (MFI) measured by RPFT in patients (n=4) with a defect in Gi 
pathway as determined by lumi-LTA.  For panel A, patients results at baseline and after 
stimulation with the corresponding agonist, horizontal dotted line represents the 95th percentile 
(cut off value) used to determine abnormal results. For panel B, the boxes represent median and 
interquartile ranges, whiskers represent 5th and 95th percentiles. For table C patient results are 
presented as an absolute number (MFI) after stimulation with the corresponding agonists with 
abnormal results shown in red text. The results were considered to be abnormal when they fall 
below the cut-off values (5th percentile) calculated from healthy controls as shown table 7.1. 
 




    
 
Figure 7.7 P-selectin and CD63 (MFI measured by RPFT in patients (n=2) with a defect in 
dense granular secretion as determined by lumi-LTA.  For panel A, patients results are shown 
at baseline and after stimulation with the corresponding agonist, horizontal dotted line 
represents the 95th percentile (cut off value) used to determine abnormal results. For panel B, 
the boxes represent median and interquartile ranges, whiskers represent 5th and 95th percentiles. 
For table C patient results are presented as an absolute number (MFI) after stimulation with the 
corresponding agonists with abnormal results shown in red text. The results were considered to 
be abnormal when they fall below the cut-off values (5th percentile) calculated from healthy 
controls as shown table 7.1.  
 




7.3.5 Performance of RPFT in patients with Cox and multiple platelet defects as classified 
by lumi-LTA 
In patients who presented with defects in the cyclooxygenase pathway as detected by lumi-
LTA, only 3/5 gave an abnormal response by RPFT (figure 7.8). Interestingly, all of 3 patients 
gave abnormal responses to Arachidonic acid/epinephrine (more details are shown in figure 
7.8C). In contrast, 3/6 patients with multiple and complex defects, gave abnormal responses by 












Figure 7.8 P-selectin and CD63 (MFI) measured by RPFT in patients (n=5) with defects in the 
cyclooxygenase pathway as determined by lumi-LTA.  For panel A, patients results are shown 
at baseline and after stimulation with the corresponding agonist, horizontal dotted line 
represents the 95th percentile (cut off value) used to determine abnormal results. For panel B, 
the boxes represent median and interquartile ranges, whiskers represent 5th and 95th percentiles. 
For table C patient results are presented as an absolute number (MFI) after stimulation with the 
corresponding agonists with abnormal results shown in red text. The results were considered to 
be abnormal when they fall below the cut-off values (5th percentile) calculated from healthy 
controls as shown table 7.1. 
 




    
 
Figure 7.9 P-selectin and CD63 (MFI) measured by RPFT in patients (n=6) with multiple 
defects as determined by lumi-LTA.  For panel A, patients results are shown at baseline and 
after stimulation with the corresponding agonists, horizontal dotted line represents the 95th 
percentile (cut off value) used to determine abnormal results. For panel B, the boxes represent 
median and interquartile ranges, whiskers represent 5th and 95th percentiles. For table C patient 
results are presented as an absolute number (MFI) after stimulation with the corresponding 
agonists with abnormal results shown in red text. The results were considered to be abnormal 
when they fall below the cut-off values (5th percentile) calculated from healthy controls as 
shown table 7.1. 




7.3.6 False positive samples identified by RPFT when compared to lumi-LTA. 
18 patients presented with abnormal responses by RPFT, but with normal responses to all 
agonists by lumi-LTA (figure 7.10). Almost all patients (17/18) had reduced level of P-selectin 
expression in response to ADP/U46619 (n=12) and to PAR-1 peptide (n=11) agonists. In 
contrast only 5(28%) patients gave low expression of CD63, all of which gave an abnormal 
response to PAR-1 peptide with one giving an abnormal response to ADP/U46619 (figure 
7.10C). Interestingly, all participants had normal responses to Arachidonic acid/epinephrine.  
13 out of 18 patients gave abnormal expression of P-selectin but CD63 was normal. Conversely, 









Figure 7.10 P-selectin and CD63 (MFI) expression measured by RPFT in patients (n=18) with 
false positive results when compared to lumi-LTA.  For panel A, patients results are shown at 
baseline and after stimulation with the corresponding agonists, horizontal dotted line represents 
the 95th percentile (cut off value) used to determine abnormal results. For panel B, the boxes 
represent median and interquartile ranges, whiskers represent 5th and 95th percentiles. For table 
C patient results are presented as an absolute number (MFI) after stimulation with the 
corresponding agonists with abnormal results shown in red text. The results were considered to 
be abnormal when they fall below the cut-off values (5th percentile) calculated from healthy 
controls as shown table 7.1 




7.4 Discussion  
This chapter presents the results from a prospective study that was performed to assess the 
potential of the RPFT in comparison to lumi-LTA for the potential diagnosis of PFDs.  The 
main advantage of RPFT is the use of small volumes of unseparated whole blood that minimises 
the time of sample processing. Furthermore, the use of a fixative allows testing to be performed 
remotely as a POC test avoiding the need of immediately processing of the blood sample before 
sending to a central laboratory for flow cytometry.   This approach could therefore improve the 
diagnosis of platelet function which is currently restricted to specialized laboratories.  
Abnormal RPFT results were defined based on the cut-off values that were calculated from the 
healthy volunteers. When the same cut off values were applied in the group of healthy controls 
a small number of participants presented with reduced platelet response on RPFT. This small 
degree of overlap in platelet responsiveness among healthy population has also been reported 
in other tests of platelet function and haemostasis (Quiroga et al., 2007). 
RPFT directly measures both alpha and dense granular secretion. When both markers were 
analysed together a poor agreement between lumi-LTA and RPFT was observed with an overall 
concordance of 57% in 30 samples. However, when each marker was analysed independently, 
a better agreement was observed between lumi-LTA and RPFT using CD63 expression with 
overall concordance of 81% of 43 samples. The latter result is very similar to a previous study 
where the overall agreement between lumi-LTA and RPFT using both markers (P-selectin and 
CD63) was shown to be concordant in 84% of cases (Dovlatova et al., 2014).  
In this study, the RPFT correctly identified a platelet function defect in all of the patients 
classified with either Gi signalling or dense granular secretion defects by lumi-LTA.  
Previously, the RPFT was reported to correctly identify all patients with secretion defects 




identified by lumi-LTA. This suggests that the RPFT is very sensitive for identifying 
abnormalities related to platelet secretion defects (Dovlatova et al., 2014). This is not 
unexpected given that the test is a direct measurement of granular secretion and also provides 
further validation that lumi-LTA is sensitive to secretion defects. However, of the two markers, 
CD63 expression has shown to be more reliable for identifying platelet defects with a specificity 
of 86% and PPV of 71% (table 7.4B). Similarly, the most sensitive agonist used within the 
RPFT is Arachidonic acid/epinephrine, where abnormal results were obtained in 3 patients with 
defects in the cyclooxygenase pathway with a NPV of 100% (figure 7.10). 
RPFT however identified false positives within 18(34%) samples that gave normal responses 
by lumi-LTA, the majority (94%) showing reduced levels of P-selectin expression. Previously, 
Dovlatova et al, also reported a false positive rate of 10% within patient samples. However, 
only one of these patients presented with a reduced level of P-selectin expression alone 
(Dovlatova et al., 2014). A low level of P-selectin expression in patients with normal 
aggregation and normal dense granules secretion may indicate impaired α-granular secretion 
(Blair and Flaumenhaft, 2009). However, deseases associated with α-granule secretion defects 
are rare and so this is an unlikely cause of the defects observed in this study. 
 A number of possibilities may have contributed to the higher false positive rates reported here, 
particularly as this study was performed as a true POC test in each Haemophilia Centre. As the 
test was used within busy clinical environments away from a well-controlled laboratory it is 
possible that the conditions of platelet activation were more poorly controlled in this study e.g. 
temperature and/or time of incubation resulting in the observed reduced platelet activity. It is 
possible given the length of the study that the long term stability of the agonists may have also 
been compromised even though the tests were performed within recommended expiry dates. 




However, the even distribution of false positive results throughout the duration of the study 
would suggest that reagent stability was not the issue. 
One of the challenges faced in this study was sample recruitment. Out of 122 RPFT kits 
distributed to 6 haemophilia centres only 53(43%) samples were analysed over a 1.5 year 
period. Furthermore, 57% of these samples were recruited from a single centre. This has not 
only undermined the overall objective and power of this study but also made the drawing of 
final conclusions more difficult. Future studies should therefore be performed with higher 
sample numbers and include multiple centres. Although adequate training of staff performing 
the RPFT test in each centre was performed it is possible that inter-individual variation between 
different centres and staff may have contributed to some of the discrepancies in this study. 
Furthermore, a more accurate comparison would be conducted by measuring samples that had 
been tested by using the RPFT both as a POC test and within the central laboratory at 
Birmingham simultaneously. This would validate whether the recommended POC conditions 
are being adhered to in each centre. This however, would not only be more costly and require 
fresh samples to be sent for RPFT analysis in the central laboratory but also introduce the 
variable of sample ageing. At the end of the study a questionnaire form was sent to all 
participated centres and were asked to provide a feedback and suggestions about their 
experience in using the RPFT kits. Overall the feedback was positive, however, addition 
training and availability of a training video to each centre was highly suggested. This might 
then improve sample handling and processing. (The full questionnaire form and the feedback 
responses are in appendix 4)  
 




CHAPTER EIGHT: GENERAL DISCUSSION 
8.1 General discussion 
Platelet function disorders (PFDs) are a heterogeneous group of disorders with a variety of 
causes and functional consequences.  Individuals with PFDs often experience mild day-to-day 
bleeding symptoms which sometimes can have impact upon the quality of life and activities of 
daily living. Furthermore the bleeding can occasionally be life-threatening in response to an 
appropriate challenge such as surgery, injury, menstruation, and childbirth. As such diagnosis 
of underlying PFDs has important clinical implications as it not only facilitates correct 
treatment but appropriate management of patients over their life time. 
This thesis has built on the previous GAPP project by further examining patients with suspected 
PFDs (Watson et al., 2013). The GAPP study uses a genotyping and platelet phenotyping 
approach with the ultimate aim of detecting the underlying causes of patients bleeding 
symptoms. An additional goal was to not only identify mutations in either known or novel 
platelet/MK genes to explain the cause of  inherited platelet defects but to further understand 
basic platelet biology which may improve both diagnosis and treatment.  
For the success of this study, multi-centre collaboration was crucial to obtain sufficient numbers 
of patients with good geographical coverage across the UK. Over the past 8 years the GAPP 
project have recruited nearly 1000 patients and healthy volunteers in 28 haemophilia referral 
centres, of these, 318 participants (206 patients and 112 healthy volunteers) were investigated 
during the period of this thesis. Similar to previous studies, patients were recruited based on the 
inclusion criteria as detailed in the methods section (chapter 2) including negative screening for 
coagulation defects and VWD. Exclusion of other haemostatic defects is also important to 
ensure that the bleeding symptoms presented are more likely to be platelet related. The bleeding 




symptoms of recruited cases were also evaluated using the ISTH BAT score. Assessment of the 
ISTH BAT score in this study and in other two studies previously published including one from 
within the GAPP project demonstrated that the ISTH BAT score value although unable to 
predict the likelihood of diagnosing platelet function defect has proved to be a powerful tool in 
documenting bleeding symptoms among patients with excessive haemorrhage (Tosetto et al., 
2011, Lowe et al., 2013).  
A qualitative defect in platelet function was observed in 44% of patients (90/206) that were 
tested by lumi-LTA. This is slightly lower than a previously reported higher frequency of 58% 
platelet defects within the early stages of the GAPP study (Dawood et al., 2012). The high 
frequency of patients with undetectable platelet function disorder observed in this study was 
surprising. This however, may highlight the importance of the patients’ clinical evaluation to 
ensure that other defects that are non-related to platelets are excluded, This may also suggest 
that there has been a selection bias in centres possibly sending their best cases during the early 
phases of GAPP but also shows the importance of developing more accurate screening 
techniques that give high negative predictive value to exclude patients with non-platelet related 
disorders.  
The platelet categories of defects observed in this study (dense granular defects, Gi and Gq 
signalling defects, and cyclooxygenase pathway defects) were similar to those found in national 
guidelines for the laboratory investigation of platelet function disorders and those previously 
published within the GAPP project (Harrison et al., 2011, Dawood et al., 2012). There were 
however, a slight high number of cases with dense granular defects than previously reported 
(Watson et al., 2013). This observed increase of secretion defects in this study may have been 




caused by inclusion of 39(19%) patients with thrombocytopenia. This group of patients have 
previously reported to have high numbers of defects in dense granules (Johnson et al., 2016).  
Analysis of WES in this cohort has identified variants in known platelet genes that could 
suggest an underlying mutation in 59% of the cases studied. This is slightly lower than previous 
finding of 68% of the cases reported within the GAPP study (Johnson et al., 2016). However, 
as the latter study analysed patients with thrombocytopenia this might suggests that genetic 
mutations that underlie thrombopoiesis are more common than those related to platelet function. 
The use of platelet phenotyping in this study was also crucial to guide the genetic investigations 
by providing important supportive information to any candidate variants that were identified in 
genes previously known to cause platelet function defects. For example some candidate genes 
identified in this study were able to be linked either to Gi signalling or platelet secretion defects 
that were consistent with the patient phenotype. Moreover, 5 variants previously reported to be 
associated with platelet function in individuals with aspirin resistance were also identified in 
patients with defects in the cyclooxygenase pathway. However, the link between the defect in 
these candidate genes and the aspirin-like defect observed in these patients is still unclear. In 
general, the fact that genetic defects identified do match with patient’s phenotype cannot be 
considered evidence for pathogenicity. Especially in this cohort where almost all of the 
candidate genes identified were of uncertain significance. However, due to the multifactorial 
nature of platelet function defects, a possible additional mutation might be present along with 
current identified variants. In combination, these might give rise to excessive bleeding and the 
platelet phenotype observed. Further investigation will still be required to confirm the 
contribution of these variants to the bleeding symptoms presented in these patients. Further 
investigation will still be required to confirm the contribution of these variants to the bleeding 
symptoms presented in these patients.  




In contrast, platelet function testing results have also enabled the exclusion of number of 
variants that were not consistent with patients phenotype. For example, MYH13, NBEAL2 and 
LYST were identified in patients but with no evidence of a functional secretion defect. 
Furthermore ANKRD26 was identified in patients with normal platelet count, and ITGA2B was 
identified in two patients with no features of GT. This finding indicates that these candidates 
are unlikely to be the probable cause of defects in these patients.       
The unavailability of family members in the majority of cases in this study has also significantly 
hampered the final identification of possible causative variants. As a result, the number of 
candidate genes identified per individual was high and in many cases multiple variants were 
consistent with patient phenotype. This made it difficult to select the most appropriate candidate 
gene without comparison with extended family members. This is exemplified by studying 
family two where the inclusion of four affected members guided selection of candidate genes 
to only one possible variant that was consistent with their phenotype. However, if additional 
unaffected family members had been included, it would have provided additional confirmation 
of this variant. This has further emphasised the importance of recruiting family members with 
and without bleeding symptoms.  
Identification of the VWF gene in four patients was consistent with previous studies where 
genetic defects in platelet function have been identified in patients with VWD including defects 
in the P2Y12 ADP receptor (Daly et al., 2009, Stockley et al., 2015). As such, this study has 
provided additional evidence of possible linkage between VWD and platelet function defects, 
and further supports the growing body of evidence that both VWD and PFD can sometimes be 
multifactorial in nature. This is consistence with the fact that a number of genetic mutations 
(e.g. TxA2 mutation;Asp304Asn and P2Y12 mutation;Lys174Glu) previously identified in 
patients with bleeding diatheses are in heterozygous state. In the first example, the heterozygous 




mutation (Asp304Asn) is unlikely on its own to be the cause of the increase bleeding as an 
extended family member with the same genetic mutation is exist without apparent history of 
bleeding (Mumford et al., 2010). In the second example, the heterozygous mutation 
(Lys174Glu) was identified in co-existence with type 1 VWD (Daly et al., 2009). Suggesting 
that, in both cases a possible combination of mutation might gives rise to excessive bleeding 
observed in these patients. Furthermore, one of the VWF mutation identified in this cohort 
(Tyr1584Cys) has recently been reported in an Italian family with coinheritance of mild 
haemophilia A and type 1 von Willebrand disease. Interestingly, only family members with 
both mutations are exhibiting excessive bleeding (Daidone et al., 2017). This finding has 
important clinical implications in the investigation of patients with either VWD or PFD. We 
anticipate that in the future genetic investigation of patients with VWD and PFD may allow 
assessment of their dual roles in the contribution to bleeding tendency in individuals with 
haemorrhagic disorders.  
The lack of variant identification in the remaining 41% of cases could have two possible 
explanations, one is that genetic variant(s) causative of disease occur in genomic regions 
beyond the coding exome which was not analysed in this cohort. The second is that the 
variant(s) occur in novel genes not yet known to affect platelet function. However, the analysis 
of these genes were beyond the scope of this study but is being continued by the GAPP team.  
The limitations of current methods for diagnosing inherited platelet function disorders and the 
urgent need for alternative new methods also encouraged us to assess a number of new 
techniques which are relatively easier to use, less time consuming and require smaller blood 
volumes compared to lumi-LTA. One of these is MEA which has the advantage of rapidly 
assessing platelet function in more physiological conditions using smaller quantities of blood. 
MEA has previously been reported to be useful for detecting severe PFDs (Awidi et al., 2009, 




Albanyan et al., 2015) and it is widely applied for measuring antiplatelet therapy (Paniccia et 
al., 2015, Velik-Salchner et al., 2008). However, in this study MEA demonstrated a lack of 
sensitivity in identifying patients with mild bleeding symptoms associated with abnormal 
platelet function and platelet secretion defects (Al Ghaithi et al., 2017). As MEA is largely an 
end point technique, it is possible that lack of detailed information provided by lumi-LTA such 
as the kinetics, biphasic responses, reversible aggregation and lack of secretion measurement 
may have contributed to the lack of sensitivity observed in this study. It is also possible that the 
MEA may be more sensitive to pre-analytical variables associated with time delays in platelet 
function testing as it is a whole blood technique (Seyfert et al., 2007, Kaiser et al., 2012). 
The T-TAS has the advantage of assessing both platelet function and coagulation pathways 
under different shear rates using a very small blood volume under more physiologically relevant 
conditions. A number of studies has demonstrated the utility of the T-TAS in monitoring 
antithrombotic drugs (Hosokawa et al., 2011, Hosokawa et al., 2013) and detecting defects in 
platelet function and coagulation abnormalities within humans and animal models (Ogawa et 
al., 2012, Minami et al., 2015). In this study T-TAS has demonstrated a good agreement with 
lumi-LTA in detecting platelet function defects in patients with mild bleeding disorders. With 
a very high NPV, the technique could possibly play a role as a screening test so that intensive 
platelet function investigations could be avoided. With an ability to detect platelet inhibition by 
various pathways, the T-TAS could also be a useful tool in monitoring antithrombotic therapy. 
Finally, the study showed the ability of T-TAS to detect thrombus formation in blood from 
mice. This could provide valuable assistance in rapidly characterising the phenotype of a variety 
of gene defects in mouse models of human disease. 
The simplicity in the use of the RPFT and the use of a fixative with a small blood volume gives 
a clear advantage of this method as a potential POC test. This approach could therefore 




significantly improve the diagnosis of platelet function testing which is currently restricted to 
specialized laboratories. An initial evaluation of the RPFT demonstrated a good agreement with 
lumi-LTA but was performed in the laboratory on GAPP samples and not as a POC test 
(Dovlatova et al., 2014). In this study however, RPFT showed a poor agreement with lumi-LTA 
with higher false positive rates measuring the expression of P-selectin. However, in contrast as 
CD63 expression yielded very similar results with the study performed by Dovlatova et al, 
(Dovlatova et al., 2014) the test still has potential as a POC test. The false positive sensitivity 
of P-selectin alone might indicate that the conditions of platelet activation such as temperature 
and/or time of incubation were more poorly controlled in the POC setting or that the receptor 
is more vulnerable to being shed under the conditions of the assay and subsequent transport to 
Birmingham. Also as higher sample numbers were analysed in multiple centres this could have 
contributed to further variability and increased false positive results 
Study limitations and Future work 
The majority of candidates recruited in this study were individual patients. As such, recruitment 
of more family members with and without bleeding symptoms would significantly help define 
candidate gene identification and therefore provide more accurate confirmation of any plausible 
candidate variants identified. 
Genetic analysis in this study was only focused on genes previously known to be associated 
with platelet defects. It is advised in the future to analyse variants in novel genes outside of the 
coding exomes especially on those individuals whom causative variants were not identified.  
Evaluation of the T-TAS was carried out to determine defects only on patients with platelet 
function defects. It would be of interest in the future to analyse samples from patients with 
VWD and coagulation defects to demonstrate the utility of this technique in identifying 




abnormalities in other haemostasis pathways as this makes the test a potential valuable 
screening tool for all bleeding disorders. 
RPFT was performed as a true POC test in each Haemophilia Centre by non-laboratory 
professionals. Despite training this could suggest that conditions of platelet activation e.g. 
temperature and/or time of incubation might have been more poorly controlled. Furthermore, 
the recruitment of samples was very limited, and the majority were referred from a single centre 
which made it impossible to compare results between different centres. Future studies should 
therefore be performed with higher sample numbers and include multiple centres. Adequate 
training should also be provide to each centre including training videos that may help to 
improve sample handling and processing. It is also suggestive that more accurate comparison 
should be conducted by measuring samples that had been tested by using the RPFT both as a 
POC test and within the central laboratory simultaneously as an internal control to ensure that 
sample activation conditions are adequate.  
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Table 1. Bleeding score 
SYMPTOMS 




 0§ 1§ 2 3 4 
EPISTAXIS  No/trivial  - > 5/year 
or 




Packing or cauterization or 
antifibrinolytic 
Blood transfusion or replacement 
therapy (use of hemostatic blood 
components and rFVIIa)  or 
desmopressin 
      
Cutaneous  No/trivial For bruises 5 or more 
(> 1cm) in exposed 
areas  
 
Consultation only* Extensive  Spontaneous hematoma requiring 
blood transfusion  
      
Bleeding from minor 
wounds 
 No/trivial  - > 5/year  
or 




Surgical hemostasis Blood transfusion, replacement 
therapy, or desmopressin 
      
Oral cavity  No/trivial Present CONSULTATION 
ONLY* 
Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
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GI bleeding  No/trivial Present (not 




Consultation only* Surgical hemostasis, 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      
Hematuria  No/trivial Present (macroscopic) CONSULTATION 
ONLY* 
Surgical hemostasis,  
iron therapy 
Blood transfusion, replacement 
therapy or desmopressin 
      
Tooth extraction  No/trivial or 
none  done  
Reported in <25% of 
all procedures, no 
intervention** 
REPORTED IN 





Resuturing or packing Blood transfusion, replacement 
therapy or desmopressin 
      
Surgery  No/trivial or 
none done 
Reported in <25% of 
all procedures, no 
intervention** 
REPORTED IN 





Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      
Menorrhagia  No/trivial Consultation only* or 
- Changing pads more 
frequently than every 
2 hours or  
- TIME OFF 
WORK/SCHOOL 
> 2/YEAR OR 
- REQUIRING 
- Requiring combined treatment 
with antifibrinolytics and 
hormonal therapy 
or 
- Acute menorrhagia requiring 
hospital admission and emergency 
treatment  
or 
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- Clot and flooding or 






- Present since menarche and > 
12 months 
- Requiring blood transfusion, 
Replacement therapy, Desmopressin,  
or 
- Requiring dilatation & curretage or 
endometrial ablation or 
hysterectomy) 
      
Post-partum hemorrhage  No/trivial or 
no deliveries  
Consultation only* 
or 
 - Use of syntocin 
or 
- Lochia > 6 weeks 
 - Iron therapy 
or 
- Antifibrinolytics 




- Requiring examination under 
anaesthesia and/or the use of 
uterin balloon/package to 
tamponade the uterus 
- Any procedure requiring critical 
care or surgical intervention (e.g. 
hysterectomy, internal iliac artery 
legation, uterine artery embolization, 




    
Muscle hematomas  
Never Post trauma, no 
therapy 
SPONTANEOUS, 
NO THERAPY  
Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy  
Spontaneous or traumatic, requiring 




    
Hemarthrosis  




Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy 
Spontaneous or traumatic, requiring 
surgical intervention or blood 
transfusion 
 
     
CNS bleeding  
Never - - Subdural, any intervention Intracerebral, any intervention 




     







Blood transfusion or replacement 
therapy or desmopressin 
 
   
  
 
In addition to the guidance offered by the table, it is mandatory to refer to the text for more detailed instructions. 
§ Distinction between 0 and 1 is of critical importance. Score 1 means that the symptom is judged as present in the patient’s history by the interviewer but does not qualify for a score 2 or 
more 
* Consultation only: the patient sought medical evaluation and was either referred to a specialist or offered detailed laboratory investigation  
** Example: 1 extraction/surgery resulting in bleeding (100%): the score to be assigned is 2; 2 extractions/surgeries, 1 resulting in bleeding (50%): the score to be assigned is 2; 3 
extractions/surgeries, 1 resulting in bleeding (33%): the score to be assigned is 2; 4 extractions/surgeries, 1 resulting in bleeding (25%): the score to be assigned is 1 
# If already available at the time of collection  
^ Include: umbilical stump bleeding, cephalohematoma, cheek hematoma caused by sucking during breast/bottle feeding, conjunctival hemorrhage or excessive bleeding following 
circumcision or venipuncture. Their presence in infancy requires detailed investigation independently from the overall score  
 




  Gene code   Gene code    Gene code    Gene code    Gene code   
  ABCA12   BLOC1S1   FERMT3   ITGA2   MYO18B   
  ABCB4   BLOC1S2   FGD3   ITGA2B   MYO3A   
  ABCC4   BLOC1S3   FGR   ITGA5   MYO5A   
  ABCG5   BLOC1S4   FHOD1   ITGB1   MYO5B   
  ABCG8   BLOC1S5   FLI1   ITGB3   NAPA   
  ACSL4   BLOC1S6   FLII   ITPR1   NAPG   
  ACTN1   BMP4   FLNA   JAK2   NBEA   
  ACVRL1   BTBD9   FMNL1   JMJD1C   NBEAL2   
  ADAMTS13   BTK   FMNL3   KIAA1109   NFE2   
  ADCY3   C14orf133   FYN   KIAA2018   NIPSNAP3A   
  ADCY6   C19orf55   GATA1   LAIR1   NOTCH1   
  ADCY7   C20orf42    GDI2   LAT   NOX1   
  ADORA2B   C6orf25   GFI1   LCP2    NRG3   
  ADRA2A   CD226   GFI1B   LPAR1   NSF   
  ADRA2B   CD36   GNA12   LTBP1   NXF1   
  ADRBK1   CHD3   GNA13   LY6G6F   ORAI1   
  AK3   CLEC1B   GNAI1   LYN   P2RX1   
  AKT1   CLEC4F   GNAI2   LYST   P2RY1   
  AKT2   CNO   GNAQ   MAP2K2   P2RY12   
  ALOX12      CSK   GNAZ   MAP2K4   P2RY13   
  ANKRD12   CTTN   GNB2   MAP3K9   PDE2A   
  ANKRD18A   CYCS   GNB3   MAPK1   PDE3A   
  ANKRD18B   DAAM1   GNG11   MAPK13   PDE4D   
  ANKRD26   DIAPH1   GNG12   MAPK14   PDE5A   
  ANKRD33   DIAPH2   GNG13   MAPK8   PDPK1   
  AP3B1   DIAPH3   GNG5   MDS1   PDZD3   
  AP3D1   DNAH11   GP1BA   MECOM   PDZK1   
  AP3M1   DNM1L   GP1BB   MKL1   PEAR1   
  AP3S1   DNM2   GP5    MLK1   PECAM1   
  APC   DNM3   GP6   MLPH   PGM3   
  ARHGAP1   DTNBP1   GP9   MMP17   PHOX2A   
  ARHGAP17   EFNB1   GRAP2   MNX1   PIK3CA   
  ARHGAP32   EPHA4   GRB2   MPL   PIK3CB   
  ARHGAP6   EPHB1   GRK5   MRPS34   PIK3CD   
  ARHGDIA   ERG   GRK6   MUC16   PIK3CG   
  ARHGDIB   ETS1   GUCY1A3   MUC2   PIK3R1   
  ARHGEF12   ETV6   GUCY1B3   MUTED   PIK3R3   
  ARHGEF3   EXOC1   HBB   MYB   PIK3R5   
  ARRB1   F2R    HOOK3   MYH10   PLA2G4A   
  ASPN   F2RL3    HOXA11   MYH13   PLA2G4C   
  BAK1   FARP2    HPS1   MYH9   PLCB2   
  BCL2L1   FCER1G   HPS4   MYL9   PLCB3   
  BCOR   FCGR2A   HTR2A   MYLK   PLCG2   
  BET1L   FERMT1   INPP5D   MYLK2   PLDN   
           
           





           
           
  Gene code   Gene code    Gene code    Gene code   
  PPP1CA   RAP1GAP2   STXBP1   VPS52   
         
  PPP1CB   RAP1GDS1   STXBP2   VPS8   
  PPP1CC   RASGRP2   STXBP3   VWF   
  PPP1R12A   RBM8A   STXBP4   WAS   
  PPP1R12C   RGS10   STXBP5L   WDR66   
  PPP1R14A   RGS18   STXBP6   ZFPMI   
  PPP1R2   RGS19   SUZ12      
  PRKACA   RGS20   SYK      
  PRKACB   RGS9   SYTL3      
  PRKACG   RHOA   SYTL4      
  PRKAR1A   RHOC   TAL1      
  PRKAR2A   RHOF   TAOK1      
  PRKCA   ROCK1   TBXA2R      
  PRKCB   ROCK2   TEC      
  PRKCD   RUNX1   TGFBR3      
  PRKCQ   SCAMP2   THPO      
  PRKD1   SCAMP5   TLN1      
  PRKG1   SCFD1   TLR2      
  PRKG2   SELP   TMCC2      
  PTEN   SERPINE2   TPM1      
  PTGIR   SH2B3   TPM4      
  PTGS1   SIRPA   TRAF4      
  PTK2   SLC35D3   TREML1      
  PTPN1   SLC9A3R1   TRPM7      
  PTPN11    SLC9A3R2   TTC37      
  PTPN12   SLFN14   TUBA3C      
  PTPN18   SMAD1   TUBB1      
  PTPN2   SMAD6   UNC13A      
  PTPN6   SNAP23   UNC13B      
  PTPN7   SNAP25   VAMP2      
  PTPN9   SNAP29   VAMP3      
  PTPRA   SNAPIN   VAMP7       
  PTPRC   SNX1   VAMP8      
  PTPRJ   SRA1   VAV1      
  RAB27A   SRC   VAV2      
  RAB27B   SRF   VAV3      
  RAB38   STIM1   VPS11      
  RAB4A   STOM   VPS16      
  RABGGTA   STX11   VPS18      
  RAC1   STX12   VPS33A      
  RAF1   STX2   VPS33B      
  RAI1   STX4   VPS39      
  RAP1B   STX6   VPS41      
  RAP1GAP   STX7   VPS4B      





